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ABSTRACT
Arenaviruses are enveloped negative-strand RNA viruses that cause significant
human disease. Despite decades of research, it is still unclear how these viruses establish a
lifelong, asymptomatic infection in their rodent hosts while infection of humans often results
in severe disease. Unable to enter a state of bona fide latency, the transcription and replication
of the viral genomic RNA is likely highly regulated in time and subcellular space. Moreover,
we hypothesize that the viral nucleoprotein (NP), responsible for the encapsidation of the viral
RNA and the most highly expressed viral gene product, plays a key role in the regulation of
the viral gene expression program. Further, exploring host-virus interactions may elucidate the
basic aspects of arenavirus biology and how they cause such severe disease in humans. To
explore these questions in greater detail, this dissertation has pursued three main avenues.
First, to better understand lymphocytic choriomeningitis mammarenavirus (LCMV)
genome replication and transcription at the single-cell level, we established a high-throughput,
single-molecule (sm)FISH image acquisition and analysis pipeline and followed viral RNA
species from viral entry through the late stages of persistent infection in vitro. This work
provided support for a cyclical model of persistence where individual cells are initially
transiently infected, clear active infection, and become re-infected from neighboring reservoir
cells within the population.
Second, we used FISH to visualize viral genomic RNA to describe the subcellular
sites where LCMV RNAs localize during infection. We observed that, viral RNA concentrates
in large subcellular structures located near the cellular microtubule organizing center and
colocalizes with the early endosomal marker Rab5c and the viral glycoprotein in a proportion
of infected cells. We propose that the virus is using the surface of a cellular membrane bound
organelle as a site for the pre-assembly of viral components including genomic RNA and viral
glycoprotein prior to their transport to the plasma membrane where new particles will bud.
Last, we used mass spectrometry to identify human proteins that interact with the NPs
of LCMV and Junín mammareanavirus (JUNV) strain Candid #1. We provided a detailed map
of the host machinery engaged by arenavirus NPs, and in particular, showed that NP associates
with the double-stranded RNA (dsRNA)-activated protein kinase (PKR), a well-characterized
antiviral protein that inhibits cap-dependent protein translation initiation via phosphorylation
of eIF2α. We demonstrated that JUNV antagonizes the antiviral activity of PKR completely,
effectively abrogating the antiviral activity of this surveillance pathway.
In sum, the work composing this dissertation has given us fresh insight into how
arenaviruses establish and maintain persistence; the nature of the subcellular site where viral
genomic RNA is transcribed, replicated, and assembled with other viral components; and a
global view of the cellular machinery hijacked by the viral nucleoprotein. This work improves
our basic understanding of the arenavirus life cycle and may suggest novel antiviral therapeutic
targets that could be exploited in the future.
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CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW
1.1. Introduction
Arenaviruses are important human pathogens. There are no FDA approved
vaccines to prevent human infections by arenaviruses. In addition, there are limited
effective antiviral therapeutics available for the treatment of infected individuals. Gaps in
our understanding of the fundamental stages of the arenavirus life cycle in the human host
is a major contributing factor to the lack of effective preventive and treatment options.
During my time in the Botten laboratory, my dissertation research has focused on
elucidating critical, yet incompletely understood, aspects of the viral life cycle. My work
has sought to improve our understanding of viral gene transcription and genomic
replication. Taking advantage of new technologies permitting the visualization of RNA
molecules with high sensitivity and specificity by fluorescence microscopy, it is possible
for the first time to probe the dynamics of these events within individual infected cells and
to explore previously intractable questions such as the nature of the viral gene expression
program during persistence. Further, this approach makes it possible to examine the
subcellular locations where these events occur to gain an appreciation for how the virus
may be utilizing particular cellular structures to promote its replication. Last, we know that
the viral nucleoprotein gene is the first viral gene expressed following infection and is the
most highly expressed viral gene product in infected cells. Its canonical role during
infection is the encapsidation of the viral genomic RNA. However, little is known
regarding what additional accessory roles the viral NP may play and how these may be
1

mediated through protein-protein interactions with host cellular proteins. We have
employed a proteomics approach to elucidate the protein-protein interaction network of the
arenavirus nucleoprotein. This work has given us new insight into how NP plays an
important role in manipulating the host cell environment to maintain conditions favorable
for viral replication. What follows is a comprehensive literature review providing the
necessary concepts to appreciate the intellectual contribution of the work constituting the
three manuscripts produced during the course of this dissertation project.
1.2. Arenaviruses
1.2.1. History of the Arenaviridae
In 1929, Viets and Watts described a cluster of six patients presenting with an
unusual form of meningitis. The cerebrospinal fluid of these patients contained abundant
lymphocytes but no detectable bacteria. Further, the absence of other symptoms
corresponding to other known causes of meningitis led the physicians to suggest a new
disease of unknown etiology, which they initially referred to as aseptic (lymphocytic)
meningitis (Viets and Watts, 1929a, b). Between 1934 and 1936 the viral etiology of this
lymphocytic meningitis syndrome was independently established by Armstrong et al.,
Traub, McNair and Rivers, and Findlay et al. (Armstrong and Dickens, 1935; Armstrong
and Lillie, 1934; Armstrong and Wooley, 1935; Findlay et al., 1936; Rivers and McNair
Scott, 1935; Rivers and Scott, 1936; Traub, 1935). In 1934, Armstrong and Lillie described
a viral agent that was able to provoke a disease closely resembling that described by Viets
and Watts just five years previously by performing intracranial injections of infected brain
2

matter into naïve Rhesus macaques (Armstrong and Lillie, 1934). Other groups showed
that cerebrospinal fluid or brain tissue from infected humans or animals was able to cause
a similar aseptic meningitis following intracranial injection into mice and guinea pigs
(Rivers and McNair Scott, 1935; Rivers and Scott, 1936; Scott and Rivers, 1936; Traub,
1935). Additional support for this being the causative agent for the aseptic lymphocytic
meningitis seen in humans came with the observation that serum from aseptic lymphocytic
meningitis survivors provided a high degree of protection to both Rhesus macaques, mice,
and guinea pigs infected with isolated strains of virus (Armstrong and Dickens, 1935;
Armstrong and Wooley, 1935; Rivers and Scott, 1936; Scott and Rivers, 1936).
Additionally, animals surviving infection with one strain displayed immunity when
subsequently reinoculated with additional strains isolated from other sources (Rivers and
Scott, 1936). The viral nature of the causative agent of the disease was demonstrated
through the ability of the infectious agent to pass through a filter with an average pore size
of 150 µm and the inability to see bacteria, fungal, or protozoal cells via histology of
infected tissue or failure to cultivate bacteria in rich growth media (Rivers and Scott, 1936).
The virus determined to be the cause of this disease, and independently isolated by multiple
researchers in both North America and Europe, came to be named lymphocytic
choriomeningitis virus (LCMV), due to the large lymphocyte infiltration observed by
histology in both the meninges and the choroid plexus in infected tissue, a pattern that was
uniquely associated with infection with this viral agent (Armstrong and Dickens, 1935;
Armstrong and Wooley, 1935; Findlay et al., 1936).
3

The study of LCMV continued during the following decades, but it was not until
the mid-1960’s that it became apparent that LCMV shared similar characteristics with other
more recently described viruses including Lassa (LASV), Junín (JUNV), Machupo
(MACV), and Tacaribe (TCRV) viruses. In 1970, an official classification for these viruses
was proposed and the name for this virus family “arenovirus” was proposed (LehmannGrube, 1971; Rowe et al., 1970). The latin root arenosus (meaning sandy) was chosen to
describe this newly classified family due to the hallmark grainy appearance of these viral
particles in negative stained electron micrographs. These electron dense granules in viral
particles were subsequently demonstrated to be host ribosomes (Farber and Rawls, 1975;
Lehmann-Grube, 1971; Leung and Rawls, 1977; Rowe et al., 1970). Additional unifying
features of this viral family consisted of their lipid envelope, serological relatedness,
pleomorphic virion form, release of viral particles from infected cells by budding, and
contained RNA (Lehmann-Grube, 1971; Rowe et al., 1970). In 1970, the International
Committee for the Taxonomy of Viruses (ICTV) approved the official classification of this
group of viruses, and the initially chosen name “arenovirus” was changed slightly to
“arenavirus” to avoid confusion with the already recognized taxon “adenovirus” (Murphy,
1975; Wildy, 1971).
Recently, several new arenavirus-like viruses were discovered in snakes
(Bodewes et al., 2014; Stenglein et al., 2012). This discovery prompted the ICTV to change
the previously recognized genus “Arenavirus” to “Mammarenavirus”. Further, within the
family Arenaviridae a new genus called “Reptarenavirus” was created containing the
4

newly described snake viruses (ICTV, 2014a). In the newly revised official nomenclature,
previously recognized names were altered such that lymphocytic choriomeningitis virus
was renamed lymphocytic choriomeningitis mammarenavirus (ICTV, 2014b).
1.2.2. Arenavirus infections in humans
During the decades following their initial discovery, we have come to understand
much about the disease pathology caused by these viruses and the molecular events
underlying each stage of their life cycles. The arenavirus family is broadly divided into the
Old World and New World groups. The classification of viruses into one group or the other
is determined by genetic relatedness of viral genomes, geographic distribution, and
serology (Buchmeier et al., 2013; Burri et al., 2012; Charrel et al., 2003; Emonet et al.,
2006) (Table 1.1 and Figure 1.1 and 1.2).
The arenaviruses are zoonotic viruses, meaning that, in nature, they are
maintained in animal reservoirs and human spillover is incidental (Buchmeier et al., 2013;
Charrel and de Lamballerie, 2010; Vela, 2012). For most members of the genus
Mammarenavirus, the viruses exploit rodent reservoirs. Only TCRV has been isolated from
bats (Buchmeier et al., 2013). The endemic geographical range where arenavirus infections
have been observed overlap with the geographical distribution of the known species of
rodent reservoir utilized by each specific arenavirus (Charrel et al., 2008).
Transmission of arenavirus from infected rodents to humans is thought to occur
primarily through inhalation, ingestion, or contact of skin wounds or abrasions with
infected rodent excreta (Buchmeier et al., 2013; Charrel et al., 2008; Grant et al., 2012).
5

Several well documented cases of nosocomial acquired infections by health care providers
have also been reported (Russier et al., 2012). LCMV can be transmitted vertically from
mother to the developing fetus and is a significant teratogenic threat (Bonthius, 2009).
Moreover, several cases of LCMV acquired through the transplantation of infected organs
have recently been reported with nearly uniform rates of lethality (Fischer et al., 2006;
Macneil et al., 2012). In immunocompetent individuals, LCMV infection is often
subclinical and inapparent but can manifest as severe aseptic meningitis (Bonthius, 2012).
Further evidence of the danger of LCMV is the high rates at which people are exposed to
its reservoir, the house mouse Mus musculus. A serological study performed in
Birmingham, Alabama, USA showed that greater than 4% of individuals were seropositive
for LCMV antigen indicating prior exposure to this human pathogen (Stephensen et al.,
1992).
Lassa virus is the greatest public health threat of any member of the arenavirus
family. It is endemic in Western Africa where it infects up to 300,000 people annually (Yun
and Walker, 2012). The ease of international airline travel has increased the risk that cases
could spread worldwide. Lassa virus is maintained in Mastomys sp. rats, which are
peridomestic and routinely come into close contact with people living in rural areas in its
endemic region (Russier et al., 2012). Lassa virus infection can cause severe disease in
humans, and can cause a hemorrhagic fever syndrome in serious cases (Russier et al., 2012;
Yun and Walker, 2012). There are currently no vaccines to prevent Lassa virus infections
despite a significant need (Charrel et al., 2011). The only antiviral therapeutic option is
6

ribavirin. However, the need for early administration and the risk of significant side effects
limit its efficacy (Bausch et al., 2010; Vela, 2012).
One of several South American arenaviruses known to cause hemorrhagic fever,
Junín virus is the etiologic agent of Argentine hemorrhagic fever (Grant et al., 2012).
Maintained in Calomys sp. rodents, which prefer to live in close proximity to agriculture,
farmers are the primary group at risk for infection with JUNV (Charrel and de Lamballerie,
2003). An attenuated strain of JUNV (strain Candid #1) was developed as a joint effort
between the US Army Medical Research Institute of Infectious Diseases and the Argentine
Ministry of Health and Social Action. This strain has been delivered as a live-attenuated
vaccine to at risk populations in Argentina, and has shown efficacy in preventing new
infections of vaccinated individuals. Despite efficacy, there is concern that the mutant virus
could revert to wild type and thus does not have US Food and Drug Agency approval
(Ambrosio et al., 2011).
1.2.3. The arenavirus life cycle
Members of the genus Mammarenavirus are enveloped with a host-derived lipid
bilayer (Figure 1.3) (Buchmeier et al., 2013). The viral envelope glycoprotein is embedded
in the virion membrane. The viral glycoprotein precursor (GPC) is proteolytically
processed in the secretory pathway into three subunits: GP1, GP2, and a stable signal
peptide, which is unusually long and remains associated with the viral glyocoprotein postprocessing (Figure 1.3) (Buchmeier et al., 2013; Burri et al., 2012; Rojek and Kunz, 2008;
Rojek et al., 2008). Three GP1, GP2, and SSP units associate to form homotrimers (Burri
7

et al., 2012). The viral Z protein is the bona fide viral matrix protein needed for viral
budding (Figure 1.3) (Urata and Yasuda, 2012; Wolff et al., 2013b). Within the viral
particle, the viral ribonucleoprotein (RNP) consists of the viral single-stranded RNA
genome (which is encoded on two distinct segments), the viral nucleoprotein (NP), which
encapsidates the genomic RNA, and the viral encoded RNA-dependent RNA polymerase
(L) (Figure 1.3) (Buchmeier et al., 2013). The last component of arenavirus particles are
packaged host ribosomes, whose presence in viral particles confers the family’s
characteristic grainy appearance in electron micrographs though their functional
importance, if any, is still unknown (Buchmeier et al., 2013; Leung and Rawls, 1977).
Though differences do exist between members of the Old and the New World
arenaviruses, the basic steps of the viral life cycle are shared among all members of the
family (Figure 1.4). The first phase of an arenavirus infection is entry of the arenavirus
particle into a naïve host cell (Burri et al., 2012; Rojek and Kunz, 2008; Rojek et al., 2008).
The attachment to the host cell is mediated by the GP1 subunit of the envelope
glycoprotein, which binds to the cell surface receptor. The Old World arenaviruses and
Clade C of the New World arenaviruses use alpha-dystroglycan and Clade B of the New
World arenaviruses use transferrin receptor (TfR1) as the cell surface receptor (Burri et al.,
2012). The binding of the viral glycoprotein to the cellular receptor triggers endocytosis of
the attached virion (Burri et al., 2012). Entry of New World arenaviruses is clathrindependent (Rojek et al., 2008). On the other hand, entry of the Old World arenaviruses is
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clathrin, caveolin, and dynamin- independent and does not rely on Rab5 or Rab7 (Rojek
and Kunz, 2008).
Upon cellular uptake by endocytosis, progressive acidification of endosomes
leads to a conformational change in the GP2 subunit of the envelope glycoprotein
triggering a fusion event between the viral envelope and the endosomal membrane (Figure
1.4) (Burri et al., 2012). Viral envelope fusion releases the viral RNP into the cytoplasm of
the newly infected cell. There, the viral L polymerase begins transcribing the viral genomic
RNA, and viral mRNAs are translated into polypeptides by host ribosomes (Figure 1.4)
(Buchmeier et al., 2013; Meyer et al., 2002). Then, full length viral genome is replicated
by the L polymerase (Figure 1.4) (Buchmeier et al., 2013; Meyer et al., 2002). Lastly, the
viral genomic RNA and the viral proteins traffic to the plasma membrane where they
assemble and bud as new infectious viral particles (Figure 1.4) (Urata and Yasuda, 2012;
Wolff et al., 2013b).
1.3. Transcription and Replication of Viral RNA during Acute and Persistent
Phases of Infection
Arenaviruses are enveloped viruses that have a single-stranded, bisegmented,
negative-sense RNA genome. Each genomic RNA segment (named S and L) contains 2
viral open reading frames encoded in ambisense orientation (Figure 1.5) (Buchmeier et al.,
2013). The canonical sequence of genetic events following release of arenavirus genomic
RNA into the cytoplasm of a newly infected cell is primary transcription of the NP and L
mRNAs from the viral S and L genomic segments, full length replication of the
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antigenomic RNA, transcription of the GPC and Z mRNAs from the S and L antigenomic
RNA, and finally replication of more genomic RNA (Figure 1.6) (Buchmeier et al., 2013;
Ferron et al., 2017).
Early work aimed at elucidating the genetic composition of these viruses
determined that they had a bisegmented single-stranded RNA genome (Carter et al., 1973).
The presence of cellular ribosomes in arenavirus particles initially was suggestive that
these viruses could possess a positive-sense RNA genome, however the presence of a viral
RNA polymerase along with RNase protection assays suggested that the viral genomic
RNAs from purified virions was indeed of negative-sense polarity (Carter et al., 1974;
Leung et al., 1977). Determination of the full-length sequence of the viral S segment
genomic RNA showed the first evidence of the arenaviral ambisense coding strategy where
the NP gene is encoded in a negative-sense polarity on the 3’ half of the viral genomic
RNA and the GPC gene is encoded in a pseudo-positive-sense polarity on the 5’ half
(Auperin et al., 1984a; Southern et al., 1987). At the same time it was determined that the
two viral genes are separated by an intergenic region (IGR) that was predicted to adopt a
hairpin secondary structure, a potential means of transcription termination (Auperin et al.,
1984a; Auperin et al., 1984b). The L segment was subsequently shown to encode the L
protein in the same negative-sense polarity and position as the NP gene on the S segment
(Singh et al., 1987). Z was shown to be encoded in pseudo-positive-sense polarity,
analogous to GPC on the S segment, and is separated from the L gene by an intergenic
region (Salvato and Shimomaye, 1989).
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The discovery of the ambisense coding strategy employed by the arenaviruses
suggested a mechanism by which these viruses could temporally regulate the expression of
their various gene products (Auperin et al., 1984b; Southern et al., 1987). The use of
sequence specific Northern blot probes made it possible to track the expression levels of
different viral RNA species over time. Using Northern blot, it was confirmed that the
appearance of the NP mRNA could be detected just 2 hours post infection, and this viral
subgenomic RNA accumulated even in the absence of protein synthesis – which the authors
inhibited with pactamycin treatment (Franze-Fernandez et al., 1987). On the other hand,
the GPC mRNA was not detected until 4 hours post infection, and its expression was
wholly dependent on the presence of active translation (Franze-Fernandez et al., 1987).
These data suggested that translation of the NP and L protein were necessary for the
production of the full length antigenomic RNA, which would serve as the template for GPC
transcription. Significantly, this was the first demonstration of the hypothesized ability of
the arenaviruses to temporally separate the different viral gene expression events. Further
work suggested that S genome was expressed to a higher degree than the L genomic RNA
(Fuller-Pace and Southern, 1988) and that viral RNAs increased in abundance over the first
few days of infection and began to decrease after achieving those peak levels (Fuller-Pace
and Southern, 1988; Iapalucci et al., 1994; Raju et al., 1990; Shivaprakash et al., 1988;
Southern et al., 1987). qRT-PCR data has confirmed the trend of initial increase in RNA
levels over the first 48 hours of infection followed by their subsequent decline (Haist et al.,
2015).
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Arenavirus mRNAs bear 5’ 7-methylguanylate caps, which the virus presumably
procures through a cap-snatching mechanism (Meyer and Southern, 1993; Polyak et al.,
1995a; Raju et al., 1990) potentially conferred by an endonuclease activity present in the
viral L polymerase (Morin et al., 2010). Further, viral mRNAs are not polyadenylated
(Auperin et al., 1984b; Leung et al., 1977). The secondary structure created by the viral
intergenic region serves as the viral transcription termination signal, and 3’ termini of viral
mRNAs are heterogeneous in length representing variablility in the position in which the
viral polymerase terminates mRNA synthesis in response to secondary structural cues
(Iapalucci et al., 1991; Lopez and Franze-Fernandez, 2007; Meyer et al., 2002; Pinschewer
et al., 2005). It seems that sequence specificity of the IGR is not of paramount importance
as chimeric genomic sequences containing heterologous IGR regions from distantly related
arenaviruses are still able to serve as transcription termination signals, and recombinant
viruses with these heterologous IGRs are viable (Iwasaki et al., 2016).
In contrast to the viral mRNAs, the viral genomic and antigenomic RNAs are
uncapped. At the 3’ and 5’ termini of the viral genomic segments, there are important
untranslated regions (UTR) that play roles in the initiation of transcription and replication.
The terminal 19 nucleotides of the 3’ UTR are highly conserved between the S and L
segments, and the reverse complement of the 3’ UTR is present in the 5’ UTR (Auperin et
al., 1982a; Auperin et al., 1982b; Meyer et al., 2002). It is proposed that the 3’ and 5’ UTRs
will base pair, leading the genomic RNA to form a closed panhandle structure (Meyer et
al., 2002). It appears that both the exact sequence and the double-stranded character of the
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3’ and 5’ UTRs are critical for effective viral transcription and replication (Hass et al.,
2006; Perez and de la Torre, 2003). In Lassa virus it appears that the requirement for
sequence specificity from bases 13-19 of the conserved UTR is relaxed, and mutation in
this region is permitted so long as double-stranded character is maintained (Hass et al.,
2006).
Another striking feature of the arenavirus genomic RNAs is the presence of one
non-templated base, most often a G, present at the 5’ terminus (Polyak et al., 1995a). The
viral L polymerase uses a “prime-realign” mechanism to initiate replication of the viral
genomic RNAs leaving a one base pair overhang at the 5’ terminus (Garcin and
Kolakofsky, 1990, 1992; Raju et al., 1990). An important functional consequence of the
presence of this 5’ nontemplated base pair is that RIG-I, an important innate immune sensor
of cytoplasmic 5’ triphosphate bearing RNAs with dsRNA character, was unable to
recognize RNA duplexes with a single nucleotide overhang and, thus, not induce the
expression of type I interferon (IFN) (Marq et al., 2010).
A hallmark characteristic of arenavirus infections is their ability to establish
lifelong persistent infection in rodents infected in utero or at birth (Francis et al., 1987). An
understanding of the mechanism by which arenaviruses are able to establish persistence
without adversely affecting their rodent hosts is important not just as a means to understand
basic steps of the virus’ life cycle but also as a way to appreciate how and why severe
disease often occurs in their incidental human hosts. Arenaviruses are unable to enter a
bona fide latent state such as retroviruses like HIV-1 or herpes viruses like Epstein Barr
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virus (Buchmeier et al., 2013; Meyer et al., 2002). Thus, persistently infected cells must
maintain arenavirus genomic RNA over long periods of time, though how this occurs is
still unclear, despite much study. A few principle models to explain the mechanism of
arenavirus persistence have been proposed, and a detailed understanding of the genetics of
persistence promises to yield a fresh outlook on this question that has long interested the
field.
It is possible to recapitulate key elements of persistenct infection in cell culture
models of infection, a fact that has greatly facilitated our ability to study arenaviral
persistence in simplified in vitro systems (Lehmann-Grube, 1967; Lehmann-Grube et al.,
1969; Meyer et al., 2002). One characteristic of cell culture models of persistent LCMV
infection is the cyclical rise and fall of

infectious virus released into cell culture

supernatants over time, and these cycles have a periodicity of a few days (Hotchin, 1974a;
Hotchin et al., 1975; Lehmann-Grube, 1967; Lehmann-Grube et al., 1969; Staneck et al.,
1972). Additional features of arenavirus persistence is the continuous expression of NP and
the downregulation of GPC surface expression (Oldstone and Buchmeier, 1982) and the
resistance of cells to super infection with homologous virus (Ellenberg et al., 2004).
One hypothesis seeking to explain how persistent infection is established and
maintained suggests that within a population of arenavirus infected cells, infection of a
single cell is transient and self-limited. Further, upon clearance of an arenaviral infection,
that cell becomes susceptible to being re-infected by neighboring reservoir cells within the
population (Hotchin, 1973, 1974a, b; Hotchin et al., 1975). The primary evidence
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supporting this model comes from the observation that when large numbers of single cell
clones are established from a population where almost all cells were infected, virus was
only detected in the supernatant of a small percentage of established clones (~5%)
(Hotchin, 1973, 1974a, b; Hotchin et al., 1975). Additional evidence of the importance of
viral clearance followed by re-infection in the maintenance of persistent arenavirus
infections comes from the observation that treatment of persistently infected cultures with
blocking arenavirus antisera leads to a progressive decline in the percentage of cells
expressing viral antigen as visualized by immunofluorescence microscopy (LehmannGrube et al., 1969). Potential mechanisms that could be employed by arenaviruses to
establish transient self-limiting infections in cells likely include the inhibition of the viral
RNA dependent RNA polymerase by the viral Z protein (Cornu and de la Torre, 2001,
2002; Jacamo et al., 2003; Kranzusch and Whelan, 2011; Lopez et al., 2001) and the
production of defective interfering particles (Burns and Buchmeier, 1993; Huang, 1973;
Huang and Baltimore, 1970; Oldstone, 1998; Welsh et al., 1972; Ziegler et al., 2016a;
Ziegler et al., 2016b).
A second hypothesis explaining arenaviral persistence suggests that the appearance
of defective genomes during the persistent phase of arenavirus persistence leads to greatly
reduced levels of infectious virus production (Rawls et al., 1981). The basis for this
hypothesis is the observation that viral genomic RNAs are expressed at high levels in vivo
in persistently infected animals (Francis and Southern, 1988b). Further it was shown that
during persistence, truncated subgenomic RNAs appear in vitro (Francis and Southern,
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1988a), and many of the genomic and antigenomic RNAs that appear to be full length
actually have short (< 50 nucleotide) deletions at the 3’ and 5’ termini (Meyer and
Southern, 1994). It was suggested that these terminally deleted genomes are replication
competent as a specific 3’ genomic deletion and the identical corresponding 5’ antigenomic
deletion were readily detected (Francis and Southern, 1988a; Meyer and Southern, 1994).
However, these deletions were never observed in the 5’ termini of viral mRNA sequences,
suggesting that these truncated genomes are not transcriptionally competent (Meyer and
Southern, 1993, 1994). There is a small amount of evidence that in some instances viral
RNAs appeared to have additional nontemplated bases at their termini, suggesting a
potential path by which terminally truncated genomes could be repaired (Meyer and
Southern, 1997). By balancing the loss and replacement of genomic and antigenomic
termini, the virus could potentially autoregulate viral transcription and production of
infectious virions during persistence (Francis and Southern, 1988a; Meyer and Southern,
1993, 1994, 1997) – explaining the oscillatory behavior of viral release observed during
persistent infection in cell culture.
Much of the work undertaken to probe the genetic events of viral transcription
and replication has relied on Northern blot (Auperin et al., 1984b; Fuller-Pace and
Southern, 1988; Polyak et al., 1995a, b; Raju et al., 1990; Shivaprakash et al., 1988;
Southern et al., 1987) and qRT-PCR (Haist et al., 2015) to examine the levels of viral RNAs
during infection. Studies using Northern blot to track viral RNAs during the course of
infection have the advantage of being able to distinguish each of the viral RNAs (Auperin
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et al., 1984b; Fuller-Pace and Southern, 1988; Polyak et al., 1995a, b; Raju et al., 1990;
Shivaprakash et al., 1988). However, the extreme variability in detection sensitivity
between independent studies and the inability to quantitatively compare the levels of viral
RNAs labeled by different probe sets is a significant disadvantage of Northern blot
(Auperin et al., 1984b; Fuller-Pace and Southern, 1988; Polyak et al., 1995a, b; Raju et al.,
1990; Shivaprakash et al., 1988; Southern et al., 1987). qRT-PCR has also been
implemented to track the dynamics of transcription and replication of viral RNAs by Haist
et al. and has the advantage of exquisite sensitivity. However, qRT-PCR has the
disadvantage of being unable to distinguish viral mRNAs from respective genomic or
antigenomic RNA (Haist et al., 2015). A limitation to both approaches is that they measure
gene expression of cell populations and are thus unsuitable to analyze the heterogeneity of
individual cells (Auperin et al., 1984b; Fuller-Pace and Southern, 1988; Haist et al., 2015;
Polyak et al., 1995a, b; Raju et al., 1990; Shivaprakash et al., 1988; Southern et al., 1987).
While these methods have provided invaluable insight into the genetics of the viral life
cycle, discerning between the two major hypotheses presented above will depend on a more
nuanced view of the genetic events of infection in individual cells over time.
1.4. Viral Replication Complexes
The nucleoprotein is the major viral protein component of the viral RNPs (Ferron
et al., 2017). LCMV NP in an infected cell localizes predominantly to punctate cytoplasmic
structures during acute infection (Knopp et al., 2015; Ortiz-Riano et al., 2011; Young et
al., 1987). In transfection experiments, ectopically expressed LCMV NP can adopt a
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distribution similar to that observed during infection (Knopp et al., 2015; Ortiz-Riano et
al., 2011). NP in cells infected with JUNV and TCRV, can exhibit a pattern of staining
ranging from diffusely cytoplasmic to concentration of NP in punctate cytoplasmic
structures (Baird et al., 2012; Ellenberg et al., 2002). The observation that NP can
concentrate in specific subcellular locations during both infection and when NP is
ectopically expressed suggests that the virus may benefit from compartmentalizing viral
machinery in specific subcellular sites. The identification and description of these sites as
well as the elucidation of how the virus may be benefitting by a particular localization
pattern are of great interest.
It is known that many viruses take advantage of specific subcellular sites to
facilitate their life cycles. A particularly rich literature exists describing the way viruses
with single-stranded positive sense genomes hijack host membrane bound compartments
to shield the transcription and replication of their genomes from cytoplasmic RIG-I like
receptor (RLR) surveillance (Chan and Gack, 2016; den Boon and Ahlquist, 2010; den
Boon et al., 2010; Novoa et al., 2005a). While less is known regarding how negative-strand
viruses, like the arenaviruses, may rely on membrane bound cellular compartments, there
are notable examples of other negative-strand viruses that rely on cellular organelles to
promote genome replication, assembly, and/or trafficking phases of their life cycle
including Influenza A virus and Bunyamwera virus (Amorim et al., 2011; Bruce et al.,
2010; Novoa et al., 2005a; Novoa et al., 2005b).
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To explore the question of whether arenaviruses take advantage of particular
subcellular sites to promote their life cycle, Baird et al. performed the first comprehensive
study to examine the subcellular localization of sites of active transcription and replication
of TCRV and JUNV viral genomic RNA (Baird et al., 2012). The authors found that active
sites of genome transcription and replication (or viral replication and transcription
complexes; RTC) were localized to punctate structures in infected cells. Moreover, viral
RNPs co-sedimented with membrane components by density-gradient centrifugation,
providing the first hint that the virus may be co-opting some existing organelle membrane
during the cytoplasmic phases of its life cycle (Baird et al., 2012). Nevertheless, Baird et
al. were unable to identify the cytoplasmic organelle hijacked by the virus, and the identity
of these subcellular sites of TCRV replication remain obscure (Baird et al., 2012).
1.5. The Viral Nucleoprotein
The arenavirus nucleoprotein, sometimes referred to as the nucleocapsid protein
(abbreviated NP or N), is the viral protein expressed at the highest levels during infection.
NP, consisting of between 558 and 570 amino acids, has a molecular weight ranging from
60-68 kDa depending upon the virus (Buchmeier, 2002). The viral gene encoding the NP
protein is located on the S gene segment and is encoded in a negative-sense polarity – such
that transcription of the genome yields a coding mRNA (Meyer et al., 2002). During the
persistent phase of infection, while the expression of the other viral proteins becomes
undetectable, NP levels remain high (Ellenberg et al., 2002). While NP plays multiple roles
in the virus life cycle, classically, encapsidation of the viral genomic RNA and replicative
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intermediate RNA (antigenomic RNA) has been considered to be NP’s fundamental role
(Buchmeier et al., 2013). Structural biology and mutagenesis approaches have made it
possible to map the regions important for NP’s various functions and in mediating its
interactions with both viral and host proteins.
The primary amino acid sequence of the NP is highly conserved across the
arenavirus family – including a high degree of similarity between the Old World and the
New World arenaviruses (Buchmeier, 2002; Lan et al., 2008; Qi et al., 2010). Crystal
structures of Lassa virus NP have been solved and have shown that NP folds into two
discrete domains – an N terminal domain roughly encompassing residues 1-338 and a C
terminal domain encompassing residues 364-561 with a flexible linking region connecting
the two (Qi et al., 2010). In the N terminal domain, there is a deep cavity lined with basic
residues at the bottom of which is located a patch of hydrophobic amino acids. It was
initially suggested that this N terminal cavity coordinated the binding to the 7methylguanylate cap (m7G cap) which members of the arenavirus family have been
demonstrated to use to cap their mRNAs. The authors hypothesized that the hydrophobic
residues deep in the cavity coordinated the m7G cap, and the basic channel coordinated the
triphosphate bridge (Qi et al., 2010). When the authors mutated several key residues
identified in this region, severe defects in viral transcription were observed – supporting
their hypothesis that NP is involved in m7G cap-snatching (Qi et al., 2010). Other groups
have questioned this proposed model (Brunotte et al., 2011; Hastie et al., 2011b). The cocrystallization of LASV NP in complex with RNA has suggested that the N terminal cleft
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does not bind m7G caps. Rather, the cleft is responsible for binding single stranded viral
RNA (Brunotte et al., 2011; Hastie et al., 2011b). It was shown that the basic amino acid
residues lining the cavity were important in mediating the electrostatic interactions between
the NP and the phosphate backbone of the ssRNA molecule (Brunotte et al., 2011; Hastie
et al., 2011b).
LASV NP crystal structures have also given insight into the role of the C terminal
domain. Two papers independently showed extensive 3d structure similarity between the
C terminal domain of LASV NP and the DEDD superfamily of exonucleases despite little
primary sequence identity (Hastie et al., 2011a; Qi et al., 2010). Structures reveal a deep
cleft at the top of the C terminal domain of LASV NP. Moreover, these catalytic residues
were shown to occupy the same positions as in the active site of the human DEDD family
3’-5’ exonuclease TREX1 (Hastie et al., 2011a; Qi et al., 2010). Characterization of the
enzymatic activity of the C terminal domain showed that NP degraded RNA but not DNA
in a 3’ to 5’ direction, and that, moreover, this exoribonuclease activity was dependent
upon a divalent Mn2+ cation coordinated by the C terminal domain (Hastie et al., 2011b;
Qi et al., 2010). While Qi et al. (Qi et al., 2010) showed that NP degraded both ssRNA and
dsRNA, Hastie et al. (Hastie et al., 2011a) demonstrated a clear preference of NP for
dsRNA.
In addition to this initial crystallography examining the structure of LASV NP, the
structure of TCRV, JUNV, and LCMV NP have all recently been solved and have been
shown to possess a C terminal 3’-5’ exoribonuclease domain (Jiang et al., 2013; West et
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al., 2014; Zhang et al., 2013). TCRV NP was further shown to possess exonuclease activity
with specificity for dsRNA ligands, like LASV NP (Jiang et al., 2013). However, JUNV
NP was shown to lack exonuclease activity in an in vitro dsRNA degradation assay (Zhang
et al., 2013). It is possible that the crystallization scheme utilized by these researchers led
to the protein adopting an inactive conformation, lacking a key Zn2+ cation shown to be
conserved in all other crystallized arenavirus NP’s (West et al., 2014; Zhang et al., 2013).
It is also possible JUNV does not possess the ability to degrade dsRNA substrates.
Nevertheless, the potential diversity in NP functionality across members of the Old World
and New World viruses is intriguing, and further work should be performed to better
understand the divergent strategies employed by these related viruses to subvert effective
host innate immune responses.
Other motifs present in the NP protein include a zinc finger motif in NP’s C
terminus (Parisi et al., 1996; Qi et al., 2010; Tortorici et al., 2001b). The zinc finger motif
identified in the C terminus of LASV and JUNV was between amino acids 500 and 530.
The position of the zinc finger motif in the crystal structure of the LASV NP suggests that
it may play a role in coordinating the exoribonuclease domain (Qi et al., 2010; Tortorici et
al., 2001b).
Important for encapsidation of the viral RNA genome, arenavirus NP has been
shown to form homo-oligomers. The interaction between individual NP monomers has
been suggested to be mediated by NP’s N terminal domain (Levingston Macleod et al.,
2011; Ortiz-Riano et al., 2011, 2012). However, C terminal to N terminal interactions also
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appear to be of importance (Brunotte et al., 2011; Hastie et al., 2011b). X-Ray
crystallography of LASV NP reveals homotrimers formed of monomers associated in a
ring-like structure (Brunotte et al., 2011; Hastie et al., 2011b; Qi et al., 2010). NP subunits
are arranged in either a symmetric head-tail fashion or an asymmetric fashion in the
trimeric ring (Brunotte et al., 2011). However, complementary EM analysis of NP trimers
in solution shows that NP trimers exist predominantly in a symmetric state (Brunotte et al.,
2011). Crystallization has also suggested that NP monomers undergo a conformational
change in their N terminal domain upon trimerization making the N terminal cleft
unavailable for RNA binding (Hastie et al., 2011b). Thus, an open and a closed
conformation of the N terminal domain of NP corresponds to monomeric and trimeric NP
respectively. While unable to bind RNA, it is possible that homotrimeric NP has distinct
biological roles in the viral life cycle. For example, it has been demonstrated that NP that
is unable to trimerize is defective in its ability to promote transcription and replication in
minigenome reporter assays but has no effect on interaction with other viral proteins or its
ability to antagonize a type I IFN response (D'Antuono et al., 2014; Lennartz et al., 2013).
It is possible that head to tail interactions between NP subunits bound upon the length of
viral genomic (or antigenomic) RNA provide the structural basis for viral RNA
encapsidation (Hastie et al., 2011b).
LCMV NP can be phosphorylated during infection on serine and threonine
residues (Howard and Buchmeier, 1983). It is unclear what the significance of NP
phosphorylation may be, though it seems that phosphorylation of the LCMV NP protein
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increases over the course of an infection (Young and Howard, 1983). It was hypothesized
that the phosphorylation of NP may play a role in regulation of the conformational changes
in NP promoting or inhibiting its multimerization (Brunotte et al., 2011). More recently,
mass spectrometry of the LCMV NP demonstrated phosphorylation at three serines, one
threonine, and one tyrosine. Further, additional serine and threonine residues that could be
phosphorylated were identified with predictive algorithms (Knopp et al., 2015). Mutation
of a threonine residue predicted to be phosphorylated greatly changed the subcellular
distribution of NP in transfected cells, negatively affected translation priming, and a
recombinant virus bearing this mutation was not viable (Knopp et al., 2015). Mutation of
the phosphorylated tyrosine was also shown to be critical as recombinant virus with a
mutation at this site was not viable (Knopp et al., 2015).
While the majority of NP expressed in infected cells exhibits a molecular weight of
60-68 kDa, it is possible to visualize a 28 kDa and 36 kDa cleavage product of NP as well
(Harnish et al., 1981). The functional importance of these two truncated NP’s is unclear,
but at late time points following infection (up to 20 days post infection), staining of NP in
nuclear inclusions was observed in infected cells only when monoclonal antibodies capable
of recognizing these short forms of NP were used (Young et al., 1987).
The first evidence to explain a potential role for these truncated NPs came with the
observations that JUNV NP appeared to be cleaved by caspases and that expression of
ectopic JUNV NP could prevent the activation of the effector caspase 3, a critical event in
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the execution of apoptosis (Wolff et al., 2013a). Thus, the short forms of NP observed
during infection may represent a strategy employed by the virus to prevent apoptosis.
Extensive work has been performed to characterize NP’s role in mediating
transcription and replication of the arenavirus’ ssRNA genome. Expression of NP and the
L protein are sufficient for the transcription and replication of a viral minigenome (Lee et
al., 2000). A commonly accepted model for the switch from transcription to replication in
arenaviruses was that an intergenic region (IGR), which separates the two genes in each
viral gene segment, adopts a secondary structure hairpin loop whose formation in a
transcribed mRNA leads to transcription termination. It was thought that as levels of NP
increased over the course of infection, the IGR would be bound by NP upon exiting the
polymerase thus becoming unable to adopt a hairpin, allowing the viral polymerase to
proceed and transcribe the full length viral antigenome. This model was supported by the
observation that when translation was blocked in cells infected with JUNV or TCRV,
transcripts encoding the NP protein but not full length antigenome accumulated (FranzeFernandez et al., 1987; Tortorici et al., 2001a).
Though appealing, this model for the regulation of viral transcription and
replication has not been supported. Instead, it seems that as NP expression increased so did
the levels of both viral minigenome replication and transcription (Pinschewer et al., 2003).
Because viral mRNAs possess a 5’ m7G cap, and genomic and antigenomic RNAs do not
(Meyer and Southern, 1993; Pinschewer et al., 2003; Tortorici et al., 2001a), it is possible
that the “decision” to initiate either transcription or replication is made by the viral
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polymerase at the moment of primer binding. That is, polymerase bound to a capped primer
will prevent the encapsidation of the nascent RNA transcript and secondary structure of the
transcribed IGR will terminate elongation. However, if the viral polymerase has bound an
uncapped primer, encapsidation of the nascent RNA will occur, the secondary structure of
the transcribed IGR will not be allowed to form, and the polymerase will continue until it
reaches the end of the gene segment resulting in a full length antigenome (Pinschewer et
al., 2003; Tortorici et al., 2001a). The authors hypothesized that increased levels of NP
could increase the activity of the viral polymerase in a general manner, as has been
observed for viruses in other families (Pinschewer et al., 2003).
The NP of all members of the arenavirus family have been shown to suppress the
induction of type I interferon (IFN) expression – with the exception of MOPV whose NP
seems to exhibit only weak anti-IFN activity (Martinez-Sobrido et al., 2007; MartinezSobrido et al., 2006; Ortiz-Riano et al., 2011; Pannetier et al., 2004). It was shown that
expression of NP, in the absence of other viral proteins, was sufficient to prevent activation
of the IRF3 responsive promoter (which controls expression of IFN-α/β) and nuclear
translocation of IRF3 in response to infection with Sendai virus – a virus known to induce
the expression of type I IFN (Martinez-Sobrido et al., 2007; Martinez-Sobrido et al., 2006).
Mutational analysis has shown that the C terminal domain of the NP protein mediates the
inhibition of the type I IFN response in LCMV (Martinez-Sobrido et al., 2009).
Specifically, residues 382-386 were shown to be critical for the inhibition of the induction
of IFN-β in LCMV and LASV (Carnec et al., 2011; Martinez-Sobrido et al., 2009). The
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equivalent residues were shown to be present in the 3’-5’ exoribonuclease domain of LASV
NP (Hastie et al., 2011b; Qi et al., 2010).
The 3’-5’ exoribonuclease domain of LASV NP is capable of degrading a wide
range of dsRNA substrates, including arenaviral RNAs and Poly I:C (Hastie et al., 2011a;
Qi et al., 2010). Moreover, mutation of residues in the exonuclease domain resulted in
mutant NPs unable to suppress induction of IFN-β expression (Harmon et al., 2013; Hastie
et al., 2011a; Huang et al., 2015; Jiang et al., 2013; Qi et al., 2010). Key residues in the
exonuclease domain including G392 and R393 of LASV (corresponding to LCMV NP
G385 and R386) are conserved in the primary sequence of every mammarenavirus
(Harmon et al., 2013; Jiang et al., 2013; Qi et al., 2010). Mutation of these catalytic residues
has been shown to inhibit the growth of mutant recombinant virus in cell lines known to
have intact type I IFN signaling pathways as well as in in vivo models of infection (Huang
et al., 2015; Pannetier et al., 2014; Russier et al., 2014).
RIG-I and MDA5 were both shown to be important in the detection of LCMV
infection and the induction of IFN-β expression. It was shown that these two cytoplasmic
sensors bound LCMV RNA. However, LCMV NP was able to suppress the induction of
IFN- β by RIG-I and MDA5. NP, RIG-I and MDA5 were shown to physically associate
which may be important for its inhibitory role in this signaling pathway (Zhou et al., 2010).
Additionally, LCMV NP has been shown to interact with the kinase IKKε. This is
significant because IKKε is a kinase important for type I IFN induction downstream of
RIG-I. (Pythoud et al., 2012). In contrast to other arenaviruses, JUNV infection results in
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robust induction of type I IFN expression, and this induction is dependent on RIG-I
expression (Huang et al., 2012). Nevertheless, JUNV infection is unaffected by IFN
treatment suggesting that it has additional mechanisms to evade a host antiviral response
(Huang et al., 2012). Both New World and Old World NPs were shown to prevent the
nuclear translocation of NF-κB and the activation of transcription of NF-κB responsive
genes providing another way that arenaviruses may negatively modulate the amplitude of
the host’s innate immune response (Rodrigo et al., 2012).
Despite the putative role of truncated forms of NP in inhibition of apoptosis (Wolff
et al., 2013a), in some cases, infected cells can undergo apoptosis. It appears that RIG-I
signaling can lead to the initiation of the apoptotic pathway in JUNV infected cells
(Kolokoltsova et al., 2014; Pythoud et al., 2015). While it was shown that LCMV
effectively inhibits the induction of type I IFN through the activation of RIG-I, RIG-I
induced apoptosis, a parallel, non-overlapping pathway, remained fully active in LCMV
infected cells (Pythoud et al., 2015). In the case of JUNV infection, it is unclear to what
extent the caspase decoy function of NP may play in modulating apoptosis, and the effect
of viral strain, cell type, timing, and other variables remain to be explored.
The interaction of NP with other viral proteins is important at multiple steps in
the arenavirus life cycle. While LCMV NP was shown to localize with GP in one study,
this result has not been reproduced in other members of the arenavirus family (Burns and
Buchmeier, 1991; Schlie et al., 2010). NP has been shown to interact with L polymerase
from TCRV, LASV, MOPV, and LCMV (Jacamo et al., 2003; Kerber et al., 2011). While
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the functional relevance of the NP-L interaction has yet to be defined, it was shown that
within the Old World arenavirus clade, the activity of the MOPV and LASV L polymerase
could be heterologously complemented by either MOPV, LASV, or LCMV NP. However,
the activity of the LCMV L polymerase could not be complemented by MOPV or LASV
NP (Kerber et al., 2011). Further, it appears that this interaction may be mediated via the
viral genomic RNA and specifically the 3’ and 5’ UTRs (Iwasaki et al., 2015).
NP has been shown to interact with Z for all arenavirus species examined, with the
exception of MOPV and TCRV (Casabona et al., 2009; Eichler et al., 2004; Jacamo et al.,
2003; Ortiz-Riano et al., 2011; Salvato et al., 1992; Shtanko et al., 2010; Shtanko et al.,
2011). The NP-Z interaction is purported to be important in the assembly of budding viral
particles. While Z protein alone is sufficient to direct the budding of VLPs, the expression
of NP along with Z can may be important for the recruitment of RNPs into budding
particles (Casabona et al., 2009; Groseth et al., 2010; Ortiz-Riano et al., 2011; Schlie et al.,
2010). The ability to interact with Z was mapped to the C terminal domain of NP, but
mutation to key residues resulting in the loss of IFN inhibitory activity did not affect the
ability of NP to bind Z suggesting that these two functions of the C terminal domain of NP
are independent of each other (Ortiz-Riano et al., 2011).
In addition to NP’s ability to interact with other viral proteins, NP has also been
shown to interact with cellular proteins. JUNV NP was shown to interact with hnRNP
A1/A2. hnRNP A1/A2 are RNA binding proteins which shuttle between the nucleus and
the cytoplasm. While knockdown of these hnRNPs resulted in a defect in viral replication,
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the mechanism of why this interaction could be important is, as yet, unknown (Maeto et
al., 2011). Furthermore, LCMV NP was shown to interact with the intermediate filament
protein Keratin 1. Cells infected with LCMV were shown to have a more extensive Keratin
network than uninfected cells and an increased concentration of desmosomes at sites of
cell to cell contact (Labudova et al., 2009). The increased stability of the intermediate
filament network and increased cell contacts observed in LCMV infected cells facilitated
the efficient transmission of virus between cells. Disruption of the keratin network resulted
in decreased cell to cell transmission of virus (Labudova et al., 2009). MOPV NP and Z
were both shown to interact with the ALIX/AIP1, part of the cellular ESCRT pathway – a
protein complex involved in the budding of vesicles into multivesicular bodies (MVBs)
(Shtanko et al., 2011). It appears that AIP1 interaction bridges NP and Z and may thus play
a role in promoting RNP recruitment into budding MOPV particles (Shtanko et al., 2011).
Lastly, it was shown that NP may play an important role in regulating host cellular
translation (Linero et al., 2011). Infection with JUNV as well ectopic expression of NP or
GPC was able to prevent the formation of stress granules in response to cellular stress
(Linero et al., 2011). Stress granules are transient non-membrane bound accumulations of
stalled small ribosomal subunits along with their bound cap-dependent mRNA transcripts.
Stress granules are temporary depots of non-essential transcripts and their accompanying
translation machinery that are formed in response to a variety of cellular stresses that
activate a member of the eIF2AK family of kinases, whose role it is to phosphorylate eIF2α
and stall global cap-dependent translation. This permits the selective translation of stress
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response mRNAs bearing alternate translation initiation signals such as internal ribosomal
entry sites (IRES). Importantly, stress granules can dissolve following the resolution of the
cellular stress and the resident mRNAs can re-enter the pool of actively translating cellular
mRNAs (Anderson and Kedersha, 2008; Buchan and Parker, 2009; Thomas et al., 2011).
As the stress of viral infection can initiate the formation of stress granules, many viruses
have been shown to interfere with stress granule formation, function, and/or hijack stress
granules to promote their own replication (Reineke and Lloyd, 2013; Valiente-Echeverria
et al., 2012; White and Lloyd, 2012). How, then, JUNV NP (and/or GPC) may be affecting
viral translation is a fascinating question. It is possible that JUNV NP’s ability to interact
with the eIF4 complex to promote cap-dependent translation (Linero et al., 2013) along
with other, as yet, undescribed mechanisms may all play important roles in maintaining
high rates of translation in infected cells.
The arenavirus nucleoprotein clearly performs many roles in the life cycle of the
virus. While its classical role has been considered to be the encapsidation of the viral
genomic and antigenomic RNA, NP’s role in interacting with other viral proteins as well
as inhibiting a cellular IFN response are also beginning to be appreciated. Crystal strutures
of LASV NP have provided new insight into the molecular mechanism by which NP is
able to perform such diverse functions as binding viral RNA, degrading immunogenic viral
RNA, and self-associate in higher order trimeric structures. It appears that the ability of NP
to associate with the viral Z protein may also be of great importance to direct the viral
RNPs into budding virions. While still poorly understood, NP’s ability to interact with host
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proteins also seems to be important. There remains much work to be done in these veins to
more fully understand the interplay between arenavirus and host in the pathogenesis of
arenaviral infections.
1.6. Summary
Arenaviruses remain major public health threats in developed countries where
populations are in constant exposure to LCMV and also worldwide where infection with
Lassa virus and several South American viruses cause extremely dangerous hemorrhagic
fever in infected individuals. Despite great effort, significant gaps remain in our
understanding of the viral life cycle and in our appreciation of how the virus takes
advantage of the host cell to its own benefit. These gaps in our understanding of arenavirus
biology are highlighted by our limited arsenal of available preventive and antiviral
therapeutic options. We believe that the development of new, more effective antiviral
strategies will likely depend upon the elucidation of key aspects of basic arenavirus
biology.
Toward this ambitious goal, a good starting point is to better understand the
regulation of viral gene expression and genome replication, how the virus may be
compartmentalizing these events within specific subcellular niches, and how the major
viral protein component of the viral RNP, the viral nucleoprotein, may be playing
heretofore unappreciated accessory roles to promote these and other steps of the viral life
cycle. It was our hope that the work in this dissertation would help us better understand
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how these viruses are able to establish persistent infections and how they are able to cause
such severe disease in humans but asymptomatic infections in their rodent reservoir.
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1.7. Tables

New World

Old World

Table 1.1. Members of the genus Mammarenavirus
Viruses of the family Arenaviridae, their geographic distribution, reservoirs and associated human diseases.
Adapted from Viruses, 5(2), S. Wolff, H. Ebihara, and A. Groseth, Arenavirus Budding: A Common Pathway
with Mechanistic Differences, p. 528-549, 2013, under a Creative Commons Attribution license (CC-BY
(Wolff et al., 2013b)
4.0).
Virus

Distribution

Reservoir

Human Disease

Dandenong virus*

Yugoslavia, Australia
(?)

Unknown

Febrile illness with
encephalopathy (transplantrelated)

Gbagroube virus*

Argentina

Mus (Nannomys)
setulosus

None known

Ippy virus

Central African
Republic

Arvicanthus spp.

None known

Lassa virus

Western Africa

Mastomys natalensis

Febrile illness, hemorrhagic
fever in severe cases

Lymphocytic
Choriomeningitis virus

Worldwide

Mus musculus

Febrile illness, aseptic
meningitis in severe cases

Lujo virus

Zambia

Unknown

Hemorrhagic fever

Luna virus*

Zambia

Mastomys natalensis

None known

Kodoko virus *

Guinea

Mus (Nannomys)
minutoides

None known

Menekre virus*

Côte d'Ivoire

Hylomyscus spp.

None known

Merino Walk virus *

South Africa

Myotomis unisulcatus

None known

Mobala virus

Central African
Republic

Praomys jacksoni

None known

Mopeia virus

Mozambique

Mastomys natalensis

None known

Morogoro virus *

Tanzania

Mastomys spp.

None known

Allpahuayo virus

Peru

Oecomys spp.

None known

Amapari virus

Brazil

Oryzomys gaeldi
Neacomys guianae

None known

Bear Canyon virus

USA

Peromyscus
californicus

None known

Big Brushy Tank virus*

USA

Neotoma albigula

None known

Catarina virus *

USA

Neotoma micropus

None known

Chapare virus

Bolivia

Unknown

Hemorrhagic fever

Cupixi virus

Brazil

Oryzomys spp.

None known

Flexal virus

Brazil

Oryzomys spp.

Febrile illness(Lab-acquired)

Guanarito virus

Venezuela

Zygodontomys
brevicauda

Hemorrhagic fever

Junín virus

Argentina

Calomys musculinus

Hemorrhagic fever

Latino virus

Bolivia

Calomys callosus

None known

Machupo virus

Bolivia

Calomys callosus

Hemorrhagic fever
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Oliveros virus

Argentina

Bolomys spp.

None known

Paraná virus

Paraguay

Oryzomys buccinatus

None known

Pichinde virus

Columbia

Oryzomys albigularis

None known

Pinhal virus

Brazil

Calomys tener

None known

Pirital virus

Venezuela

Sigmodon alstoni

None known

Real de Catorce virus *

Mexico

Neotoma leucodon

None known

Sabiá virus

Brazil

Unknown

Hemorrhagic fever

Skinner Tank virus *

USA

Neotoma mexicana

None known

Tacaribe virus

Trinidad

Artibeus spp. (bat)

Possible febrile illness (Labacquired)

Tamiami virus

USA

Sigmodon hispidus

None known

Tonto Creek virus

USA

Neotoma albigula

None known

Whitewater Arroyo
virus

USA

Neotoma albigula

Possible hemorrhagic fever
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1.8. Figures

Figure 1.1. Phylogeny of the genus Mammarenavirus
Phylogenetic tree of arenavirus Z protein. Amino acid sequences of Z protein were used for analysis. The
phylogenetic tree was drawn using GENETYX [1]. The scale bar indicates substitutions per site. Accession
numbers for reference sequences are: ABY20731 (Dandenong), YP_516232 (Ippy), NP_694871.1 (LASV,
Josiah), ABC96003 (LCMV, Armstrong), YP_002929492 (Lujo virus), YP_516228 (Mobala virus),
ABC71136 (Mopeia virus), YP_003090216 (Morogoro virus), YP_004933732 (Luna virus), YP_001649213
(Allpahuayo virus), AEQ59327 (Bear Canyon virus), AEQ59329 (Catarina virus), YP_001936023 (Flexal
virus), YP_001936027 (Parana virus), YP_138535 (Pichinde virus), YP_025092 (Pirital virus), AEQ59336
(Skinner Tank virus), YP_001911119 (Whitewater arroyo virus), YP_001649217 (Amapari virus),
YP_001816784 (Chapare virus), YP_001649219 (Cupixi virus), NP_899220 (Guanarito virus), NP_899216
(Junin virus, XJ-13), NP_899215 (Machupo virus), YP_089659 (Sabia virus), Q88470 (Tacaribe virus),
YP_001911117 (Tamiami virus), YP_001936025 (Latino virus), YP_001649215 (Oliveros virus).
Reproduced from Viruses, 4(10), S. Urata and J. Yasuda, Molecular Mechanism of Arenavirus Assembly
and Budding, p. 2049-2079, 2012, under a Creative Commons Attribution license (CC-BY 4.0). (Urata and
Yasuda, 2012)
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Figure 1.2. Geographic distribution of mammarenaviruses
Geographic distribution of human pathogenic arenaviruses. This map summarizes the distribution of human
pathogenic New and Old World mammarenavirus species. The year of the first description is indicated in
brackets. Reproduced from Viruses, 4(11), S. K. Fehling, F. Lennartz, and T. Strecker, Multifunctional
Nature of the Arenavirus RING Finger Protein Z, p. 2973-3011, 2012, under a Creative Commons Attribution
license (CC-BY 4.0). (Fehling et al., 2012)
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Figure 1.3. Arenavirus particle
Arenavirus particles are enveloped by a host-derived lipid bilayer. The viral envelope glycoprotein is a
transmembrane protein made up of three subunits: GP1, GP2, and the SSP. Mature glycoprotein form
homotrimers in the viral envelope (not shown). The viral Z protein is the bona fide viral matrix protein and
is responsible for budding of nascent virions. The viral ribonucleoprotein complexes (vRNP) are made up of
the viral genomic RNA, the viral L polymerase, and the viral nucleoprotein (NP). Though their functional
relevance is unclear, arenaviruses also package cellular ribosomes in virions.
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Figure 1.4. Arenavirus Life cycle
(1) The arenavirus life cycle begins with the envelope glycoprotein binding to its cell surface receptor. (2)
Receptor binding triggers the uptake of the viral particle into an endocytic compartment. (3) Endosome
acidification triggers a conformation change in GP2 and the fusion of the viral envelope with the endosomal
membrane. (4) The released RNP is transcribed in the cytoplasm and viral mRNAs are translated into protein
by host ribosomes. (5) Upon accumulation of viral protein, full length replication of the viral genomic RNA
is permitted. (6) The individual viral protein and RNA components assemble and (7) bud as newly formed
infectious virions from the cellular plasma membrane.
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Figure 1.5. Arenavirus genomic organization
The single-stranded, negative-sense RNA genome is contained on two segments. The S segment encodes the
NP gene in a negative orientation and the GPC gene in a pseudo-positive orientation. The L segment encodes
the L gene in a negative orientation and the Z gene in a pseudo-positive orientation. For both the S and the L
segment the two encoded gene products are separated by an intergenic region (IGR) that adopts a hairpin
secondary structure and serves as the transcription termination signal. There are 3’ and 5’ untranslated regions
(UTR) that provide critical sequence information needed for L polymerase recruitment and viral gene
transcription and genome replication.
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Figure 1.6. Arenavirus genomic RNA transcription and replication
The events of viral genome transcription are shown. The order of all events is identical for both the S and the
L segment. For simplicity, only the S segment is shown. (1) First, the NP gene (the gene encoded a negative
orientation) is transcribed by the viral L polymerase. The NP mRNA can be translated by cellular ribosomes.
Upon accumulation of viral antigen, a switch to full length genome replication (2) occurs. The full-length
RNA molecule complementary to the viral genome is called the antigenome. It serves as both the template
for replication of more genomic RNA and (3) the transcription of the GPC gene (now in a negative
orientation). The GPC mRNA can be translated into protein by cellular ribosomes.

41

1.9. References
Ambrosio, A., Saavedra, M., Mariani, M., Gamboa, G., and Maiza, A. (2011). Argentine
hemorrhagic fever vaccines. Hum Vaccin 7, 694-700.
Amorim, M.J., Bruce, E.A., Read, E.K., Foeglein, A., Mahen, R., Stuart, A.D., and Digard,
P. (2011). A Rab11- and microtubule-dependent mechanism for cytoplasmic transport of
influenza A virus viral RNA. Journal of virology 85, 4143-4156.
Anderson, P., and Kedersha, N. (2008). Stress granules: the Tao of RNA triage. Trends
Biochem Sci 33, 141-150.
Armstrong, C., and Dickens, P.F. (1935). Benign Lymphocytic Choriomeningitis (Acute
Aseptic Meningitis): A New Disease Entity. Public Health Reports 50, 831-842.
Armstrong, C., and Lillie, R.D. (1934). Experimental Lymphocytic Choriomeningitis of
Monkeys and Mice Produced by a Virus Encountered in Studies of the 1933 St. Louis
Encephalitis Epidemic. Public Health Reports 49, 1019-1027.
Armstrong, C., and Wooley, J.G. (1935). Studies on the Origin of a Newly Discovered
Virus Which Causes Lymphocytic Choriomeningitis in Experimental Animals. Public
Health Reports 50, 537-541.
Auperin, D., Dimock, K., Cash, P., Rawls, W.E., Leung, W.C., and Bishop, D.H. (1982a).
Analyses of the genomes of prototype pichinde arenavirus and a virulent derivative of
Pichinde Munchique: evidence for sequence conservation at the 3' termini of their viral
RNA species. Virology 116, 363-367.
Auperin, D.D., Compans, R.W., and Bishop, D.H. (1982b). Nucleotide sequence
conservation at the 3' termini of the virion RNA species of New World and Old World
arenaviruses. Virology 121, 200-203.
Auperin, D.D., Galinski, M., and Bishop, D.H. (1984a). The sequences of the N protein
gene and intergenic region of the S RNA of pichinde arenavirus. Virology 134, 208-219.
Auperin, D.D., Romanowski, V., Galinski, M., and Bishop, D.H. (1984b). Sequencing
studies of pichinde arenavirus S RNA indicate a novel coding strategy, an ambisense viral
S RNA. Journal of virology 52, 897-904.
Baird, N.L., York, J., and Nunberg, J.H. (2012). Arenavirus infection induces discrete
cytosolic structures for RNA replication. Journal of virology 86, 11301-11310.

42

Bausch, D.G., Hadi, C.M., Khan, S.H., and Lertora, J.J. (2010). Review of the literature
and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa
fever. Clin Infect Dis 51, 1435-1441.
Bodewes, R., Raj, V.S., Kik, M.J., Schapendonk, C.M., Haagmans, B.L., Smits, S.L., and
Osterhaus, A.D. (2014). Updated phylogenetic analysis of arenaviruses detected in boid
snakes. Journal of virology 88, 1399-1400.
Bonthius, D.J. (2009). Lymphocytic choriomeningitis virus: a prenatal and postnatal threat.
Adv Pediatr 56, 75-86.
Bonthius, D.J. (2012). Lymphocytic choriomeningitis virus: an underrecognized cause of
neurologic disease in the fetus, child, and adult. Semin Pediatr Neurol 19, 89-95.
Bruce, E.A., Digard, P., and Stuart, A.D. (2010). The Rab11 pathway is required for
influenza A virus budding and filament formation. Journal of virology 84, 5848-5859.
Brunotte, L., Kerber, R., Shang, W., Hauer, F., Hass, M., Gabriel, M., Lelke, M., Busch,
C., Stark, H., Svergun, D.I., Betzel, C., Perbandt, M., and Gunther, S. (2011). Structure of
the Lassa virus nucleoprotein revealed by X-ray crystallography, small-angle X-ray
scattering, and electron microscopy. The Journal of biological chemistry 286, 3874838756.
Buchan, J.R., and Parker, R. (2009). Eukaryotic stress granules: the ins and outs of
translation. Molecular cell 36, 932-941.
Buchmeier, M.J. (2002). Arenaviruses: protein structure and function. Current topics in
microbiology and immunology 262, 159-173.
Buchmeier, M.J., de la Torre, J.C., and Peters, C.J. (2013). Arenaviridae. In Fields
Virology, D.M. Knipe, P.M. Howley, J.I. Cohen, D.E. Griffin, R.A. Lamb, M.A. Martin,
V.R. Racaniello, and B. Roizman, eds. (Philadelphia, PA: Wolters Kluwer
Heath/Lippincott Williams & Wilkins), pp. 1283-1303.
Burns, J.W., and Buchmeier, M.J. (1991). Protein-protein interactions in lymphocytic
choriomeningitis virus. Virology 183, 620-629.
Burns, J.W., and Buchmeier, M.J. (1993). Glycoproteins of the arenaviruses. In The
Arenaviridae, M.S. Salvato, ed. (New York: Plenum Press), pp. 17-35.
Burri, D.J., da Palma, J.R., Kunz, S., and Pasquato, A. (2012). Envelope glycoprotein of
arenaviruses. Viruses 4, 2162-2181.

43

Carnec, X., Baize, S., Reynard, S., Diancourt, L., Caro, V., Tordo, N., and Bouloy, M.
(2011). Lassa virus nucleoprotein mutants generated by reverse genetics induce a robust
type I interferon response in human dendritic cells and macrophages. Journal of virology
85, 12093-12097.
Carter, M.F., Biswal, N., and Rawls, W.E. (1973). Characterization of nucleic acid of
pichinde virus. Journal of virology 11, 61-68.
Carter, M.F., Biswal, N., and Rawls, W.E. (1974). Polymerase activity of Pichinde virus.
Journal of virology 13, 577-583.
Casabona, J.C., Levingston Macleod, J.M., Loureiro, M.E., Gomez, G.A., and Lopez, N.
(2009). The RING domain and the L79 residue of Z protein are involved in both the rescue
of nucleocapsids and the incorporation of glycoproteins into infectious chimeric
arenavirus-like particles. Journal of virology 83, 7029-7039.
Chan, Y.K., and Gack, M.U. (2016). Viral evasion of intracellular DNA and RNA sensing.
Nature reviews. Microbiology 14, 360-373.
Charrel, R.N., Coutard, B., Baronti, C., Canard, B., Nougairede, A., Frangeul, A., Morin,
B., Jamal, S., Schmidt, C.L., Hilgenfeld, R., Klempa, B., and de Lamballerie, X. (2011).
Arenaviruses and hantaviruses: from epidemiology and genomics to antivirals. Antiviral
Res 90, 102-114.
Charrel, R.N., and de Lamballerie, X. (2003). Arenaviruses other than Lassa virus.
Antiviral Res 57, 89-100.
Charrel, R.N., and de Lamballerie, X. (2010). Zoonotic aspects of arenavirus infections.
Vet Microbiol 140, 213-220.
Charrel, R.N., de Lamballerie, X., and Emonet, S. (2008). Phylogeny of the genus
Arenavirus. Curr Opin Microbiol 11, 362-368.
Charrel, R.N., Lemasson, J.J., Garbutt, M., Khelifa, R., De Micco, P., Feldmann, H., and
de Lamballerie, X. (2003). New insights into the evolutionary relationships between
arenaviruses provided by comparative analysis of small and large segment sequences.
Virology 317, 191-196.
Cornu, T.I., and de la Torre, J.C. (2001). RING finger Z protein of lymphocytic
choriomeningitis virus (LCMV) inhibits transcription and RNA replication of an LCMV
S-segment minigenome. Journal of virology 75, 9415-9426.

44

Cornu, T.I., and de la Torre, J.C. (2002). Characterization of the arenavirus RING finger Z
protein regions required for Z-mediated inhibition of viral RNA synthesis. Journal of
virology 76, 6678-6688.
D'Antuono, A., Loureiro, M.E., Foscaldi, S., Marino-Buslje, C., and Lopez, N. (2014).
Differential contributions of tacaribe arenavirus nucleoprotein N-terminal and C-terminal
residues to nucleocapsid functional activity. Journal of virology 88, 6492-6505.
den Boon, J.A., and Ahlquist, P. (2010). Organelle-like membrane compartmentalization
of positive-strand RNA virus replication factories. Annual review of microbiology 64, 241256.
den Boon, J.A., Diaz, A., and Ahlquist, P. (2010). Cytoplasmic viral replication complexes.
Cell host & microbe 8, 77-85.
Eichler, R., Strecker, T., Kolesnikova, L., ter Meulen, J., Weissenhorn, W., Becker, S.,
Klenk, H.D., Garten, W., and Lenz, O. (2004). Characterization of the Lassa virus matrix
protein Z: electron microscopic study of virus-like particles and interaction with the
nucleoprotein (NP). Virus research 100, 249-255.
Ellenberg, P., Edreira, M., Lozano, M., and Scolaro, L. (2002). Synthesis and expression
of viral antigens in Vero cells persistently infected with Junin virus. Archives of virology
147, 1543-1557.
Ellenberg, P., Edreira, M., and Scolaro, L. (2004). Resistance to superinfection of Vero
cells persistently infected with Junin virus. Archives of virology 149, 507-522.
Emonet, S., Lemasson, J.J., Gonzalez, J.P., de Lamballerie, X., and Charrel, R.N. (2006).
Phylogeny and evolution of old world arenaviruses. Virology 350, 251-257.
Farber, F.E., and Rawls, W.E. (1975). Isolation of ribosome-like sturctures from Pichinde
virus. The Journal of general virology 26, 21-31.
Fehling, S.K., Lennartz, F., and Strecker, T. (2012). Multifunctional nature of the
arenavirus RING finger protein Z. Viruses 4, 2973-3011.
Ferron, F., Weber, F., de la Torre, J.C., and Reguera, J. (2017). Transcription and
replication mechanisms of Bunyaviridae and Arenaviridae L proteins. Virus research 234,
118-134.
Findlay, G.M., Alcock, N.S., and Stern, R.O. (1936). The Virus Ætiology Of One Form Of
Lymphocytic Meningitis. Lancet 227, 650-654.

45

Fischer, S.A., Graham, M.B., Kuehnert, M.J., Kotton, C.N., Srinivasan, A., Marty, F.M.,
Comer, J.A., Guarner, J., Paddock, C.D., DeMeo, D.L., Shieh, W.J., Erickson, B.R.,
Bandy, U., DeMaria, A., Jr., Davis, J.P., Delmonico, F.L., Pavlin, B., Likos, A., Vincent,
M.J., Sealy, T.K., Goldsmith, C.S., Jernigan, D.B., Rollin, P.E., Packard, M.M., Patel, M.,
Rowland, C., Helfand, R.F., Nichol, S.T., Fishman, J.A., Ksiazek, T., Zaki, S.R., and Team,
L.i.T.R.I. (2006). Transmission of lymphocytic choriomeningitis virus by organ
transplantation. N Engl J Med 354, 2235-2249.
Francis, S.J., and Southern, P.J. (1988a). Deleted viral RNAs and lymphocytic
choriomeningitis virus persistence in vitro. The Journal of general virology 69 ( Pt 8),
1893-1902.
Francis, S.J., and Southern, P.J. (1988b). Molecular analysis of viral RNAs in mice
persistently infected with lymphocytic choriomeningitis virus. Journal of virology 62,
1251-1257.
Francis, S.J., Southern, P.J., Valsamakis, A., and Oldstone, M.B. (1987). State of viral
genome and proteins during persistent lymphocytic choriomeningitis virus infection.
Current topics in microbiology and immunology 133, 67-88.
Franze-Fernandez, M.T., Zetina, C., Iapalucci, S., Lucero, M.A., Bouissou, C., Lopez, R.,
Rey, O., Daheli, M., Cohen, G.N., and Zakin, M.M. (1987). Molecular structure and early
events in the replication of Tacaribe arenavirus S RNA. Virus research 7, 309-324.
Fuller-Pace, F.V., and Southern, P.J. (1988). Temporal analysis of transcription and
replication during acute infection with lymphocytic choriomeningitis virus. Virology 162,
260-263.
Garcin, D., and Kolakofsky, D. (1990). A novel mechanism for the initiation of Tacaribe
arenavirus genome replication. Journal of virology 64, 6196-6203.
Garcin, D., and Kolakofsky, D. (1992). Tacaribe arenavirus RNA synthesis in vitro is
primer dependent and suggests an unusual model for the initiation of genome replication.
Journal of virology 66, 1370-1376.
Grant, A., Seregin, A., Huang, C., Kolokoltsova, O., Brasier, A., Peters, C., and Paessler,
S. (2012). Junin virus pathogenesis and virus replication. Viruses 4, 2317-2339.
Groseth, A., Wolff, S., Strecker, T., Hoenen, T., and Becker, S. (2010). Efficient budding
of the tacaribe virus matrix protein z requires the nucleoprotein. Journal of virology 84,
3603-3611.

46

Haist, K., Ziegler, C., and Botten, J. (2015). Strand-Specific Quantitative Reverse
Transcription-Polymerase Chain Reaction Assay for Measurement of Arenavirus Genomic
and Antigenomic RNAs. PloS one 10, e0120043.
Harmon, B., Kozina, C., Maar, D., Carpenter, T.S., Branda, C.S., Negrete, O.A., and
Carson, B.D. (2013). Identification of critical amino acids within the nucleoprotein of
Tacaribe virus important for anti-interferon activity. The Journal of biological chemistry
288, 8702-8711.
Harnish, D.G., Leung, W.C., and Rawls, W.E. (1981). Characterization of polypeptides
immunoprecipitable from Pichinde virus-infected BHK-21 cells. Journal of virology 38,
840-848.
Hass, M., Westerkofsky, M., Muller, S., Becker-Ziaja, B., Busch, C., and Gunther, S.
(2006). Mutational analysis of the lassa virus promoter. Journal of virology 80, 1241412419.
Hastie, K.M., Kimberlin, C.R., Zandonatti, M.A., MacRae, I.J., and Saphire, E.O. (2011a).
Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3' to 5' exonuclease
activity essential for immune suppression. Proceedings of the National Academy of
Sciences of the United States of America 108, 2396-2401.
Hastie, K.M., Liu, T., Li, S., King, L.B., Ngo, N., Zandonatti, M.A., Woods, V.L., Jr., de
la Torre, J.C., and Saphire, E.O. (2011b). Crystal structure of the Lassa virus nucleoproteinRNA complex reveals a gating mechanism for RNA binding. Proceedings of the National
Academy of Sciences of the United States of America 108, 19365-19370.
Hotchin, J. (1973). Transient virus infection: spontaneous recovery mechanism of
lymphocytic choriomeningitis virrus-infected cells. Nat New Biol 241, 270-272.
Hotchin, J. (1974a). Cyclical phenomena in persistent virus infection. J Reticuloendothel
Soc 15, 304-311.
Hotchin, J. (1974b). The role of transient infection in arenavirus persistence. Prog Med
Virol 18, 81-93.
Hotchin, J., Kinch, W., Benson, L., and Sikora, E. (1975). Role of substrains in persistent
lymphocytic choriomeningitis virus infection. Bull World Health Organ 52, 457-463.
Howard, C.R., and Buchmeier, M.J. (1983). A protein kinase activity in lymphocytic
choriomeningitis virus and identification of the phosphorylated product using monoclonal
antibody. Virology 126, 538-547.

47

Huang, A.S. (1973). Defective interfering viruses. Annual review of microbiology 27, 101117.
Huang, A.S., and Baltimore, D. (1970). Defective viral particles and viral disease
processes. Nature 226, 325-327.
Huang, C., Kolokoltsova, O.A., Yun, N.E., Seregin, A.V., Poussard, A.L., Walker, A.G.,
Brasier, A.R., Zhao, Y., Tian, B., de la Torre, J.C., and Paessler, S. (2012). Junin virus
infection activates the type I interferon pathway in a RIG-I-dependent manner. PLoS Negl
Trop Dis 6, e1659.
Huang, Q., Shao, J., Lan, S., Zhou, Y., Xing, J., Dong, C., Liang, Y., and Ly, H. (2015). In
vitro and in vivo characterizations of pichinde viral nucleoprotein exoribonuclease
functions. Journal of virology 89, 6595-6607.
Iapalucci, S., Chernavsky, A., Rossi, C., Burgin, M.J., and Franze-Fernandez, M.T. (1994).
Tacaribe virus gene expression in cytopathic and non-cytopathic infections. Virology 200,
613-622.
Iapalucci, S., Lopez, N., and Franze-Fernandez, M.T. (1991). The 3' end termini of the
Tacaribe arenavirus subgenomic RNAs. Virology 182, 269-278.
ICTV, A.S.G. (2014a). Create a new genus, Reptarenavirus, comprising three new species
in the family
Arenaviridae. (Internation Committee on the Taxonomy of Viruses).
ICTV, A.S.G. (2014b). Rename one (1) genus and twenty-five (25) species in the family
Arenaviridae. (International Committee on Taxonomy of Viruses
).
Iwasaki, M., Cubitt, B., Sullivan, B.M., and de la Torre, J.C. (2016). The High Degree of
Sequence Plasticity of the Arenavirus Noncoding Intergenic Region (IGR) Enables the Use
of a Nonviral Universal Synthetic IGR To Attenuate Arenaviruses. Journal of virology 90,
3187-3197.
Iwasaki, M., Ngo, N., Cubitt, B., and de la Torre, J.C. (2015). Efficient Interaction between
Arenavirus Nucleoprotein (NP) and RNA-Dependent RNA Polymerase (L) Is Mediated by
the Virus Nucleocapsid (NP-RNA) Template. Journal of virology 89, 5734-5738.
Jacamo, R., Lopez, N., Wilda, M., and Franze-Fernandez, M.T. (2003). Tacaribe virus Z
protein interacts with the L polymerase protein to inhibit viral RNA synthesis. Journal of
virology 77, 10383-10393.

48

Jiang, X., Huang, Q., Wang, W., Dong, H., Ly, H., Liang, Y., and Dong, C. (2013).
Structures of arenaviral nucleoproteins with triphosphate dsRNA reveal a unique
mechanism of immune suppression. The Journal of biological chemistry 288, 1694916959.
Kerber, R., Rieger, T., Busch, C., Flatz, L., Pinschewer, D.D., Kummerer, B.M., and
Gunther, S. (2011). Cross-species analysis of the replication complex of old world
arenaviruses reveals two nucleoprotein sites involved in L protein function. Journal of
virology 85, 12518-12528.
Knopp, K.A., Ngo, T., Gershon, P.D., and Buchmeier, M.J. (2015). Single nucleoprotein
residue modulates arenavirus replication complex formation. mBio 6, e00524-00515.
Kolokoltsova, O.A., Grant, A.M., Huang, C., Smith, J.K., Poussard, A.L., Tian, B., Brasier,
A.R., Peters, C.J., Tseng, C.T., de la Torre, J.C., and Paessler, S. (2014). RIG-I enhanced
interferon independent apoptosis upon Junin virus infection. PloS one 9, e99610.
Kranzusch, P.J., and Whelan, S.P. (2011). Arenavirus Z protein controls viral RNA
synthesis by locking a polymerase-promoter complex. Proceedings of the National
Academy of Sciences of the United States of America 108, 19743-19748.
Labudova, M., Tomaskova, J., Skultety, L., Pastorek, J., and Pastorekova, S. (2009). The
nucleoprotein of lymphocytic choriomeningitis virus facilitates spread of persistent
infection through stabilization of the keratin network. Journal of virology 83, 7842-7849.
Lan, S., McLay, L., Aronson, J., Ly, H., and Liang, Y. (2008). Genome comparison of
virulent and avirulent strains of the Pichinde arenavirus. Archives of virology 153, 12411250.
Lee, K.J., Novella, I.S., Teng, M.N., Oldstone, M.B., and de La Torre, J.C. (2000). NP and
L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient
transcription and replication of LCMV genomic RNA analogs. Journal of virology 74,
3470-3477.
Lehmann-Grube, F. (1967). A carrier state of lymphocytic choriomeningitis virus in L cell
cultures. Nature 213, 770-773.
Lehmann-Grube, F. (1971). Lymphocytic choriomeningitis virus, Vol 10 (Wien: SpringerVerlag).
Lehmann-Grube, F., Slenczka, W., and Tees, R. (1969). A persistent and inapparent
infection of L cells with the virus of lymphocytic choriomeningitis. The Journal of general
virology 5, 63-81.
49

Lennartz, F., Hoenen, T., Lehmann, M., Groseth, A., and Garten, W. (2013). The role of
oligomerization for the biological functions of the arenavirus nucleoprotein. Archives of
virology 158, 1895-1905.
Leung, W.C., Ghosh, H.P., and Rawls, W.E. (1977). Strandedness of Pichinde virus RNA.
Journal of virology 22, 235-237.
Leung, W.C., and Rawls, W.E. (1977). Virion-associated ribosomes are not required for
the replication of Pichinde virus. Virology 81, 174-176.
Levingston Macleod, J.M., D'Antuono, A., Loureiro, M.E., Casabona, J.C., Gomez, G.A.,
and Lopez, N. (2011). Identification of two functional domains within the arenavirus
nucleoprotein. Journal of virology 85, 2012-2023.
Linero, F., Welnowska, E., Carrasco, L., and Scolaro, L. (2013). Participation of eIF4F
complex in Junin virus infection: blockage of eIF4E does not impair virus replication.
Cellular microbiology 15, 1766-1782.
Linero, F.N., Thomas, M.G., Boccaccio, G.L., and Scolaro, L.A. (2011). Junin virus
infection impairs stress-granule formation in Vero cells treated with arsenite via inhibition
of eIF2alpha phosphorylation. The Journal of general virology 92, 2889-2899.
Lopez, N., and Franze-Fernandez, M.T. (2007). A single stem-loop structure in Tacaribe
arenavirus intergenic region is essential for transcription termination but is not required for
a correct initiation of transcription and replication. Virus research 124, 237-244.
Lopez, N., Jacamo, R., and Franze-Fernandez, M.T. (2001). Transcription and RNA
replication of tacaribe virus genome and antigenome analogs require N and L proteins: Z
protein is an inhibitor of these processes. Journal of virology 75, 12241-12251.
Macneil, A., Stroher, U., Farnon, E., Campbell, S., Cannon, D., Paddock, C.D., Drew, C.P.,
Kuehnert, M., Knust, B., Gruenenfelder, R., Zaki, S.R., Rollin, P.E., Nichol, S.T., and
Team, L.T.I. (2012). Solid organ transplant-associated lymphocytic choriomeningitis,
United States, 2011. Emerg Infect Dis 18, 1256-1262.
Maeto, C.A., Knott, M.E., Linero, F.N., Ellenberg, P.C., Scolaro, L.A., and Castilla, V.
(2011). Differential effect of acute and persistent Junin virus infections on the nucleocytoplasmic trafficking and expression of heterogeneous nuclear ribonucleoproteins type
A and B. The Journal of general virology 92, 2181-2190.
Marq, J.B., Kolakofsky, D., and Garcin, D. (2010). Unpaired 5' ppp-nucleotides, as found
in arenavirus double-stranded RNA panhandles, are not recognized by RIG-I. The Journal
of biological chemistry 285, 18208-18216.
50

Martinez-Sobrido, L., Emonet, S., Giannakas, P., Cubitt, B., Garcia-Sastre, A., and de la
Torre, J.C. (2009). Identification of amino acid residues critical for the anti-interferon
activity of the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis
virus. Journal of virology 83, 11330-11340.
Martinez-Sobrido, L., Giannakas, P., Cubitt, B., Garcia-Sastre, A., and de la Torre, J.C.
(2007). Differential inhibition of type I interferon induction by arenavirus nucleoproteins.
Journal of virology 81, 12696-12703.
Martinez-Sobrido, L., Zuniga, E.I., Rosario, D., Garcia-Sastre, A., and de la Torre, J.C.
(2006). Inhibition of the type I interferon response by the nucleoprotein of the prototypic
arenavirus lymphocytic choriomeningitis virus. Journal of virology 80, 9192-9199.
Meyer, B.J., de la Torre, J.C., and Southern, P.J. (2002). Arenaviruses: genomic RNAs,
transcription, and replication. Current topics in microbiology and immunology 262, 139157.
Meyer, B.J., and Southern, P.J. (1993). Concurrent sequence analysis of 5' and 3' RNA
termini by intramolecular circularization reveals 5' nontemplated bases and 3' terminal
heterogeneity for lymphocytic choriomeningitis virus mRNAs. Journal of virology 67,
2621-2627.
Meyer, B.J., and Southern, P.J. (1994). Sequence heterogeneity in the termini of
lymphocytic choriomeningitis virus genomic and antigenomic RNAs. Journal of virology
68, 7659-7664.
Meyer, B.J., and Southern, P.J. (1997). A novel type of defective viral genome suggests a
unique strategy to establish and maintain persistent lymphocytic choriomeningitis virus
infections. Journal of virology 71, 6757-6764.
Morin, B., Coutard, B., Lelke, M., Ferron, F., Kerber, R., Jamal, S., Frangeul, A., Baronti,
C., Charrel, R., de Lamballerie, X., Vonrhein, C., Lescar, J., Bricogne, G., Gunther, S., and
Canard, B. (2010). The N-terminal domain of the arenavirus L protein is an RNA
endonuclease essential in mRNA transcription. PLoS pathogens 6, e1001038.
Murphy, F.A. (1975). Arenavirus taxonomy: a review. Bull World Health Organ 52, 389391.
Novoa, R.R., Calderita, G., Arranz, R., Fontana, J., Granzow, H., and Risco, C. (2005a).
Virus factories: associations of cell organelles for viral replication and morphogenesis.
Biology of the cell / under the auspices of the European Cell Biology Organization 97, 147172.

51

Novoa, R.R., Calderita, G., Cabezas, P., Elliott, R.M., and Risco, C. (2005b). Key Golgi
factors for structural and functional maturation of bunyamwera virus. Journal of virology
79, 10852-10863.
Oldstone, M.B. (1998). Viral persistence: mechanisms and consequences. Curr Opin
Microbiol 1, 436-441.
Oldstone, M.B., and Buchmeier, M.J. (1982). Restricted expression of viral glycoprotein
in cells of persistently infected mice. Nature 300, 360-362.
Ortiz-Riano, E., Cheng, B.Y., de la Torre, J.C., and Martinez-Sobrido, L. (2011). The CTerminal Region of Lymphocytic Choriomeningitis Virus Nucleoprotein Contains Distinct
and Segregable Functional Domains Involved in NP-Z Interaction and Counteraction of
the Type I Interferon Response. Journal of virology 85, 13038-13048.
Ortiz-Riano, E., Cheng, B.Y., de la Torre, J.C., and Martinez-Sobrido, L. (2012). Selfassociation of Lymphocytic Choriomeningitis Virus Nucleoprotein is mediated by its Nterminal region and is not required for its anti-interferon function. Journal of virology.
Pannetier, D., Faure, C., Georges-Courbot, M.C., Deubel, V., and Baize, S. (2004). Human
macrophages, but not dendritic cells, are activated and produce alpha/beta interferons in
response to Mopeia virus infection. Journal of virology 78, 10516-10524.
Pannetier, D., Reynard, S., Russier, M., Carnec, X., and Baize, S. (2014). Production of
CXC and CC chemokines by human antigen-presenting cells in response to Lassa virus or
closely related immunogenic viruses, and in cynomolgus monkeys with lassa fever. PLoS
Negl Trop Dis 8, e2637.
Parisi, G., Echave, J., Ghiringhelli, D., and Romanowski, V. (1996). Computational
characterisation of potential RNA-binding sites in arenavirus nucleocapsid proteins. Virus
genes 13, 247-254.
Perez, M., and de la Torre, J.C. (2003). Characterization of the genomic promoter of the
prototypic arenavirus lymphocytic choriomeningitis virus. Journal of virology 77, 11841194.
Pinschewer, D.D., Perez, M., and de la Torre, J.C. (2003). Role of the virus nucleoprotein
in the regulation of lymphocytic choriomeningitis virus transcription and RNA replication.
Journal of virology 77, 3882-3887.
Pinschewer, D.D., Perez, M., and de la Torre, J.C. (2005). Dual role of the lymphocytic
choriomeningitis virus intergenic region in transcription termination and virus propagation.
Journal of virology 79, 4519-4526.
52

Polyak, S.J., Zheng, S., and Harnish, D.G. (1995a). 5' termini of Pichinde arenavirus S
RNAs and mRNAs contain nontemplated nucleotides. Journal of virology 69, 3211-3215.
Polyak, S.J., Zheng, S., and Harnish, D.G. (1995b). Analysis of Pichinde arenavirus
transcription and replication in human THP-1 monocytic cells. Virus research 36, 37-48.
Pythoud, C., Rodrigo, W.W., Pasqual, G., Rothenberger, S., Martinez-Sobrido, L., de la
Torre, J.C., and Kunz, S. (2012). Arenavirus nucleoprotein targets interferon regulatory
factor-activating kinase IKKepsilon. Journal of virology 86, 7728-7738.
Pythoud, C., Rothenberger, S., Martinez-Sobrido, L., de la Torre, J.C., and Kunz, S. (2015).
Lymphocytic Choriomeningitis Virus Differentially Affects the Virus-Induced Type I
Interferon Response and Mitochondrial Apoptosis Mediated by RIG-I/MAVS. Journal of
virology 89, 6240-6250.
Qi, X., Lan, S., Wang, W., Schelde, L.M., Dong, H., Wallat, G.D., Ly, H., Liang, Y., and
Dong, C. (2010). Cap binding and immune evasion revealed by Lassa nucleoprotein
structure. Nature 468, 779-783.
Raju, R., Raju, L., Hacker, D., Garcin, D., Compans, R., and Kolakofsky, D. (1990).
Nontemplated bases at the 5' ends of Tacaribe virus mRNAs. Virology 174, 53-59.
Rawls, W.E., Chan, M.A., and Gee, S.R. (1981). Mechanisms of persistence in arenavirus
infections: a brief review. Can J Microbiol 27, 568-574.
Reineke, L.C., and Lloyd, R.E. (2013). Diversion of stress granules and P-bodies during
viral infection. Virology 436, 255-267.
Rivers, T.M., and McNair Scott, T.F. (1935). Meningitis in Man Caused by a Filterable
Virus. Science 81, 439-440.
Rivers, T.M., and Scott, T.F. (1936). Meningitis in Man Caused by a Filterable Virus : Ii.
Identification of the Etiological Agent. J Exp Med 63, 415-432.
Rodrigo, W.W., Ortiz-Riano, E., Pythoud, C., Kunz, S., de la Torre, J.C., and MartinezSobrido, L. (2012). Arenavirus nucleoproteins prevent activation of nuclear factor kappa
B. Journal of virology 86, 8185-8197.
Rojek, J.M., and Kunz, S. (2008). Cell entry by human pathogenic arenaviruses. Cellular
microbiology 10, 828-835.
Rojek, J.M., Sanchez, A.B., Nguyen, N.T., de la Torre, J.C., and Kunz, S. (2008). Different
mechanisms of cell entry by human-pathogenic Old World and New World arenaviruses.
Journal of virology 82, 7677-7687.
53

Rowe, W.P., Murphy, F.A., Bergold, G.H., Casals, J., Hotchin, J., Johnson, K.M.,
Lehmann-Grube, F., Mims, C.A., Traub, E., and Webb, P.A. (1970). Arenoviruses:
proposed name for a newly defined virus group. Journal of virology 5, 651-652.
Russier, M., Pannetier, D., and Baize, S. (2012). Immune responses and Lassa virus
infection. Viruses 4, 2766-2785.
Russier, M., Reynard, S., Carnec, X., and Baize, S. (2014). The exonuclease domain of
Lassa virus nucleoprotein is involved in antigen-presenting-cell-mediated NK cell
responses. Journal of virology 88, 13811-13820.
Salvato, M.S., Schweighofer, K.J., Burns, J., and Shimomaye, E.M. (1992). Biochemical
and immunological evidence that the 11 kDa zinc-binding protein of lymphocytic
choriomeningitis virus is a structural component of the virus. Virus research 22, 185-198.
Salvato, M.S., and Shimomaye, E.M. (1989). The completed sequence of lymphocytic
choriomeningitis virus reveals a unique RNA structure and a gene for a zinc finger protein.
Virology 173, 1-10.
Schlie, K., Maisa, A., Freiberg, F., Groseth, A., Strecker, T., and Garten, W. (2010). Viral
protein determinants of Lassa virus entry and release from polarized epithelial cells.
Journal of virology 84, 3178-3188.
Scott, T.F., and Rivers, T.M. (1936). Meningitis in Man Caused by a Filterable Virus : I.
Two Cases and the Method of Obtaining a Virus from Their Spinal Fluids. J Exp Med 63,
397-414.
Shivaprakash, M., Harnish, D., and Rawls, W. (1988). Characterization of temperaturesensitive mutants of Pichinde virus. Journal of virology 62, 4037-4043.
Shtanko, O., Imai, M., Goto, H., Lukashevich, I.S., Neumann, G., Watanabe, T., and
Kawaoka, Y. (2010). A role for the C terminus of Mopeia virus nucleoprotein in its
incorporation into Z protein-induced virus-like particles. Journal of virology 84, 54155422.
Shtanko, O., Watanabe, S., Jasenosky, L.D., Watanabe, T., and Kawaoka, Y. (2011).
ALIX/AIP1 is required for NP incorporation into Mopeia virus Z-induced virus-like
particles. Journal of virology 85, 3631-3641.
Singh, M.K., Fuller-Pace, F.V., Buchmeier, M.J., and Southern, P.J. (1987). Analysis of
the genomic L RNA segment from lymphocytic choriomeningitis virus. Virology 161, 448456.

54

Southern, P.J., Singh, M.K., Riviere, Y., Jacoby, D.R., Buchmeier, M.J., and Oldstone,
M.B. (1987). Molecular characterization of the genomic S RNA segment from lymphocytic
choriomeningitis virus. Virology 157, 145-155.
Staneck, L.D., Trowbridge, R.S., Welsh, R.M., Wright, E.A., and Pfau, C.J. (1972).
Arenaviruses: cellular response to long-term in vitro infection with parana and lymphocytic
choriomeningitis viruses. Infect Immun 6, 444-450.
Stenglein, M.D., Sanders, C., Kistler, A.L., Ruby, J.G., Franco, J.Y., Reavill, D.R., Dunker,
F., and Derisi, J.L. (2012). Identification, characterization, and in vitro culture of highly
divergent arenaviruses from boa constrictors and annulated tree boas: candidate etiological
agents for snake inclusion body disease. mBio 3, e00180-00112.
Stephensen, C.B., Blount, S.R., Lanford, R.E., Holmes, K.V., Montali, R.J., Fleenor, M.E.,
and Shaw, J.F. (1992). Prevalence of serum antibodies against lymphocytic
choriomeningitis virus in selected populations from two U.S. cities. J Med Virol 38, 2731.
Thomas, M.G., Loschi, M., Desbats, M.A., and Boccaccio, G.L. (2011). RNA granules:
the good, the bad and the ugly. Cellular signalling 23, 324-334.
Tortorici, M.A., Albarino, C.G., Posik, D.M., Ghiringhelli, P.D., Lozano, M.E., Rivera
Pomar, R., and Romanowski, V. (2001a). Arenavirus nucleocapsid protein displays a
transcriptional antitermination activity in vivo. Virus research 73, 41-55.
Tortorici, M.A., Ghiringhelli, P.D., Lozano, M.E., Albarino, C.G., and Romanowski, V.
(2001b). Zinc-binding properties of Junin virus nucleocapsid protein. The Journal of
general virology 82, 121-128.
Traub, E. (1935). A Filterable Virus Recovered from White Mice. Science 81, 298-299.
Urata, S., and Yasuda, J. (2012). Molecular mechanism of arenavirus assembly and
budding. Viruses 4, 2049-2079.
Valiente-Echeverria, F., Melnychuk, L., and Mouland, A.J. (2012). Viral modulation of
stress granules. Virus research 169, 430-437.
Vela, E. (2012). Animal models, prophylaxis, and therapeutics for arenavirus infections.
Viruses 4, 1802-1829.
Viets, H.R., and Watts, J.W. (1929a). Aseptic (Lymphocytic) Meningitis. JAMA 93, 15531555.

55

Viets, H.R., and Watts, J.W. (1929b). Three Cases of Aseptic (Lymphocytic) Meningitis.
N Engl J Med 200, 633-634.
Welsh, R.M., O'Connell, C.M., and Pfau, C.J. (1972). Properties of defective lymphocytic
choriomeningitis virus. The Journal of general virology 17, 355-359.
West, B.R., Hastie, K.M., and Saphire, E.O. (2014). Structure of the LCMV nucleoprotein
provides a template for understanding arenavirus replication and immunosuppression. Acta
Crystallogr D Biol Crystallogr 70, 1764-1769.
White, J.P., and Lloyd, R.E. (2012). Regulation of stress granules in virus systems. Trends
in microbiology 20, 175-183.
Wildy, P. (1971). Classification and Nomenclature of Viruses. In Monographs in Virology,
J.L. Melnick, ed. (Basel/New York: S. Karger).
Wolff, S., Becker, S., and Groseth, A. (2013a). Cleavage of the Junin virus nucleoprotein
serves a decoy function to inhibit the induction of apoptosis during infection. Journal of
virology 87, 224-233.
Wolff, S., Ebihara, H., and Groseth, A. (2013b). Arenavirus budding: a common pathway
with mechanistic differences. Viruses 5, 528-549.
Young, P.R., Chanas, A.C., Lee, S.R., Gould, E.A., and Howard, C.R. (1987). Localization
of an arenavirus protein in the nuclei of infected cells. The Journal of general virology 68
( Pt 9), 2465-2470.
Young, P.R., and Howard, C.R. (1983). Fine structure analysis of Pichinde virus
nucleocapsids. The Journal of general virology 64 (Pt 4), 833-842.
Yun, N.E., and Walker, D.H. (2012). Pathogenesis of Lassa fever. Viruses 4, 2031-2048.
Zhang, Y., Li, L., Liu, X., Dong, S., Wang, W., Huo, T., Guo, Y., Rao, Z., and Yang, C.
(2013). Crystal structure of Junin virus nucleoprotein. The Journal of general virology 94,
2175-2183.
Zhou, S., Cerny, A.M., Zacharia, A., Fitzgerald, K.A., Kurt-Jones, E.A., and Finberg, R.W.
(2010). Induction and inhibition of type I interferon responses by distinct components of
lymphocytic choriomeningitis virus. Journal of virology 84, 9452-9462.
Ziegler, C.M., Eisenhauer, P., Bruce, E.A., Beganovic, V., King, B.R., Weir, M.E., Ballif,
B.A., and Botten, J. (2016a). A novel phosphoserine motif in the LCMV matrix protein Z
regulates the release of infectious virus and defective interfering particles. The Journal of
general virology 97, 2084-2089.
56

Ziegler, C.M., Eisenhauer, P., Bruce, E.A., Weir, M.E., King, B.R., Klaus, J.P.,
Krementsov, D.N., Shirley, D.J., Ballif, B.A., and Botten, J. (2016b). The Lymphocytic
Choriomeningitis Virus Matrix Protein PPXY Late Domain Drives the Production of
Defective Interfering Particles. PLoS pathogens 12, e1005501.

57

CHAPTER 2:
FOLLOWING ARENAVIRUS RNA SPECIES IN INDIVIDUAL CELLS BY
SINGLE-MOLECULE FLUORESCENCE IN SITU HYBRIDIZATION (smFISH)
REVEALS A MODEL OF CYCLICAL INFECTION AND CLEARANCE
DURING PERSISTENCE

Benjamin R. King1,2, Aubin Samacoits3,4, Philip L. Eisenhauer1, Christopher M. Ziegler1,
Emily A. Bruce1, Daniel Zenklusen5, Christophe Zimmer3,4, Florian Mueller3,4, and Jason
Botten1,6#

1

Department of Medicine, Division of Immunobiology, University of Vermont,

Burlington, VT 05405, USA, 2Cellular, Molecular, and Biomedical Sciences Graduate
Program, University of Vermont, Burlington, VT 05405, USA, 3Unité Imagerie et
Modélisation, Institut Pasteur, Paris, France, 4 C3BI, USR 3756 IP CNRS, Paris, France,
5

Departement de Biochimie et Médecine Moléculaire, Université de Montréal, Montréal,

QC H3T 1J4, Canada, 6Department of Microbiology and Molecular Genetics, University
of Vermont, Burlington, VT 05405, USA, #Corresponding author

Running Title: Cyclical LCMV infection and clearance in persistence

58

2.1. Abstract
Lymphocytic choriomeningitis mammarenvirus (LCMV) is an enveloped,
negative-strand RNA virus that causes serious disease in humans but establishes an
asymptomatic, lifelong infection in reservoir rodents. Different models have been proposed
to describe how arenaviruses regulate the replication and transcription of their
bisegmented, single-stranded RNA genomes, particularly during persistent infection.
However, these models were largely based on viral RNA profiling data derived from entire
populations of cells. To better understand LCMV replication and transcription at the singlecell level, we established a high-throughput, single-molecule (sm)FISH image acquisition
and analysis pipeline and followed viral RNA species from viral entry through the late
stages of persistent infection in vitro. We observed transcription of viral nucleoprotein and
polymerase mRNAs from the incoming S and L segment genomic RNAs, respectively,
within 1 hr of infection, whereas transcription of glycoprotein mRNA from the S segment
antigenome required ~4-6 hr. This confirms the temporal separation of viral gene
expression expected due to the ambisense coding strategy of arenaviruses and also suggests
that antigenomic RNA contained in virions is not transcriptionally active upon entry. Viral
replication and transcription peaked at 36 hours post-infection, followed by a progressive
loss of viral RNAs over the next several days. During persistence, the majority of cells in
culture showed repeating cyclical waves of viral transcription and replication followed by
clearance of viral RNA. Thus, our data support a model of LCMV persistence whereby
infected cells spontaneously clear infection and become reinfected by viral reservoir cells
that remain in the population.
59

2.2. Importance
Arenaviruses are human pathogens that can establish asymptomatic, life-long
infections in their rodent reservoirs. Lymphocytic choriomeningitis mammarenavirus
(LCMV) is carried in nature by the common house mouse and can be transmitted from
mother to pup. Because pups recognize viral antigens as self, they are unable to mount
an effective T cell response to clear infection. Yet LCMV, despite being able to infect
most cells in the host, restricts its spread and several models have been proposed to
explain this regulation. We developed a high throughput, single-molecule RNA FISH
assay to profile the dynamics of LCMV genome replication and transcription in
individual cells. Our findings provide novel insights in the timing of replication and
transcription, the composition of virus particles and the functionality of their packaged
viral RNA species, and suggest a revised model for how LCMV restricts its spread among
susceptible host cells during persistent infection.
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2.3. Introduction
Several members of the arenavirus family are significant threats to human health.
Lassa virus and Junín virus cause hemorrhagic fever syndromes while lymphocytic
choriomeningitis virus (LCMV), the prototypic member of the family, is a well-known
cause of severe birth defects and is highly lethal in immunocompromised individuals
(Buchmeier et al., 2007; Fischer et al., 2006). A critical imperative to better understand the
key steps of the arenavirus life cycle is made evident by the fact that there are no FDAapproved vaccines to prevent arenavirus transmission and only a very limited repertoire of
antivirals (Enria et al., 2008; McCormick et al., 1986). New strategies to prevent and treat
arenavirus infections will likely hinge upon an improved understanding of key phases of
the life cycle of these important human pathogens.
Arenaviruses are enveloped viruses that have a single-stranded, bisegmented,
negative-sense RNA genome. The ~3.5 kb small (S) and ~7.2 kb large (L) genomic RNA
segments each encode two viral open reading frames in ambisense orientation (Figure
2.1A) (Buchmeier et al., 2007). The nucleoprotein (NP) and polymerase (L) genes are
encoded in typical negative-sense orientation on genomic RNA while the glycoprotein
(GPC) and matrix protein (Z) genes are encoded in pseudo positive-sense orientation. The
canonical sequence of genetic events following the release of arenavirus genomic RNA
into the cytoplasm of a newly infected cell is (i) primary transcription of the NP and L
mRNAs from the viral S and L genomic segments, respectively, followed by (ii) full length
replication of the S and L segment antigenomic RNAs and subsequent transcription of the
GPC and Z mRNAs from the S and L antigenomic RNAs, respectively, and (iii) replication
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of additional full-length genomic RNAs from the antigenomic RNA templates (Figure
2.1A) (Buchmeier et al., 2007; Meyer et al., 2002).
While rodent-borne arenaviruses cause severe diseases in humans, they are thought
to be asymptomatic in their sylvatic hosts, where they can establish a persistent, life-long
infection (Buchmeier et al., 2007). LCMV is carried by the common house mouse and can
be transmitted vertically from mother to pup (Buchmeier et al., 1980; Buchmeier and Zajac,
1999; Lehmann-Grube et al., 1983). The pups are born infected but never mount an
effective immune response to clear the virus as viral proteins are seen as self-antigens by
the pup’s developing immune system (Buchmeier et al., 1980; Buchmeier and Zajac, 1999;
Lehmann-Grube et al., 1983) . Paradoxically, while LCMV can infect most cells in the host
rodent, it tightly regulates its spread and therefore does not overrun its host. Several
hypotheses have been proposed for how LCMV restricts its spread, including through (i)
the production of defective interfering (DI) particles (Burns and Buchmeier, 1993; Huang
and Baltimore, 1970; Oldstone, 1998), which can enter susceptible host cells and make
them refractory to productive infection (Huang, 1973; Welsh et al., 1972) and (ii) the
accumulation of transcriptionally-defective genomic and antigenomic RNAs, which limit
viral protein expression and infectious virus production (Meyer et al., 2002; Meyer and
Southern, 1994, 1997). It has also been proposed that LCMV can establish a cyclical,
transient pattern of infection such that susceptible cells are productively infected for a short
time before clearing the virus and once again becoming susceptible to reinfection by
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neighboring cells that remain productively infected (Hotchin, 1973, 1974a, b; Hotchin et
al., 1975).
A current gap in our knowledge of how arenaviruses restrict their dissemination is
that we lack a detailed understanding of how the events of viral genome replication and
transcription are regulated during the acute and persistent phases of infection. Previous
studies examining the genetic events of arenavirus replication and transcription, including
those described above regarding the accumulation of transcriptionally defective RNAs
(Meyer et al., 2002; Meyer and Southern, 1994, 1997), relied on techniques such as
Northern blot or quantititative RT-PCR. Both are powerful techniques used to examine
RNA. Quantitative RT-PCR is exquisitely sensitive (Haist et al., 2015), and Northern blot
is able to specifically distinguish between each of the viral RNA species (Auperin et al.,
1984b; Francis and Southern, 1988a, b; Franze-Fernandez et al., 1987; Fuller-Pace and
Southern, 1988, 1989; Meyer and Southern, 1997; Polyak et al., 1995b; Shivaprakash et
al., 1988; Southern et al., 1987). However, both techniques measure RNA at a population
level and thus provide population average data. Variability in RNA expression between
individual cells in a heterogeneous population cannot be evaluated using these approaches.
Single-molecule RNA fluorescence in situ hybridization (smFISH) can bridge this
technical gap to allow for detection of RNAs with single-copy sensitivity in individual cells
by fluorescence microscopy (Raj et al., 2008). In the present study, we designed specific
smFISH probe sets to fluorescently-label different LCMV RNA species (Figure 2.1A) and
to quantitatively characterize their expression in single cells during the entire time course
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of arenavirus infection. Our studies confirm the temporal separation of LCMV negativesense and pseudo positive-sense gene expression and reveal a striking pattern of cyclical
loss and reappearance of viral RNA in individual cells during persistence. Our studies
provide fresh insight into the functional genetic composition of infectious virions, the
kinetics of transcription and replication in the hours immediately following initial
infection, and suggest a revised model of how viral replication and transcription are
regulated during persistence to restrict virus spread. Further, the image acquisition and
analysis pipeline developed here is easily adaptable to other viruses.
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2.4. Results
2.4.1. Visualization of LCMV RNA species in infected cells.
To visualize LCMV RNAs in cells by fluorescence microscopy, we designed
smFISH probe sets complementary to different viral RNA species (see overview in Figure
2.1A). An important feature of smRNA FISH is the ability to detect single RNA molecules
using multiple, singly-labeled oligonucleotide probes (Raj et al., 2008). The high signalto-noise ratio of the probe set binding to a specific target RNA yields single RNAs that
appear as bright spots. To validate our ability to specifically label arenavirus RNAs, we
used a cellular mRNA smFISH probe set specific for the housekeeping gene MDN1 as a
control (Figure 2.1B) for comparison with a smFISH probe set designed to target both the
viral S genome RNA and GPC mRNA (Figure 2.1C). MDN1 probes detect single
cytoplasmic mRNAs as well as sites of active transcription in the nucleus, where multiple
nascent RNAs are detected as more intense signals (Figure 2.1B). Next, we confirmed that
the viral RNA smFISH probe set is highly specific as fluorescent signal was absent in
uninfected cells, but bright spots were detected in LCMV-infected cells fixed at 24 hpi
(Figure 2.1C). Moreover, similar to smFISH staining obtained with our control MDN1,
individual smFISH spots were homogeneous in size, shape, and fluorescence intensity
(Figure 2.1B and C) consistent with the detection of single RNAs, as shown previously
(Raj et al., 2008; Zenklusen et al., 2008). Furthermore, in contrast to the nuclear transcribed
MDN1 mRNAs, viral RNAs were largely excluded from the nucleus, consistent with the
cytoplasmic viral life cycle (Figure 2.1B to C).
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2.4.2. smFISH probes complementary to viral mRNA species provide high signalto-noise staining.
We designed multiple smFISH probe sets to have specificity for different RNA
species produced during the course of the LCMV life cycle (Figure 2.1A). Specifically,
these probe sets target (i) S genome only, (ii) GPC mRNA and S genome, (iii) NP mRNA
and S antigenome, or (iv) L mRNA and L antigenome. When infected cells were stained
with probe sets complementary to “S genome only” or “S genome and GPC mRNA”
(referred to has “GPC mRNA/S genome” from this point forward), we noted high quality
staining with the GPC mRNA/S genome probes as evidenced by homogeneity in spot size,
shape, and intensity (Figure 2.2A) and high signal-to-noise ratio (Figure 2.3). The NP
mRNA/S antigenome and L mRNA/L antigenome probe sets yielded similar high quality
staining as evidenced by high signal-to-noise ratios (Figure 2.3). However, we noted lower
quality staining with the “S genome only” probes as evidenced by the dimmer staining
(Figure 2.2) and low signal-to-noise ratio (Figure 2.3). Moreover, the “S genome only”
probes yielded greater non-specific staining in uninfected cells, potentially leading to
detection of false-positive spurious events (Figure 2.2C) – perhaps an artifact of the long
exposure times and high light intensity needed to detect this less sensitive probe set binding
to its target. Similarly low signal-to-noise ratios were observed with probe sets specific for
“S antigenome only” or “L genome only” (data not shown). It is possible that the
encapsidation of genome and antigenome by viral nucleoprotein partially occludes smFISH
probe hybridization with these target RNA sequences and thus leads to the lower signal66

to-noise ratio observed with these probe sets. Therefore, use of these probe sets with cells
containing small numbers of viral RNAs would be problematic due to the level of
background staining observed (Figure 2.2C). However, these probe sets are effective when
paired with cells containing abundant copies of viral genome or antigenome (Figure 2.2B
and data not shown), which easily exceeds the quantity of background spots observed in
mock-infected control cells (Figure 2.2C). Because the probe sets that targeted an mRNA
plus either genome or antigenome provided the highest quality staining and sensitivity, we
elected to use these probe sets to follow the kinetics of viral transcription and replication
events in infected cells.
2.4.3. smFISH spot detection and quantification in individual LCMV-infected cells.
A primary goal of our study was to globally describe the kinetics of transcription
and replication of the LCMV genome from the early hours following viral entry through
the late stages of persistence. Ideally, we would be able to infect cells at a high multiplicity
of infection (MOI) and take snapshots of a population of synchronously infected cells at
time points throughout the entire course of arenavirus infection. However, we were obliged
to infect cells at a low MOI due to the characteristic high prevalence of DI particles present
in LCMV stocks (Ziegler et al., 2016b). Because only a small proportion of cells would be
productively infected upon viral inoculation, we needed to image a large population of cells
at each time point tested to provide an accurate portrait of the heterogeneity present in a
population of asynchronously infected cells. Thus, it was important for this study to both
image and quantitatively characterize the smFISH staining of viral RNAs in a high67

throughput fashion. To accomplish this goal, we automatically segmented the nuclei using
DAPI and cell outlines using CellMask Green fluorescent staining with CellProfiler
software (Kamentsky et al., 2011) (Figure 2.4A). Next, smFISH-labeled viral RNAs were
detected using FISH-quant software (Mueller et al., 2013) (Figure 2.4B). We were able to
image two distinct RNA smFISH probe sets labeled with spectrally-distinct fluorophores
in individual cells. This allowed us to characterize relative viral RNA expression levels
and compare localization of different viral RNAs (Figures 2.4B to C). We were able to
robustly quantify viral RNAs using FISH-quant across a range of expression levels. We
observed a linear relationship between the quantity of detected viral RNAs and the total
fluorescence signal in the smFISH channel up to approximately 1,000 RNAs/cell, after
which the number of detected viral RNAs reached a plateau (Figure 2.4D). This represents
the point at which smFISH spots are so dense, that we were no longer able to accurately
distinguish closely spaced RNAs. Examples of a cell displaying moderate levels of viral
RNAs where identification of diffraction limited spots was robust (Figure 2.4B) and a cell
with very high expression of viral RNAs where overcrowded spots are unable to be
effectively spatially resolved (Figure 2.4C) are shown for reference. Thus, when viral RNA
levels are relatively low (less than several hundred copies per cell) we have high confidence
in the accuracy of the quantification provided by FISH-quant. However, when viral RNA
levels are at their peak and RNAs are very dense, quantification should be considered an
underestimate of RNA expression levels.
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2.4.4. Viral RNA transcription and replication following viral entry.
We next aimed to monitor the early events of viral genomic transcription and
replication immediately following viral entry. Cells were infected with LCMV at an MOI
of 0.1, fixed at multiple time points, stained for NP mRNA/S antigenome, GPC mRNA/S
genome, or L mRNA/L antigenome, and several hundred cells were imaged and analyzed
at each time point (Table S2.1). As discussed above in relation to Figure 2.2, our probes
sets specific for only genome or antigenome (but not an additional complementary viral
mRNA) have low signal-to-noise ratios and sensitivity when compared to probe sets that
also target a viral mRNA. Importantly, FISH-quant was unable to detect viral genome or
antigenome spots in cells that had been infected with LCMV for less than 8 h (Figure 2.2
and data not shown). However, by 8 hpi and later, genome and antigenome spots become
detectable with these probe sets (Figure 2.2, B.R. King, S. Kellner, P.L. Eisenhauer, E.A.
Bruce, C.M. Ziegler, D. Zenklusen, and J. Botten, submitted for publication, and data not
shown). Therefore, in this set of experiments, smFISH spots detected with the NP mRNA/S
antigenome, GPC mRNA/S genome, or L mRNA/L antigenome probe sets prior to 8 hpi
are presumed to represent only the designated mRNA target in each case, whereas at 8 hpi
and later it is possible to detect a mixture of the targeted RNAs.
Representative images of cells infected from 0 to 6 hpi are shown (Figure 2.5A to
B). Notably, transcription of the NP mRNA and L mRNA is detected as early as 1 hour
following infection (Figure 2.5 and 2.6A to B) indicating primary transcription of the S
and L genomic RNA occurs soon after entry and uncoating of arenavirus virions. The GPC
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mRNA, on the other hand, is first detected at 6 hours following infection (Figure 2.5A and
2.6A and C). This delayed appearance of the GPC mRNA indicates that transcriptionally
competent S antigenomic RNA is not delivered into cells by incoming virions. Further, it
suggests that a 4-6 hour lag is required for the production of S antigenomic RNA, which
serves as the template for transcription of GPC mRNA (Figure 2.1A). This result is in
agreement with previous studies that examined arenavirus mRNA synthesis via Northern
blot (Franze-Fernandez et al., 1987; Meyer et al., 2002).
When examining the subcellular localization of NP mRNA and GPC mRNA or NP
mRNA and L mRNA pairs at 6 hpi or earlier, no overt colocalization between viral mRNAs
was noted (Figure 2.5A to B).
2.4.5. Disproportionate transcription of S segment genes early after infection.
For each probe set used in the experiments shown in Figures 2.5 and 2.6, the number
of false-positive viral RNAs detected in mock-infected cells was used to establish a
threshold to classify cells as either “positive” or “negative” for each of the tested viral RNA
species. At 6 hpi (a time point before virus in the initially infected cells could have
completed its life cycle and spread to adjacent, initially uninfected cells (Buchmeier et al.,
1978; Dutko and Pfau, 1978; Lehmann-Grube, 1971; Lehmann-Grube et al., 1975), we
observed that 65-90% of cells were positive for NP mRNA and 40% were positive for GPC
mRNA (Figure 2.6C to D). This high frequency of cells containing S segment-derived
transcripts was surprising given the fact we initially infected cells at an MOI of 0.1, and
thus would have expected approximately only 10% of cells to have been expressing viral
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RNAs at this early time point. However, at this same early time point, only 8% of cells
were positive for L segment-derived L mRNA (Figure 2.6D), which is consistent with the
expected frequency of viral RNA-positive cells based on the initial MOI. This result may
suggest that a high proportion of viral particles either fail to package the L genome or
alternatively deliver a transcriptionally-defective L genome.
2.4.6. Viral RNA replication and transcription at peak of acute infection.
To profile LCMV RNAs at the peak of infectious virus release during acute
infection, cells were infected with LCMV at an MOI of 0.01, fixed at various time points
between 12 and 96 hpi, stained for NP mRNA/S antigenome, GPC mRNA/S genome, or L
mRNA/L antigenome, and several hundred cells were imaged and analyzed at each time
point (Table S2.1). Levels of viral RNAs detected by each probe set rapidly increased over
the first 24 hours of infection (Figure 2.7A to B and 2.8A to B). The proportion of cells
positive for these viral RNAs also rapidly increased over the first 24 hours of infection
such that almost all cells had substantial levels of all viral RNAs (Figure 2.8C to D). Peak
viral transcription and replication occurred at 36 hours post infection (Figure 2.7A to B and
2.8A to B). At this time point, viral smFISH signal was very dense and true levels of viral
NP mRNA and GPC mRNA were likely underestimated due to inability of FISH-quant to
accurately count tightly packed viral RNAs in the cytoplasm of infected cells (Figure 2.4B
to C, 2.7A to B, and 2.8A to B). Furthermore, RNAs detected by the S segment-specific
probe sets greatly exceeded those detected by the L segment-specific probe set (10-35 fold
greater) between 12 and 96 hpi (Figure 2.8A to B, Table 2.1). Following peak viral
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transcription and replication at 36 hours post-infection, levels of viral RNAs began to
decrease (Figure 2.7A to B and 2.8A to B). The proportion of cells positive for L mRNA/L
antigenome expression decreased steadily beginning at 48 hours post-infection (Figure
2.8D). In contrast, all cells maintained NP mRNA/S antigenome and GPC mRNA/S
expression over this entire time period (Figure 2.8C to D).
2.4.7. Cyclical patterns of genome transcription and replication during persistent
infection.
Lastly, we wanted to examine the transcription and replication dynamics of
arenavirus genomic RNA during the persistent phase of infection. Cells were infected with
LCMV at an MOI of 0.01, fixed at multiple time points between 1.5 and 41 days (d)pi,
stained for NP mRNA/S antigenome, GPC mRNA/S genome, or L mRNA/L antigenome,
and several hundred cells were imaged and analyzed at each time point (Table S2.1).
Following peak RNA transcription and replication at 36 hpi, we observed the levels of NP
mRNA/S antigenome, GPC mRNA/S genome, or L mRNA/L antigenome decrease over
the next several days such that at 8 dpi, the majority of cells are negative for all of these
viral RNAs (Figure 2.9A to F). However, by 13 dpi, the levels of viral RNAs detected by
each probe set increase and the majority of cells are again positive for all viral RNAs
(Figure 2.9C and F). Viral RNA levels again fall and many cells are no longer positive for
viral RNA by 16 dpi. (Figure 2.9C and F). These cycles of increased levels of viral RNA
expression and increased frequency of viral RNA expressing cells in the population repeat
in a cyclical fashion multiple times over the first 41 days following infection (Figure 2.9).
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In summary, the sequential loss and reappearance of viral gene expression observed here
suggest a potential genetic signature of populations of cells persistently infected with
LCMV.
Throughout the time course of persistence examined in this study, NP mRNA/S
antigenome is generally expressed at higher levels than GPC mRNA/S genome (up to 5fold higher levels) (Figure 2.9B and Table 2.1). The ratio between levels of NP mRNA/S
antigenome and L mRNA/L antigenome over this time period is much more variable. At
time points such as 13 and 20 dpi when most cells in the culture are positively expressing
all viral RNA species, NP mRNA/S antigenome greatly outnumbers L mRNA/L
antigenome (~25-fold higher levels) (Figure 2.9E and Table 2.1). However, at other times
such as 8, 16, 27, and 34 dpi when substantial proportions of cells have lost expression of
one or more viral RNAs, the ratio between NP mRNA/S antigenome and L mRNA/L
antigenome in the double-positive cells is greatly reduced (~2-fold higher levels of NP than
L mRNA) (Figure 2.9E and Table 2.1). Notably, the magnitude of viral RNA expression
during persistence never returned the high levels observed at the peak of acute infection
(Figure 2.9).
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2.5. Discussion
In the current study, we developed a high throughput smFISH assay that allowed
us to visualize, single copies of LCMV RNAs in individual cells. Taking advantage of the
sensitivity and quantitative aspect of this assay, we tracked the dynamics of viral
replication and transcription spanning the moments following initial virus entry to late
times during persistent infection. We observed that transcription of the negative-sense
encoded NP and L mRNAs precede that of the pseudo positive-sense encoded GPC mRNA,
confirming the temporal separation of gene expression predicted by the ambisense coding
strategy of the arenaviruses and suggesting that antigenomic RNA in virions is not
transcriptionally active following release into a newly infected cell. Our studies
demonstrated a hierarchal pattern of expression among viral RNAs and indicate that many
infecting virus particles may lack L genomic RNA. Finally, over the course of persistent
infection, we observed repeated cycles whereby cells transition from supporting active
viral replication and transcription to clearing all viral RNAs. Collectively, these studies
advance our understanding of the natural history of arenavirus replication and transcription
and suggest a modified model for how arenaviruses may regulate these processes to limit
their impact on the fitness of their rodent reservoirs.
The smFISH assay developed here provided us with an opportunity to build upon
prior studies and examine arenavirus genome replication and transcription with greater
sensitivity and detail. Previous studies aimed at elucidating the early events of arenavirus
transcription and genome replication used Northern blot to visualize individual viral RNA
species (Franze-Fernandez et al., 1987; Fuller-Pace and Southern, 1988; Shivaprakash et
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al., 1988). Analysis of RNA from cells infected with LCMV or the New World arenavirus
Pichinde failed to detect viral RNA from infected cells prior to 9 hpi (Fuller-Pace and
Southern, 1988) or 12 hpi (Shivaprakash et al., 1988), respectively. In the setting of
infection with the New World arenavirus Tacaribe, Franze-Fernandez et al. detected S
genomic RNA and NP mRNA at 2 hpi and S antigenomic RNA at 4 hpi, while GPC mRNA
appeared several hours following the synthesis of S antigenomic RNA (Franze-Fernandez
et al., 1987). The earliest the viral L segment has been observed was at 12 hpi (Fuller-Pace
and Southern, 1988). In the current study, we are able to detect viral NP and L mRNAs at
1 hpi. Our data supports previous observations that viral NP mRNA expression occurs
immediately following infection, and that GPC mRNA expression occurs following a lag
of several hours (Franze-Fernandez et al., 1987; Meyer et al., 2002). By probing single
cells, we build upon this prior work by demonstrating that GPC mRNA expression is not
detected, even at low levels, in the first hours following infection. In light of previous
observations that antigenomic L and S segment RNAs are packaged in viral particles
(Franze-Fernandez et al., 1987; Haist et al., 2015), our inability to observe GPC mRNA in
cells immediately following viral entry suggests that S antigenomic RNA packaged in
virions is unable to be transcribed. Further, it suggests that GPC mRNAs are not packaged
into viral particles, as has been suggested for Z mRNA (Salvato and Shimomaye, 1989).
An interesting observation from our study was that, despite infecting cells at an
MOI of 0.1, ~65-90% of cells expressed one or more genes encoded on the S genomic
RNA segment at 6 hpi. Because it takes ~ 8 h for an infected cell to make new infectious
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progeny (Buchmeier et al., 1978; Dutko and Pfau, 1978; Lehmann-Grube, 1971; LehmannGrube et al., 1975), we were surprised to see such a high frequency of cells expressing
these viral mRNAs at a time when the originally-infected cells could not yet have spread
virus to additional uninfected cells in the monolayer. Notably, at this same 6 hpi time point,
approximately 8% of cells expressed viral L mRNAs, which is consistent with the utilized
MOI. This suggests that, within the viral stock, there may be a significant population of
incomplete viral particles that possess the S segment but lack the L segment genomic RNA
or a functional copy of this RNA. Considering that the genetic basis for how arenavirus DI
particles block the propagation of infectious virus particles is unknown, these results may
provide clues for future studies to define the mechanism at work.
A hallmark characteristic of LCMV infection is the ability to establish an
asymptomtatic, persistent infection in reservoir rodents (Francis et al., 1987). Further, it is
possible to recapitulate key aspects of this persistent infection in cell culture models of
infection (Lehmann-Grube, 1967; Lehmann-Grube et al., 1969; Meyer et al., 2002;
Oldstone and Buchmeier, 1982). One notable characteristic of cell culture models of
LCMV infection is the cyclical rise and fall of release of infectious virus seen during
persistence (Hotchin, 1974a; Hotchin et al., 1975; Lehmann-Grube, 1967; Lehmann-Grube
et al., 1969; Staneck et al., 1972). Several models have been proposed to explain how
LCMV restricts its spread to establish and maintain a noncytopathic persistent infection,
both in vitro and in vivo. The first suggests that DI particles, which are produced in
abundance by LCMV, can enter permissive host cells and interfere with the ability of
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standard infectious virus particles to successfully infect and complete the viral life cycle
(Burns and Buchmeier, 1993; Huang, 1973; Huang and Baltimore, 1970; Oldstone, 1998;
Welsh et al., 1972). Hotchin proposed a second model that he termed cyclical, transient
infection. In this model, cells infected with LCMV are initially productive in making
infectious virus particles, but later become refractory to superinfection and ultimately clear
virus, only to once again become susceptible to reinfection by the small number of cells
that remain productively infected (Hotchin, 1973, 1974a, b; Hotchin et al., 1975). Southern
and colleagues proposed a third model that was based upon the dynamics and genetic
identity of viral RNA species profiled during acute and persistent infection. In particular,
they demonstrated by Northern blot that LCMV RNAs (genome, antigenome, and mRNAs)
accumulate to high levels during persistence, both in vitro and in vivo (Francis and
Southern, 1988b; Meyer et al., 2002; Meyer and Southern, 1994, 1997). Further, they
showed that a proportion of these genomic and antigenomic RNAs, but not mRNAs,
contained short deletions in the untranslated regions at their termini (Meyer et al., 2002;
Meyer and Southern, 1993, 1994, 1997). They proposed that these deleted RNAs were
replication competent, but transcriptionally incompetent. These data suggest a model
where, during persistence, viral protein expression and infectious virus production are
inhibited due to the accumulation of high levels of transcriptionally defective genomic and
antigenomic RNAs. Further, because these deleted RNAs were found in virions, it was
proposed that they serve as the molecular basis for DI particle interference. Finally, it was
proposed that these deleted RNAs can be repaired by the viral polymerase to initiate bursts
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of productive replication/infectious virus production during persistence. This would
support the cyclical aspect of Hotchin’s model, but not the transience of infection as viral
genetic material would not be cleared from infected cells. Each of these models, whether
acting independently or in combination, would presumably restrict virus spread, allowing
the virus to minimize its impact on host fitness while retaining its ability to propagate and
ultimately maintain itself in nature.
In reality, it seems likely that a holistic model describing the establishment and
maintenance of arenavirus persistence will incorporate elements of each model. The data
in the current study, indeed, suggest elements of each could be important. Our observation
that many cells lose then regain expression of viral RNAs at multiple time points during
persistence strongly supports the hypothesis of coordinated cycles of viral clearance
followed by reinfection. Hotchins et al. demonstrated a similar pattern using the expression
of viral antigen and production of infectious virus as readouts (Hotchin, 1973, 1974a, b;
Hotchin et al., 1975). One interpretation of our data is that the loss of antigen expression
(and infectious virus production) seen in those studies was the result of cells completely
clearing virus, including viral genetic material. Alternatively, it is possible that loss of viral
antigen expression could have been due to the accumulation of transcriptionally-defective
genomes in infected cells. Because our smFISH probe sets for encapsidated genomic and
antigenomic RNAs lack the sensitivity seen by those that are specific for unencapsidated
viral mRNAs, it is possible that some of the cells examined do in fact contain very low
levels of terminally-deleted genomic or antigenomic RNAs. However, in this scenario, we
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feel the subsequent cycles of viral RNA rescue in most cells would be unlikely if
completely dependent on the repair of terminally truncated genomes through the addition
of random non-templated bases to regenerate functional terminal untranslated regions. We
think it more likely that the accumulation of transcriptionally non-functional genomes
along with the polymerase inhibitory activity of the viral Z protein (Cornu and de la Torre,
2001, 2002; Kranzusch and Whelan, 2011; Lopez et al., 2001) both play a key role in
negatively regulating viral transcription and replication following the peak of acute
infection, providing an environment that permits cells to eliminate infection. The
accumulation of terminally-deleted viral RNAs, if they are indeed the basis for DI particle
interference with standard virus, could further work to preserve host fitness by driving the
formation of DI particles to preserve nearby uninfected cells from infection. Reinfection
of susceptible cells with virus from productively-infected reservoir cells within the
population that express full length functional genome could restart the infection cycle as
evidenced by the near 100% of cells expressing viral RNAs at multiple subsequent
persistent time points. Being able to specifically visualize genomic and antigenomic RNAs
with improved sensitivity by smFISH will be important to further define the exact
mechanism employed by arenaviruses to restrict their spread and impact on host cells
during persistent infection.
In summary, we have used fluorescence microscopy to visualize fluorescentlylabeled arenavirus RNA molecules in infected cells. Further, we have described a flexible
labeling, imaging, and image analysis pipeline that could be easily adapted to interrogate
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the events of transcription or genomic replication of any RNA virus, particularly where it
is critical to image and quantify RNA levels in hundreds to thousands of cells per
experimental condition. We have taken advantage of this pipeline to gain new insights into
the transcription and replication kinetics of LCMV RNAs over the course of infection that
build upon previous studies. In particular, our data strongly support the transient, cyclical
infection model originally proposed by Hotchin (Hotchin, 1973, 1974a, b; Hotchin et al.,
1975) and suggest that, following a period of productive infection, cells can clear infection,
including viral genetic material, before becoming susceptible to reinfection. Further, our
data suggest that viral antigenomic RNA in virions may not be transcriptionally functional
upon virus entry and that a significant fraction of virus particles may lack functional L
genomic RNA. Our findings give new insights into longstanding questions about how viral
RNA transcription and replication are regulated during infection and how viruses may
establish a long-lived, persistent infection. Developing the ability to label genomic and
antigenomic RNAs with greater sensitivity will be an important next step toward the
construction of a quantitative model of the regulation of viral RNA replication and
transcription over time with the goal of explaining the oscillatory behavior of viral RNA
synthesis during persistence.
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2.6. Materials and Methods
2.6.1. Cells and Viruses.
A549 (CCL-185) were obtained from American Type Culture Collection (ATCC,
Manassas, VA). A549 cells were cultured in DMEM-F12 (11320-033, Thermo Fisher),
containing 10% fetal bovine serum and 1% Penicillin-Streptomycin (15140-163, Thermo
Fisher). LCMV Armstrong 53b was provided by J. L. Whitton (The Scripps Research
institute, La Jolla, CA). A549 cells were infected with LCMV Arm53b at an MOI of 0.1
(Figure 2.5 to 2.6) or an MOI of 0.01 (Figure 2.1, 2.2, 2.4, 2.7, 2.8, and 2.9). For
experiments examining late, persistent time points following infections, a T25 tissue
culture flask of A549 cells was infected. The flask of infected cells was trypsinized and
cells were plated on glass coverslips 24 hours prior to the reported time points where cover
slips were fixed, stained, and imaged as described below (Figure 2.9). Remaining cells
were diluted and re-plated in a T25 flask until 24 hours before the next examined time point
where this process was repeated.
2.6.2. Single molecule RNA-FISH.
Cells were plated on 14 mm round #1 glass coverslips. Following infection, cells
were briefly washed in room temperature DPBS (with Calcium and Magnesium)
(14040133, Thermo Fisher) and fixed in 4% PFA in 1x PBS for 10 minutes at room
temperature. Coverslips were washed twice in room temperature PBS and fixed again at 20○ C with 70% ethanol for at least two hours. Coverslips were washed twice with 2x SSC
(AM9770, Thermo Fisher) and washed once with 2x SSC and 10% Formamide (BP227,
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Fisher Scientific). smFISH probes to different viral RNA species (Figure 2.1A) were
designed using the Stellaris Probe Designer at https://www.biosearchtech.com/ (Table
S2.2). Unlabeled smFISH probes had a 3’ modified base with an amine functional group.
Pools of 48 individual smFISH probes to a particular target RNA were combined at
equimolar ratios and were covalently labeled with Cy3 (PA23001, GE Healthcare),
AlexaFluor 568 (A20003, Thermo Fisher), or Cy5 (PA25001, GE Healthcare) as
previously described (Zenklusen and Singer, 2010). Coverslips were placed face down on
a 100 ul drop of hybridization mix containing 75 ng of smFISH probe dissolved in
hybridization buffer composed of 10% dextran sulfate (D8906, Sigma-Aldrich), 2x SSC,
and 10% Formamide. Hybridization occurred in a humidified chamber at 37○ C overnight.
Coverslips were washed twice in 2x SSC, 10% formamide at 37○ C for 30 minutes.
Coverslips were then washed once in 1x PBS. For cellular segmentation, cells were stained
with HCS CellMask™ Green stain (H32714, Thermo Fisher) diluted at 50 ng/ml in PBS
for 5 minutes at room temperature (note: this is significantly more dilute than
recommended in the product information, but we found it necessary to prevent overstaining
cells and thus to prevent spectral bleed through into the AlexaFluor 568 fluorescence
channel). Nuclei were stained with 4’, 6-diamidino-2-phenylindole hydrochloride 30
(DAPI) (D9542, Sigma-Aldrich) at 1 µg/ml in PBS for 5 minutes at room temperature.
Cells were washed a final time in PBS, briefly washed in water, dried and mounted with
ProLong Gold Antifade Reagent (P36934, Thermo Fisher).
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2.6.3. Image Acquisition.
Wide-field fluorescent Z-stacks were acquired using a Nikon Ti Eclipse microscope
with a 60 × 1.4 NA objective. Samples were illuminated with an LED light-source
(Lumencor Spectra X light engine) with appropriate filter sets and images were captured
with a Hamamatsu Orca flash 4.0 LT sCMOS camera. Z-stacks were captured at 300 nm
increments, and the microscope was controlled by Nikon NIS Elements software. Captured
ND2 images were converted to Tiffs using the open source Bio-formats tool kit
(http://www.openmicroscopy.org/) (Goldberg et al., 2005).
2.6.4. Image Segmentation and Analysis.
DAPI and CellMask Green Z-stacks were projected using a focus-based projection
method as previously described (Tsanov et al., 2016). Projected DAPI images were used
for automatic nuclear segmentation in CellProfiler (Broad Institute) (Kamentsky et al.,
2011) and served as the seed for automatic secondary cellular segmentation using the
projected CellMask Green images (Figure 2.4A). Statistics including average pixel
intensity within the regions defined by primary and secondary segmentation were extracted
from maximum intensity projections of smFISH Z-stacks using CellProfiler (Figure 2.4B
to D).
Single smFISH labeled RNAs were detected and localized in 3D using FISH-quant
(Mueller et al., 2013). Briefly, smFISH Z-stacks were filtered using the “Dual Gaussian
Filter” and spots were detected using the “Local Maximum” method. As a large number of
acquired images required analysis, images were analyzed in “Batch Mode” with settings
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determined to give low rates of false positive detections. The signal-to-noise ratio of
different smFISH probe sets was determined as the average signal amplitude of identified
smFISH spots in an individual cell divided by the standard deviation of the fluorescent
signal in a region of the same cell where smFISH spots were absent (Figure 2.3).
Box and whisker plots were created using the ggplot2 package in R. The box
represents the interquartile range of the data with the center line representing the median.
Individual dots represent cells that are more than 1.5 times the interquartile range away
from the median of the data.

84

2.7. Funding Information
We also gratefully acknowledge funding support from NIH grants T32
HL076122-10 (BRK), T32 AI055402 (CMZ), R21 AI088059 (JB), and P20RR021905 &
P30GM118228 (Immunobiology and Infectious Disease COBRE awards) (JB). DZ is
supported by the Canadian Institute for Health Research (Project Grant-366682), Fond de
recherche du Quebec (Chercheur-boursier Junior 2), and the Canadian Foundation for
Innovation. CZ, FM, and AS were supported by Institut Pasteur and the Fondation pour la
Recherche Médicale (FRM). BRK was supported by a Chateaubriand fellowship from the
Office for Science & Technology at the Embassy of France in the United States. The
funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.

85

2.8. Acknowledgments
We gratefully acknowledge J. Lindsay Whitton for providing us with LCMV
strain Arm53b and Samir Rahman, Philippe Clerc, Christian Weber, and Sophie Abélanet
for technical assistance. We thank Pablo Navarro and Jason Stumpff for graciously offering
the use of their microscopy equipment and for providing their expertise and Jean-Michel
Arbona and Wei Ouyang for helpful discussions.

86

2.9. Tables
Table 2.1. Ratio in the expression levels of viral mRNAs in individual infected cells.

Early time
points (hpi)
MOI = 0.1

Peak time
points (hpi)
MOI = 0.01

Persistent
time (dpi)
MOI = 0.01

Time
Ratio NP mRNA and S
Ratio NP mRNA and S
points antigenome /GPC mRNA and S antigenome /L mRNA and
genome (± SD)
L antigenome (± SD)
0.5
ND
ND
1

ND

ND

2

ND

ND

3

ND

ND

4

a

4.3

±

3.4

6

a

6.0

±

4.0

14.7

±

9.5

8

4.9

±

4.1

14.8

±

12.1

10

5.6

±

5.4

12.5

±

9.7

12

5.0

±

4.9

10.8

±

9.5

12

4.6

±

4.1

8.8

±

6.7

24

3.5

±

3.4

14.8

±

7.2

36

2.3

±

1.9

18.0

±

12.8

48

2.2

±

1.2

28.7

±

14.8

60

2.9

±

1.2

34.1

±

13.3

72

2.9

±

1.1

30.1

±

16.2

96

4.0

±

1.9

24.5

±

13.4

1.5

2.3

±

1.6

10.2

±

12.3

4

4.3

±

2.0

10.5

±

10.4

6

3.9

±

2.4

4.9

±

6.8

8

1.0

±

0.7

2.0

±

3.0

13

4.4

±

2.8

24.1

±

23.9

16

1.8

±

1.7

2.4

±

3.5

20

6.2

±

3.7

28.1

±

23.5

23

3.2

±

2.0

5.8

±

7.3

27

4.9

±

4.2

2.7

±

4.5

30

4.0

±

2.3

9.1

±

8.9

34

0.7

±

1.2

2.2

±

3.4

37

4.5

±

3.8

6.1

±

9.1

41

1.0

±

1.3

7.3

±

9.0

ND

a

Note that for time points prior to 8 hpi, genomic and antigenomic RNAs are not detectable by FISH probe
sets with exclusive specificity for these RNAs (data not shown). Therefore, spots detected before 8 hpi are
presumed to represent only the mRNAs, but not the genome or antigenome, recognized by each respective
probe set. Spots detect at 8 hpi or later are presumed to be a mixture of all RNAs recognized by a particular
probe set (e.g. mRNA and genome or antigenome).
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2.10. Figures

88

Figure 2.1. LCMV RNA species can be specifically visualized using multiple, singly-labeled
oligonucleotide smFISH probes.
(A) Overview of the scheme used by arenaviruses to transcribe and replicate their single-stranded, ambisense,
bisegmented genome. smFISH probes that recognize the S segment genomic RNA are shown in gray, probes
that recognize the S segment genome and GPC mRNA are shown in red, probes that recognize the S segment
antigenome and NP mRNA are shown in green, and probes that recognize the L segment antigenome and L
mRNA are shown in pink. smFISH probe sets consist of pools of 48 individual 20mer oligonucleotides each
labeled with a single fluorophore at their 3’ terminus. (B) Uninfected cells were stained with a control
smFISH probe set specific to the cellular mRNA MDN1 labeled with Cy3. (C) Cells were either infected
with LCMV at an MOI of 0.01 or, as a control, remained uninfected (mock). Cells were fixed at 24 hpi and
stained with a Cy5-labeled smFISH probe set specific for S segment genomic RNA and GPC mRNA. Boxed
regions of the cell are magnified and shown in columns labeled “Zoom”. Green arrows indicate example
smFISH stained spots most likely representing single labeled RNAs. Nuclear (hatched line) and cytoplasmic
(solid line) boundaries are shown in blue. The same intensity levels for a particular probe set were applied to
all images of mock- and LCMV-infected cells to permit comparisons. Scale bars are 10 µm.
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Figure 2.2. smFISH probe sets recognizing viral mRNA species exhibit high signal-to-noise staining.
Mock- or LCMV-infected cells (24 hr pi) were simultaneously stained with smFISH probe sets specific for
either GPC mRNA and S genome (Cy5; green) or S genome only (AlexaFluor 568; red). Representative
LCMV infected cells with moderate (A) or high (B) levels of viral RNA as well as a representative mockinfected cell (C) are displayed. Multiple Z stacks were acquired spanning the thickness of the cell and max
intensity projections are displayed. Boxed regions of the cell are magnified and shown in rows labeled
“Zoom”. Nuclear (hatched line) and cytoplasmic (solid line) boundaries are shown in blue. (A to C) The
same intensity levels for a particular probe set were applied to all images of mock- and LCMV-infected cells
to permit comparisons. Scale bars are 10 µm.
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Figure 2.3. smFISH probe sets recognizing viral mRNA species exhibit high signal-to-noise staining
Signal-to-noise ratio of different smFISH probe sets labeled with the indicated fluorophores. Signal-to-noise
ratio was calculated as average amplitude of detected smFISH spots divided by the standard deviation of
signal in a region of the cell with no detected spots. The signal-to-noise ratio of 20 cells per smFISH probe
set labeled with the indicated fluorophore was calculated, and the mean and standard deviation are graphed.
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Figure 2.4. Automated detection and quantitation of LCMV RNAs labeled with spectrally distinct
fluorophores.
(A) Cell nuclei and cytoplasms were automatically segmented using focus-based projections of DAPI
(nuclei) or CellMask Green (cytoplasm) Z stacks acquired through the thickness of the cell. Note that pixel
intensities of the CellMask Green projection displayed here have been log transformed to aid visualization.
Nuclear (hatched line) and cytoplasmic (solid line) boundaries are shown in white. The scale bar is 10 µm.
(B and C) Maximum intensity projections of LCMV-infected cells were fixed 24 hpi and stained with
smFISH probe sets to the NP mRNA/S antigenome (Cy5; green) and GPC mRNA/S genome (A568; red).
The boxed region of each cell is magnified and shown in the row labeled “Zoom”. Cells were segmented
based on DAPI and CellMask Green staining (see panel A) and spots were detected and localized in 3D using
FISH-quant. Individually detected RNAs are circled in green (NP mRNA/S antigenome) or red (GPC
mRNA/S genome). The “Spots only” column shows only the position of detected spots in relation to the cell
boundaries defined by segmentation. Nuclear (hatched line) and cytoplasmic (solid line) boundaries are
shown in blue. The same intensity levels for a particular probe set were applied to both images of LCMVinfected cells to permit comparisons. The scale bar is 10 µm.
(D) Scatter plot shows the relationship between the fluorescence intensity in the smFISH channel in the
maximum intensity projection of smFISH images and the number of smFISH spots detected by FISH-quant
for LCMV-infected cells fixed 24 hpi and stained with the Cy5-labeled smFISH probes specific for NP
mRNA/S antigenome.
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Figure 2.5. Transcription of NP and L genes is detectable soon following infection while GPC
transcription exclusively occurs after a several hour lag.
Cells were infected with LCMV at an MOI of 0.1, fixed at various times following infection, and stained for
NP mRNA (green) using a Cy5-labeled NP mRNA/S antigenome probe set, GPC mRNA (red) using an
A568-labled GPC mRNA/S genome probe set (A) or NP mRNA (green) using an A568-labeled NP mRNA/S
antigenome probe set and L mRNA (magenta) using a Quasar 670-labeled L mRNA/L antigenome probe set
(B). Note that for the time points shown (less than 8 hpi), genomic and antigenomic RNAs are not detectable
by smFISH probe sets with exclusive specificity for these RNAs (data not shown). Therefore, spots detected
in this figure are presumed to represent only the mRNAs, but not the genome or antigenome, targeted by
each respective probe set. Nuclear (hatched line) and cytoplasmic (solid line) boundaries as determined by
Cell Profiler are shown in blue. Identified spots are outline by circles that are green for NP mRNA, red for
GPC mRNA, and magenta for L mRNA. (A and B) The same intensity levels for a particular probe set were
applied to all images of mock- and LCMV-infected cells across the time course to permit comparisons.
Representative maximum intensity projections from 1 of 2 independent experiments are shown. Scale bar is
10 µm.
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Figure 2.6. Transcription of NP and L genes is detectable immediately upon infection while GPC
transcription exclusively occurs after a several hour lag.
Related to Figure 2.5. (A and B) Boxplots represent the number of viral RNAs detected in cells at early time
points following infection with LCMV (see Figure 2.5). (C and D) Stacked bar graphs show the proportion
of cells expressing RNAs detected by one, both, or neither viral RNA smFISH probe set. Between 620 and
1316 cells were examined at each time point (see Table S2.1 for exact numbers). In each case RNAs identified
by specific probe sets are designated by color (green for NP mRNA/S antigenome probes, red for GPC
mRNA/S genome probes, and magenta for L mRNA/L antigenome probes). Note that for time points prior
to 8 hpi, genomic and antigenomic RNAs are not detectable by smFISH probe sets with exclusive specificity
for these RNAs (data not shown). Therefore, spots detected before 8 hpi are presumed to represent only the
mRNAs, but not the genome or antigenome, recognized by each respective probe set. Spots detected at 8 hpi
or later are presumed to be a mixture of all RNAs recognized by a particular probe set (e.g. mRNA and
genome or antigenome).
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Figure 2.7. Peak viral RNA replication and transcription occurs 36 hpi and is slowly lost from infected
cells over the following days.
Cells were infected with LCMV at an MOI of 0.01, fixed at various times following infection, and stained
using smFISH probe sets specific for NP mRNA/S antigenome (Cy5; green) and GPC mRNA/S genome
(A568; red) (A) or NP mRNA/S antigenome (A568; green) and L mRNA/L antigenome (Quasar 670;
magenta) (B). (A and B) Representative maximum intensity projections of fields of infected cells at various
time points from 1 of 2 independent experiments are shown. Each probe set is shown in its own row to
highlight the difference in levels to which these RNAs accumulate. The same intensity levels for a particular
probe set were applied to all images of mock- and LCMV-infected cells across the time course to permit
comparisons. Scale bars = 10 µm.
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Figure 2.8. Peak viral RNA replication and transcription occurs 36 hpi and is slowly lost from infected
cells over the following days.
Related to Figure 2.7. (A and B) Boxplots represent the number of mRNAs detected in cells at time points
during the peak period of LCMV infection. (C and D) Stacked bar graph shows the proportion of cells
expressing RNAs detected by one, both, or neither viral smFISH probe set. Between 480 and 1659 cells were
examined at each time point (see Table S2.1 for exact numbers). RNAs identified by specific probe sets are
designated by color (green for NP mRNA/S antigenome probes, red for GPC mRNA/S genome probes, and
magenta for L mRNA/L antigenome probes).
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Figure 2.9. Cyclic periods of viral RNA production and viral RNA loss occur during persistence.
Cells were infected with LCMV at an MOI of 0.01, fixed at the indicated time points following infection,
and stained using smFISH probe sets specific for NP mRNA/S antigenome (Cy5; green) and GPC mRNA/S
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genome (A568; red) (A) or NP mRNA/S antigenome (A568; green) and L mRNA/L antigenome (Quasar
670; magenta) (D). (A and D) Representative maximum intensity projections of fields of infected cells at
various time points from 1 of 2 independent experiments are shown. Each probe set is shown in its own row
to highlight the difference in levels to which these RNAs accumulate. The same intensity levels for a
particular probe set were applied to all images of mock- and LCMV-infected cells across the time course to
permit comparisons. Scale bar is 10 µm. (B and E) Line graphs show the average number of the indicated
viral RNAs detected in cells at time points during the persistent phase of LCMV infection. (C and F) Stacked
bar graph shows the proportion of cells expressing RNAs detected by one, both, or neither viral smFISH
probe set. Between 316 and 1218 cells were examined at each time point (see Table S2.1 for exact numbers).
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2.12. Supplemental Tables
Table S2.1. Number of cells analyzed at each time point in selected Figures
Number of cells analyzed per FISH probe set per time point in Figures 5 & 6

Hours post infection

NP mRNA/ S antigenome GPC
mRNA/ S genome

L mRNA/L antigenome NP
mRNA/ S antigenome

0

752

634

1

759

659

2

1228

699

3

1316

748

4

1173

691

6

758

620

8

1037

645

10

940

629

12

1195

740

Number of cells analyzed per FISH probe set per time point in Figures 7 & 8

Hours post infection

NP mRNA/ S antigenome GPC
mRNA/ S genome

L mRNA/L antigenome NP
mRNA/ S antigenome

0

1119

760

12

733

494

24

757

480

36

731

565

48

789

585

60

719

494

72

886

713

96

1659

1064

Number of cells analyzed per FISH probe set per time point in Figure 9

Days post infection

NP mRNA/ S antigenome GPC
mRNA/ S genome

L mRNA/L antigenome NP
mRNA/ S antigenome

0

813

787

1.5

541

440

4

659

602

6

1130

649

8

955

787

13

649

316

106

16

1006

920

20

1181

902

23

997

903

27

1143

956

30

1046

874

34

1183

824

37

970

802

41

1218

926
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Table S2.2. Full list and sequence of the FISH probes used in the current study
Target

Probe Sequence

Probe Name

Fluorophore

LCMV S Genome

tttagaggcccaaatgttgt

LCMV_S_Genome_1

AlexaFluor 568

LCMV S Genome

gctcccagatctgaaaactg

LCMV_S_Genome_2

AlexaFluor 568

LCMV S Genome

cactcatggactgcatcatt

LCMV_S_Genome_3

AlexaFluor 568

LCMV S Genome

tcgatgttgaaatgaccagg

LCMV_S_Genome_4

AlexaFluor 568

LCMV S Genome

ggactcacagaataggaagg

LCMV_S_Genome_5

AlexaFluor 568

LCMV S Genome

ccgatgacatcagaaagctt

LCMV_S_Genome_6

AlexaFluor 568

LCMV S Genome

atggttctaagctgtcaagg

LCMV_S_Genome_7

AlexaFluor 568

LCMV S Genome

tcgtcagttataggtgctct

LCMV_S_Genome_8

AlexaFluor 568

LCMV S Genome

gatcttgccgacctcttcaa

LCMV_S_Genome_9

AlexaFluor 568

LCMV S Genome

gattccaagtactcacacgg

LCMV_S_Genome_10

AlexaFluor 568

LCMV S Genome

ggaacccgttgatcaaaaac

LCMV_S_Genome_11

AlexaFluor 568

LCMV S Genome

cgggcagttcatacactttt

LCMV_S_Genome_12

AlexaFluor 568

LCMV S Genome

tgatccagtggaaatagcaa

LCMV_S_Genome_13

AlexaFluor 568

LCMV S Genome

caacgctcctacatggattg

LCMV_S_Genome_14

AlexaFluor 568

LCMV S Genome

tacagccagacaatgctttt

LCMV_S_Genome_15

AlexaFluor 568

LCMV S Genome

agaaacctgcagtcaattca

LCMV_S_Genome_16

AlexaFluor 568

LCMV S Genome

gcatgggaaaacacaacaat

LCMV_S_Genome_17

AlexaFluor 568

LCMV S Genome

gatggccatacatagcttgt

LCMV_S_Genome_18

AlexaFluor 568

LCMV S Genome

aaagtttgcctttcaggtga

LCMV_S_Genome_19

AlexaFluor 568

LCMV S Genome

caggaacccttatgaaaaca

LCMV_S_Genome_20

AlexaFluor 568

LCMV S Genome

ttgtttcagaccaagttggg

LCMV_S_Genome_21

AlexaFluor 568

LCMV S Genome

ggccaagagaaaactcaaca

LCMV_S_Genome_22

AlexaFluor 568

LCMV S Genome

gacctcttgaaggcagttct

LCMV_S_Genome_23

AlexaFluor 568

LCMV S Genome

ttttgatcaagccaagcaac

LCMV_S_Genome_24

AlexaFluor 568

LCMV S Genome

aactttagtcttggtgctgc

LCMV_S_Genome_25

AlexaFluor 568

LCMV S Genome

gtcatcactgaacagcagtc

LCMV_S_Genome_26

AlexaFluor 568

LCMV S Genome

tcttgaaaggctgaaagaca

LCMV_S_Genome_27

AlexaFluor 568

LCMV S Genome

ggcttgctttacacagtcaa

LCMV_S_Genome_28

AlexaFluor 568

LCMV S Genome

tcaatgacgttgtacaagcg

LCMV_S_Genome_29

AlexaFluor 568

LCMV S Genome

ctatggcttgtatggccaaa

LCMV_S_Genome_30

AlexaFluor 568

LCMV S Genome

aatcaatttggcacaatgcc

LCMV_S_Genome_31

AlexaFluor 568

LCMV S Genome

gggatgtgaaagactcatca

LCMV_S_Genome_32

AlexaFluor 568

LCMV S Genome

ttgggatgagaaagcctcag

LCMV_S_Genome_33

AlexaFluor 568

LCMV S Genome

gaccaaagatctcagatcct

LCMV_S_Genome_34

AlexaFluor 568

LCMV S Genome

gggaacttaacaacacagca

LCMV_S_Genome_35

AlexaFluor 568

LCMV S Genome

ccaggcttcaggggtatata

LCMV_S_Genome_36

AlexaFluor 568

LCMV S Genome

ccaagatcatgaggtctgaa

LCMV_S_Genome_37

AlexaFluor 568
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LCMV S Genome

gctgaccttgagaagctgaa

LCMV_S_Genome_38

AlexaFluor 568

LCMV S Genome

cagtgcagaagaactgatgt

LCMV_S_Genome_39

AlexaFluor 568

LCMV S Genome

actgtacattctcttgtgga

LCMV_S_Genome_40

AlexaFluor 568

LCMV S Genome

gagactcagaagtctcaacc

LCMV_S_Genome_41

AlexaFluor 568

LCMV S Genome

aagagagatgacaaagacct

LCMV_S_Genome_42

AlexaFluor 568

LCMV S Genome

cttctctgaggtcagcaatg

LCMV_S_Genome_43

AlexaFluor 568

LCMV S Genome

ccaaccttctgaatgggttg

LCMV_S_Genome_44

AlexaFluor 568

LCMV S Genome

ggctgctgtcattaaggatg

LCMV_S_Genome_45

AlexaFluor 568

LCMV S Genome

gcagagcttcacatcagatg

LCMV_S_Genome_46

AlexaFluor 568

LCMV S Genome

cgcaagcattgagaagagaa

LCMV_S_Genome_47

AlexaFluor 568

LCMV S Genome

aggaagttaagagcttccaa

LCMV_S_Genome_48

AlexaFluor 568

LCMV NP mRNA/ S antigenome

ttggaagctcttaacttcct

LCMV_NP_mRNA_1

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

ttctcttctcaatgcttgcg

LCMV_NP_mRNA_2

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

catctgatgtgaagctctgc

LCMV_NP_mRNA_3

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

catccttaatgacagcagcc

LCMV_NP_mRNA_4

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

caacccattcagaaggttgg

LCMV_NP_mRNA_5

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

cattgctgacctcagagaag

LCMV_NP_mRNA_6

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

gttcttctgcactgagcctc

LCMV_NP_mRNA_7

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

aggtcagccgcaagagacat

LCMV_NP_mRNA_8

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

ctgaagcctggggcctttca

LCMV_NP_mRNA_9

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

tgtgttgttaagttccccat

LCMV_NP_mRNA_10

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

ctgagatctttggtctagtt

LCMV_NP_mRNA_11

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

tcatcccaactatctgtagg

LCMV_NP_mRNA_12

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

cttgcaccctgctgaggctt

LCMV_NP_mRNA_13

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

gatgagtctttcacatccca

LCMV_NP_mRNA_14

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

tgtgccaaattgattgttca

LCMV_NP_mRNA_15

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

aagccatagttagacttggc

LCMV_NP_mRNA_16

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

gtctgtgactgtttggccat

LCMV_NP_mRNA_17

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

ttgtacaacgtcattgagcg

LCMV_NP_mRNA_18

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

ttgactgtgtaaagcaagcc

LCMV_NP_mRNA_19

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

tgtctttcagcctttcaaga

LCMV_NP_mRNA_20

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

gcagcaccaagactaaagtt

LCMV_NP_mRNA_21

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

gttgcttggcttgatcaaaa

LCMV_NP_mRNA_22

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

gagaactgccttcaagaggt

LCMV_NP_mRNA_23

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

tgttgagttttctcttggcc

LCMV_NP_mRNA_24

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

cccaacttggtctgaaacaa

LCMV_NP_mRNA_25

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

tgttttcataagggttcctg

LCMV_NP_mRNA_26

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

tcacctgaaaggcaaacttt

LCMV_NP_mRNA_27

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

acaagctatgtatggccatc

LCMV_NP_mRNA_28

AlexaFluor 568 or Cy5
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LCMV NP mRNA/ S antigenome

attgttgtgttttcccatgc

LCMV_NP_mRNA_29

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

gagttgactgcaggtttctc

LCMV_NP_mRNA_30

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

aggtggacctgctgctccag

LCMV_NP_mRNA_31

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

cattgtctggctgtagctta

LCMV_NP_mRNA_32

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

ctcccatgaggtcttttaaa

LCMV_NP_mRNA_33

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

caatccatgtaggagcgttg

LCMV_NP_mRNA_34

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

ttgctatttccactggatca

LCMV_NP_mRNA_35

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

aaaagtgtatgaactgcccg

LCMV_NP_mRNA_36

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

gtttttgatcaacgggttcc

LCMV_NP_mRNA_37

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

tgagtacttggaatcttgct

LCMV_NP_mRNA_38

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

agaggtcggcaagatccatg

LCMV_NP_mRNA_39

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

gtcaacccgggttgcgcatt

LCMV_NP_mRNA_40

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

cggaagagcacctataactg

LCMV_NP_mRNA_41

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

ttgacagcttagaaccatcc

LCMV_NP_mRNA_42

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

gctttctgatgtcatcggag

LCMV_NP_mRNA_43

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

ttcctattctgtgagtccag

LCMV_NP_mRNA_44

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

aacatcgataagcttaatgt

LCMV_NP_mRNA_45

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

tcgaagcttccctggtcatt

LCMV_NP_mRNA_46

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

tttcagatctgggagccttg

LCMV_NP_mRNA_47

AlexaFluor 568 or Cy5

LCMV NP mRNA/ S antigenome

cacaacatttgggcctctaa

LCMV_NP_mRNA_48

AlexaFluor 568 or Cy5

LCMV GPC mRNA/ S genome

agagcctcaaacattgtcac

LCMV_GPC_mRNA_1

AlexaFluor 568

LCMV GPC mRNA/ S genome

cacctcatcgatgatgtgag

LCMV_GPC_mRNA_2

AlexaFluor 568

LCMV GPC mRNA/ S genome

cgtgatcacgataagcacaa

LCMV_GPC_mRNA_3

AlexaFluor 568

LCMV GPC mRNA/ S genome

gcaaaattgtagacagcctt

LCMV_GPC_mRNA_4

AlexaFluor 568

LCMV GPC mRNA/ S genome

caatgcgaatatcccacagg

LCMV_GPC_mRNA_5

AlexaFluor 568

LCMV GPC mRNA/ S genome

cagccagaagtaggaaactg

LCMV_GPC_mRNA_6

AlexaFluor 568

LCMV GPC mRNA/ S genome

cttaagaccgtacatgccac

LCMV_GPC_mRNA_7

AlexaFluor 568

LCMV GPC mRNA/ S genome

ctcctttgtaaatgtcgggt

LCMV_GPC_mRNA_8

AlexaFluor 568

LCMV GPC mRNA/ S genome

actccactgacttaaattgg

LCMV_GPC_mRNA_9

AlexaFluor 568

LCMV GPC mRNA/ S genome

catggtcaggttcagatgtg

LCMV_GPC_mRNA_10

AlexaFluor 568

LCMV GPC mRNA/ S genome

gagttgttggctgaacatgc

LCMV_GPC_mRNA_11

AlexaFluor 568

LCMV GPC mRNA/ S genome

agaagtccccatactgatgt

LCMV_GPC_mRNA_12

AlexaFluor 568

LCMV GPC mRNA/ S genome

cattggtgaaggtcaattct

LCMV_GPC_mRNA_13

AlexaFluor 568

LCMV GPC mRNA/ S genome

cagattgcaaaagttgtgac

LCMV_GPC_mRNA_14

AlexaFluor 568

LCMV GPC mRNA/ S genome

ggctcgaaactatactcatg

LCMV_GPC_mRNA_15

AlexaFluor 568

LCMV GPC mRNA/ S genome

ttccctctgatactgaggtg

LCMV_GPC_mRNA_16

AlexaFluor 568

LCMV GPC mRNA/ S genome

ggatactgccttatagttgg

LCMV_GPC_mRNA_17

AlexaFluor 568

LCMV GPC mRNA/ S genome

ttatgccattgttgaagtcg

LCMV_GPC_mRNA_18

AlexaFluor 568

LCMV GPC mRNA/ S genome

gttctacactggctctgagc

LCMV_GPC_mRNA_19

AlexaFluor 568
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LCMV GPC mRNA/ S genome

atctaggactctacctctga

LCMV_GPC_mRNA_20

AlexaFluor 568

LCMV GPC mRNA/ S genome

ccccgaaggcagttctaaac

LCMV_GPC_mRNA_21

AlexaFluor 568

LCMV GPC mRNA/ S genome

aggtggtcttgccatctgag

LCMV_GPC_mRNA_22

AlexaFluor 568

LCMV GPC mRNA/ S genome

gtattggtaactcgtctggc

LCMV_GPC_mRNA_23

AlexaFluor 568

LCMV GPC mRNA/ S genome

ccaaaaggacctgcatatgt

LCMV_GPC_mRNA_24

AlexaFluor 568

LCMV GPC mRNA/ S genome

ggaaaggagaatcctggaca

LCMV_GPC_mRNA_25

AlexaFluor 568

LCMV GPC mRNA/ S genome

agtgaagaacttagtcttct

LCMV_GPC_mRNA_26

AlexaFluor 568

LCMV GPC mRNA/ S genome

tgaatgtgcccgctagtctc

LCMV_GPC_mRNA_27

AlexaFluor 568

LCMV GPC mRNA/ S genome

ccctgaagagtctgacaaag

LCMV_GPC_mRNA_28

AlexaFluor 568

LCMV GPC mRNA/ S genome

gcaataaccacctggattct

LCMV_GPC_mRNA_29

AlexaFluor 568

LCMV GPC mRNA/ S genome

tgcagcaagaatcatccatt

LCMV_GPC_mRNA_30

AlexaFluor 568

LCMV GPC mRNA/ S genome

tgttcccgaaacacttaagc

LCMV_GPC_mRNA_31

AlexaFluor 568

LCMV GPC mRNA/ S genome

tacattgcatttcgcaactg

LCMV_GPC_mRNA_32

AlexaFluor 568

LCMV GPC mRNA/ S genome

tcaattagtcgcagcatgtc

LCMV_GPC_mRNA_33

AlexaFluor 568

LCMV GPC mRNA/ S genome

ttactcaaagcagccttgtt

LCMV_GPC_mRNA_34

AlexaFluor 568

LCMV GPC mRNA/ S genome

aagtgcaaggcagattctac

LCMV_GPC_mRNA_35

AlexaFluor 568

LCMV GPC mRNA/ S genome

tcaaagaattcactgttgtt

LCMV_GPC_mRNA_36

AlexaFluor 568

LCMV GPC mRNA/ S genome

agtggttcctcatcagtagt

LCMV_GPC_mRNA_37

AlexaFluor 568

LCMV GPC mRNA/ S genome

gtaattgcaatatggcaccc

LCMV_GPC_mRNA_38

AlexaFluor 568

LCMV GPC mRNA/ S genome

tgttctaggtaccaaaactt

LCMV_GPC_mRNA_39

AlexaFluor 568

LCMV GPC mRNA/ S genome

actagtttcgccggtctttg

LCMV_GPC_mRNA_40

AlexaFluor 568

LCMV GPC mRNA/ S genome

agtaagaaccattggtgaca

LCMV_GPC_mRNA_41

AlexaFluor 568

LCMV GPC mRNA/ S genome

tcactgaagtgggtctcatt

LCMV_GPC_mRNA_42

AlexaFluor 568

LCMV GPC mRNA/ S genome

atcggcttcctgttcgattt

LCMV_GPC_mRNA_43

AlexaFluor 568

LCMV GPC mRNA/ S genome

gcaggaagatgctgactaga

LCMV_GPC_mRNA_44

AlexaFluor 568

LCMV GPC mRNA/ S genome

cttttatgtgcctgtgtgtt

LCMV_GPC_mRNA_45

AlexaFluor 568

LCMV GPC mRNA/ S genome

tcctttgttggttaatcggt

LCMV_GPC_mRNA_46

AlexaFluor 568

LCMV GPC mRNA/ S genome

caccaggcaccttaaatgca

LCMV_GPC_mRNA_47

AlexaFluor 568

LCMV GPC mRNA/ S genome

cgtcttttccagacggtttt

LCMV_GPC_mRNA_48

AlexaFluor 568

LCMV L mRNA/L antigenome

ctctcatcctgttctatata

LCMV_L_mRNA_1

Quasar 670

LCMV L mRNA/L antigenome

tcccagaaagttgagtttct

LCMV_L_mRNA_2

Quasar 670

LCMV L mRNA/L antigenome

caatcagaaccattctgggt

LCMV_L_mRNA_3

Quasar 670

LCMV L mRNA/L antigenome

cagcgtgacagcaacttgag

LCMV_L_mRNA_4

Quasar 670

LCMV L mRNA/L antigenome

ttgtctgcactgtctatttc

LCMV_L_mRNA_5

Quasar 670

LCMV L mRNA/L antigenome

tgtttccacagacttatcgt

LCMV_L_mRNA_6

Quasar 670

LCMV L mRNA/L antigenome

tgtctatcagcttgtaacca

LCMV_L_mRNA_7

Quasar 670

LCMV L mRNA/L antigenome

caaaactggctggagtgctc

LCMV_L_mRNA_8

Quasar 670

LCMV L mRNA/L antigenome

ctgatgcatgccaatttgtt

LCMV_L_mRNA_9

Quasar 670

LCMV L mRNA/L antigenome

tggaactaatgtgacacccg

LCMV_L_mRNA_10

Quasar 670
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LCMV L mRNA/L antigenome

gatagtagtcttcagggact

LCMV_L_mRNA_11

Quasar 670

LCMV L mRNA/L antigenome

ttttcatagagtccataccg

LCMV_L_mRNA_12

Quasar 670

LCMV L mRNA/L antigenome

attatgagttgacctcgcat

LCMV_L_mRNA_13

Quasar 670

LCMV L mRNA/L antigenome

ggcacatcctcataatttca

LCMV_L_mRNA_14

Quasar 670

LCMV L mRNA/L antigenome

atctcttctaaacctgctga

LCMV_L_mRNA_15

Quasar 670

LCMV L mRNA/L antigenome

gtttctctttaatttcccac

LCMV_L_mRNA_16

Quasar 670

LCMV L mRNA/L antigenome

cttcagggtttactttctga

LCMV_L_mRNA_17

Quasar 670

LCMV L mRNA/L antigenome

gagctcagagaattccttga

LCMV_L_mRNA_18

Quasar 670

LCMV L mRNA/L antigenome

tcatcactatcagcaaggtt

LCMV_L_mRNA_19

Quasar 670

LCMV L mRNA/L antigenome

ctccctgcttaatgttaaga
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LCMV_L_mRNA_35

Quasar 670

LCMV L mRNA/L antigenome

aattaaatgaccatccgggc
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CHAPTER 3:
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3.1. Abstract
We report a fluorescence in situ hybridization (FISH) assay that allows the
visualization of lymphocytic choriomeningitis mammarenavirus (LCMV) genomic RNAs
in individual cells. We show that viral S segment genomic and antigenomic RNA, along
with viral nucleoprotein, colocalize in subcellular structures we presume to be viral
replication factories. These viral RNA structures are highly dynamic during acute infection,
with the many small foci seen early coalescing into larger perinuclear foci later in infection.
These late-forming perinuclear viral RNA aggregates are located near the cellular
microtubule organizing center and colocalize with the early endosomal marker Rab5c and
the viral glycoprotein in a proportion of infected cells. We propose that the virus is using
the surface of a cellular membrane bound organelle as a site for the pre-assembly of viral
components including genomic RNA and viral glycoprotein prior to their transport to the
plasma membrane where new particles will bud.
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3.2. Main Text
The major events of transcription and replication of the arenavirus genomic RNA
are well understood at a population level (Figure 3.1A) (Fuller-Pace and Southern, 1988;
Haist et al., 2015). However, technical limitations of Northern blot and quantitative RTPCR have hindered our ability to examine these processes in individual cells and to
visualize these events with subcellular resolution. Recent improvements in fluorescence in
situ hybridization (FISH) technologies now permit the fluorescent labeling and
microscopic visualization of RNA species at the single-cell and single-molecule level (Raj
et al., 2008). This labeling strategy, relying on pools of fluorescently labeled 20mer
oligonucleotide probes, allows visualization of target RNAs with a high signal-to-noise
ratio and exquisite specificity (Raj et al., 2008). The replication dynamics of influenza A
and Rift Valley Fever viruses (an orthomyxovirus and bunyavirus, respectively) have been
examined using this RNA FISH labeling strategy, and have revealed subcellular sites of
genomic RNA replication, assembly, and/or selectivity of genome recruitment into
assembling particles (Chou et al., 2013; Lakdawala et al., 2014; Wichgers Schreur and
Kortekaas, 2016).
Arenaviruses, like orthomyxoviruses and bunyaviruses, have a single-stranded,
segmented, negative-sense RNA genome (Buchmeier et al., 2013). Previous work has
suggested that the genomic RNA of Tacaribe virus (a New World arenavirus) associates
with intracellular membranes (Baird et al., 2012). However, fluorescence microscopy
visualizing the subcellular distribution of viral RNAs (nonspecifically-labeled with a
chemically modified nucleotide) with various protein markers failed to identify the
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subcellular compartment targeted by the virus (Baird et al., 2012). In the present study, we
used pools of singly labeled FISH probes to specifically visualize the genomic RNA of
lymphocytic choriomeningitis virus (LCMV), the prototypic mammarenavirus, with the
goal to (i) define the dynamics of genomic RNA replication during the course of acute
infection, (ii) characterize the subcellular localization of the genomic and antigenomic
RNA, (iii) identify the membrane-bound compartment targeted by arenavirus genomic
RNA, and (iv) describe how the virus may be taking advantage of this virus-targeted,
intracellular compartment.
The arenaviruses have a bisegmented genome with each genomic segment
encoding two genes in ambisense polarity (Buchmeier et al., 2013). The S genomic
segment contains the negative-sense nucleoprotein (NP) gene and the pseudo-positivesense glycoprotein precursor (GPC) gene (Figure 3.1A) (Buchmeier et al., 2013). The
Stellaris Probe Designer tool (Biosearch Technologies, Inc.) was used to design custom
pools of 3' amine oligo FISH probes that would specifically hybridize to the S genomic or
S antigenomic RNAs (Figure 3.1A, Table S3.1). Probes were labeled post synthesis with
Cy3 or Cy5 dyes and purified as described previously (Zenklusen and Singer, 2010). To
follow the replication dynamics of the S genomic and S antigenomic RNAs, we infected
A549 cells with LCMV at a MOI of 0.01, fixed infected cells as previously described (Raj
et al., 2008) at the indicated times post-infection, and performed FISH hybridization with
S genome and S antigenome probes as previously described (Castelnuovo et al., 2013). 3D
datasets spanning the entire volume of the cells were acquired using a DeltaVision
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restoration microscopy system (GE Healthcare), and images were deconvolved using
softWoRx software. Bright signal was observed in cells infected with LCMV, but very
little signal was detected in uninfected cells, confirming that FISH probes specifically
recognize S genome and S antigenome (Figure 3.1B to C). As expected, RNA signal was
mainly observed in the cytoplasm, where S genome and S antigenome concentrated in
cytoplasmic foci of varying size, brightness, and subcellular localization (Figure 3.1B to
C). It is known that genomic and antigenomic RNA is encapsidated by the viral NP
(Buchmeier et al., 2013). Thus, we stained for both the viral NP and the S genome to
confirm their colocalization. For joint protein and RNA staining, we combined the
immunofluorescence and FISH staining protocols as previously described (Song et al.,
2015). NP and S genome strongly colocalized in LCMV-infected cells (Figure 3.1D). The
line scan of the two fluorescent signals (shown in the inset in Figure 3.1D) further confirms
the colocalization between NP and S genome (Figure 3.1E).
Baird et al. (Baird et al., 2012) referred to foci of Tacaribe virus RNA colocalizing
with viral NP as “replication-transcription complexes.” With the ability to label bona fide
arenavirus genomic and antigenomic RNA, we next wanted to profile the composition and
dynamics of these viral replication complexes. We first asked whether S genome and S
antigenome traffic to distinct subcellular locations or whether they remain associated in the
same subcellular compartments. We therefore stained for both viral RNAs within the same
cells and found that S genome and S antigenome exhibit strong colocalization, supporting
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the idea that the genomic and antigenomic RNAs remain in close spatial proximity at the
peak of acute infection (Figure 3.1F to G).
To explore the temporal evolution of viral replication complexes, we next infected
A549 cells with LCMV, fixed cells at different time points post-infection, and stained for
S genome and S antigenome (Figure 3.2). At 8 hours post-infection (h p.i.), S genome and
S antigenome first become visible as small spots that are distributed throughout the
cytoplasm, likely representing single viral genomes (Figure 3.2). Interestingly, few of these
individual genome and anti-genome signal co-localize, suggesting that clustering of viral
RNAs occur at a later stage during infection. At 12 and 24 h p.i., many cytoplasmic S
genome/S antigenome foci are visible, and their size and intensity progressively increases,
as well as the frequency of co-localization of genome and anti-genome signal (Figure 3.2).
At 48 h p.i., in many cells, the multiple bright cytoplasmic foci coalesce into one or a few
large aggregates located adjacent to the nucleus (Figure 3.2).
We were intrigued by the perinuclear localization of genomic RNA at the peak of
acute infection and hypothesized that the arenavirus S genome RNA foci seen earlier in
infection might be utilizing minus end-directed transport along microtubules to coalesce in
larger structures near the cell’s microtubule organizing center (MTOC). To test this, we
stained cells for both gamma-tubulin (a marker of the MTOC) and S genome. Indeed, in
most cases we found the perinuclear S genome aggregate was located immediately adjacent
to the MTOC (Figure 3.3A). Previous observations that arenavirus ribonucleoprotein
complexes copurified with cellular membranes (Baird et al., 2012), together with our
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observation that perinuclear S genome aggregates concentrate near the MTOC, led us to
postulate that the S genome could be localizing to endosomal membranes and taking
advantage of this organelle’s directed transport along microtubules (Nielsen et al., 1999).
It was previously demonstrated that Rab5c, an early endosomal marker (Bucci et al., 1995),
was required for the propagation of LCMV (Panda et al., 2011). Rab5c is a Rab GTPase, a
family of proteins that play critical roles in establishment of vesicular identity, trafficking,
and effector protein recruitment (Stenmark, 2009). Thus, we hypothesized that S genomic
RNA may be localizing to Rab5c positive membranes to promote some aspect of the
LCMV life cycle. To test this, we stained cells infected with LCMV for either 24 or 48
hours with an antibody specifically recognizing Rab5c and with FISH probes specific for
S genome. Notably, at 48 h p.i., in a subset of cells, we observed increased levels of Rab5c
and a perinuclear redistribution of this protein that resulted in strong colocalization with
viral genome (Figure 3.3B to D). However, the colocalization of S genome appeared highly
time-dependent as no colocalization was observed at 24 h p.i. (Figure 3B to D). These data
suggest that Rab5c may play an important role late in the LCMV life cycle, complementing
previous work showing the importance of Rab5 for arenavirus entry (Martinez et al., 2009;
Rojek et al., 2008). Furthermore, our observation of Rab5c’s involvement in the replication
of arenaviral RNA is intriguing in light of other studies showing Rab5c as a cellular
dependency factor for the replication of Zika virus, a flavivirus (Savidis et al., 2016).
Our finding that Rab5c colocalizes with LCMV RNA was somewhat surprising
given that previous work by Baird et al. did not observe any colocalization of Tacaribe
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virus replication-transcription complexes with endosomal markers, including Rab5a,
which is closely related to Rab5c (Baird et al., 2012; Bucci et al., 1995). The previous
studies of Tacaribe virus examined a single time point after infection. Given the temporal
specificity of the Rab5c-LCMV RNA association observed in the current study, it is
possible that New World arenaviruses like Tacaribe do associate with endosomal markers,
but that a kinetic study would be required to uncover such a result. Alternatively, it is
possible that individual arenaviruses utilize different host machinery for genome
replication and virus assembly. Indeed, related studies in our laboratory have demonstrated
that replication of LCMV, but not the New World arenavirus Junín Candid #1, is impaired
following siRNA silencing of Rab5c (C. M. Ziegler, P. Eisenhauer, J. A. Kelly, L. N. Dang,
V. Beganovic, E. A. Bruce, B. R. King, D. J. Shirley, M. E. Weir, B. A. Ballif, and J.
Botten, unpublished results). This result, which confirms the previously demonstrated
importance of Rab5c for LCMV propagation (Panda et al., 2011), suggests that Old World
arenaviruses such as LCMV, but not those of the New World lineage, are uniquely
dependent upon Rab5c for successful completion of the life cycle. Further studies will be
required to determine the extent to which Rab5c and other proteins in the Rab GTPase
family are utilized by genetically diverse arenaviruses.
It is known that arenaviruses bud from the plasma membrane of infected cells
(Buchmeier et al., 2007). Why, then, would LCMV S genome concentrate on the surface
of Rab5c positive vesicular structures in infected cells? One possibility is that these
structures represent sites where different viral components pre-assemble before being
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trafficked together to the plasma membrane for budding. Indeed, it has been suggested that
influenza

A

virus

uses

Rab11-positive

membranes

for

trafficking

of

viral

ribonucleoproteins to the plasma membrane (Amorim et al., 2011; Eisfeld et al., 2011;
Momose et al., 2011). To test this possibility in the current system, we stained for another
LCMV structural protein, its glycoprotein (GPC) (monoclonal antibody 33.6 (Weber and
Buchmeier, 1988)), and S genome at 12, 24, and 48 h p.i.. We found that at 48 h p.i., in
most cells, there was a high degree of colocalization between GPC and S genome (Figure
3.3E to G). As with Rab5c, the colocalization between these two viral components was
variable at different stages of infection, and little colocalization was observed at earlier
time points (Figure 3.3E to G). As no direct NP-GPC interaction has been reported in the
literature, GPC recruitment to encapsidated S genomic RNA would likely be dependent on
the presence of the viral matrix protein, Z, which has been shown to interact with both NP
and GPC (Capul et al., 2007; Eichler et al., 2004).
In summary, we describe the use of single-molecule resolution RNA FISH to
specifically visualize LCMV S genome and S antigenome during the course of acute
infection. For the first time, we reveal that the S genome and antigenome largely
colocalize in the same subcellular structures during acute infection. Viral genomic RNA
is highly dynamic during the course of acute infection with many dim genomic RNA
foci, likely representing individual viral genomes, progressively increasing in intensity
and eventually coalescing into larger perinuclear structures, which, in many cells, appear
to colocalize with the early endosomal marker Rab5c –shown by us and others to have a
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critical role in supporting the LCMV life cycle (Panda et al., 2011) (C. M. Ziegler, P.
Eisenhauer, J. A. Kelly, L. N. Dang, V. Beganovic, E. A. Bruce, B. R. King, D. J. Shirley,
M. E. Weir, B. A. Ballif, and J. Botten, unpublished results). We propose LCMV is using
this intracellular membrane as a scaffold for genome replication and possibly preassembly of viral components prior to being trafficked to the plasma membrane where
they will bud as infectious virions.
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3.5. Figures
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Figure 3.1. Visualization of S genome and antigenomic RNAs by multiple, singly-labeled FISH probes.
(A) Diagram showing the transcription and replication scheme of the LCMV S genomic RNA. Briefly, S
genome serves as the template for the viral polymerase to generate full-length, antigenome replicative
intermediates. S genome and S antigenome serve as templates for transcription of the NP and GPC mRNAs,
respectively. FISH probe sets (each containing 48 individual 20mer probes bearing a single fluorophore at
their 3’ terminus) were used to specifically visualize either the S genomic or S antigenomic RNA.
(B) Maximum intensity projection of either mock- or LCMV-infected cells (48 h p.i.) stained with S genome
FISH probes labeled with Cy3.
(C) Maximum intensity projection of either mock- or LCMV-infected cells (48 h p.i.) stained with S
antigenome FISH probes labeled with Cy3.
(D) Single Z stack of either mock- or LCMV-infected cells (48 h p.i.) stained for S genome (Cy5) and LCMV
nucleoprotein (1-1.3 (from M. Buchmeier, University of California Irvine) [primary antibody] as previously
described (King et al., 2017); goat, anti-mouse AlexaFluor 488) [secondary antibody]).
(E) Fluorescence line scan of S genome and NP signals along the line indicated in the inset of the merged
image in (d).
(F) Single Z stack of either mock- or LCMV-infected cells (48 h p.i.) stained with S genome (Cy5) and S
antigenome (Cy3) FISH probes.
(G) Fluorescence line scan of S genome and S antigenome signals along the line indicated in the inset of the
merged image in (f). Scale bar = 10 µm.
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Figure 3.2. Dynamics of S genome and S antigenome during acute LCMV infection.
Cells were infected with LCMV at an MOI of 0.01 or not (mock) and fixed at multiple time points following
infection. Maximum intensity projections of cells stained with S genome (Cy5) and S antigenome (Cy3)
FISH probes are presented. Scale bar = 10 µm.
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Figure 3.3. LCMV S segment genome selectively colocalizes with Rab5c and viral glycoprotein later
during acute infection.
(A) At 48 h p.i., perinuclear S genome aggregates localize near the microtubule organizing center (MTOC)
as visualized by gamma-tubulin (GTU-88, Sigma-Aldrich [primary]; goat, anti-mouse AlexaFluor 488)
[secondary]) and S genome (Cy5-labeled FISH probes). A maximum intensity projection of a representative
cell is shown.
(B) Single Z stack of either mock- or LCMV-infected cells at the indicated time points after infection were
stained for S genome (Cy5-labeled FISH probes) and Rab5c (sc-365667, Santa Cruz Biotechnology
[primary]; goat, anti-rabbit AlexaFluor 488) [secondary]).
(C) Fluorescence line scan of S genome and Rab5c along the line indicated in the inset of the merged image
at 48 h p.i. (b) is shown.
(D) The Pearson’s correlation coefficient between S genome and Rab5c fluorescence signal in individual
infected cells at either 24 or 48 h p.i. was calculated in softWoRx software and the scores of individual cells
were graphed.
(E) Single Z stacks of either mock- or LCMV-infected cells that were stained for S genome (Cy5-labeled
FISH probes) and viral glyocoprotein (GPC) (mouse anti-GPC, 33.6 (from M. Buchmeier, University of
California Irvine) [primary] at 1:500; goat, anti-mouse AlexaFluor 488) [secondary]) are shown.
(F) Fluorescence line scan of S genome and GPC along the line indicated in the inset of the merged image at
48 h p.i. (e) is shown.
(g) The Pearson’s correlation coefficient between S genome and GPC fluorescence signal in individual
infected cells at either 12, 24, or 48 h p.i. was calculated in softWoRx software and the scores of individual
cells were graphed.
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3.7. Supplemental Table
Table S3.1. Full list and sequence of the FISH probes used in the current study.
Target

Probe Name

Probe Sequence (5' to 3')

LCMV S Genome

Genome 1

tttagaggcccaaatgttgt

LCMV S Genome

Genome 2

gctcccagatctgaaaactg

LCMV S Genome

Genome 3

cactcatggactgcatcatt

LCMV S Genome

Genome 4

tcgatgttgaaatgaccagg

LCMV S Genome

Genome 5

ggactcacagaataggaagg

LCMV S Genome

Genome 6

ccgatgacatcagaaagctt

LCMV S Genome

Genome 7

atggttctaagctgtcaagg

LCMV S Genome

Genome 8

tcgtcagttataggtgctct

LCMV S Genome

Genome 9

gatcttgccgacctcttcaa

LCMV S Genome

Genome 10

gattccaagtactcacacgg

LCMV S Genome

Genome 11

ggaacccgttgatcaaaaac

LCMV S Genome

Genome 12

cgggcagttcatacactttt

LCMV S Genome

Genome 13

tgatccagtggaaatagcaa

LCMV S Genome

Genome 14

caacgctcctacatggattg

LCMV S Genome

Genome 15

tacagccagacaatgctttt

LCMV S Genome

Genome 16

agaaacctgcagtcaattca

LCMV S Genome

Genome 17

gcatgggaaaacacaacaat

LCMV S Genome

Genome 18

gatggccatacatagcttgt

LCMV S Genome

Genome 19

aaagtttgcctttcaggtga

LCMV S Genome

Genome 20

caggaacccttatgaaaaca

LCMV S Genome

Genome 21

ttgtttcagaccaagttggg

LCMV S Genome

Genome 22

ggccaagagaaaactcaaca

LCMV S Genome

Genome 23

gacctcttgaaggcagttct

LCMV S Genome

Genome 24

ttttgatcaagccaagcaac

LCMV S Genome

Genome 25

aactttagtcttggtgctgc

LCMV S Genome

Genome 26

gtcatcactgaacagcagtc

LCMV S Genome

Genome 27

tcttgaaaggctgaaagaca

LCMV S Genome

Genome 28

ggcttgctttacacagtcaa

LCMV S Genome

Genome 29

tcaatgacgttgtacaagcg

LCMV S Genome

Genome 30

ctatggcttgtatggccaaa

LCMV S Genome

Genome 31

aatcaatttggcacaatgcc

LCMV S Genome

Genome 32

gggatgtgaaagactcatca

LCMV S Genome

Genome 33

ttgggatgagaaagcctcag

LCMV S Genome

Genome 34

gaccaaagatctcagatcct

LCMV S Genome

Genome 35

gggaacttaacaacacagca
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LCMV S Genome

Genome 36

ccaggcttcaggggtatata

LCMV S Genome

Genome 37

ccaagatcatgaggtctgaa

LCMV S Genome

Genome 38

gctgaccttgagaagctgaa

LCMV S Genome

Genome 39

cagtgcagaagaactgatgt

LCMV S Genome

Genome 40

actgtacattctcttgtgga

LCMV S Genome

Genome 41

gagactcagaagtctcaacc

LCMV S Genome

Genome 42

aagagagatgacaaagacct

LCMV S Genome

Genome 43

cttctctgaggtcagcaatg

LCMV S Genome

Genome 44

ccaaccttctgaatgggttg

LCMV S Genome

Genome 45

ggctgctgtcattaaggatg

LCMV S Genome

Genome 46

gcagagcttcacatcagatg

LCMV S Genome

Genome 47

cgcaagcattgagaagagaa

LCMV S Genome

Genome 48

aggaagttaagagcttccaa

LCMV S Antigenome

Antigenome 1

ggtgtaaaaaccgtctggaa

LCMV S Antigenome

Antigenome 2

accgattaaccaacaaagga

LCMV S Antigenome

Antigenome 3

ataaaaggtggctcatgtcc

LCMV S Antigenome

Antigenome 4

ctagtcagcatcttcctgca

LCMV S Antigenome

Antigenome 5

gatgttttccacatctgcat

LCMV S Antigenome

Antigenome 6

ccctagcattgatggacctt

LCMV S Antigenome

Antigenome 7

aacaggaagccgataacatg

LCMV S Antigenome

Antigenome 8

aaatgagacccacttcagtg

LCMV S Antigenome

Antigenome 9

gcttgtcaccaatggttctt

LCMV S Antigenome

Antigenome 10

gaaactagtgtccccaagtg

LCMV S Antigenome

Antigenome 11

acctagaacatgcaaagacc

LCMV S Antigenome

Antigenome 12

gggtgccatattgcaattac

LCMV S Antigenome

Antigenome 13

actactgatgaggaaccact

LCMV S Antigenome

Antigenome 14

gtagaatctgccttgcactt

LCMV S Antigenome

Antigenome 15

aggctgctttgagtaagttc

LCMV S Antigenome

Antigenome 16

gctgcgactaattgactaca

LCMV S Antigenome

Antigenome 17

tcatgatgccgaattctgtg

LCMV S Antigenome

Antigenome 18

cagttgcgaaatgcaatgta

LCMV S Antigenome

Antigenome 19

gcttaagtgtttcgggaaca

LCMV S Antigenome

Antigenome 20

aatggatgattcttgctgca

LCMV S Antigenome

Antigenome 21

agaatccaggtggttattgc

LCMV S Antigenome

Antigenome 22

acattcacctggactttgtc

LCMV S Antigenome

Antigenome 23

tcttcactaggagactagcg

LCMV S Antigenome

Antigenome 24

tctcctttcccaagagaaga

LCMV S Antigenome

Antigenome 25

acatatgcaggtccttttgg

LCMV S Antigenome

Antigenome 26

atagaacctgggaaaaccac
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LCMV S Antigenome

Antigenome 27

gccagacgagttaccaatac

LCMV S Antigenome

Antigenome 28

atgtttagaactgccttcgg

LCMV S Antigenome

Antigenome 29

agtgtagaaccttcagaggt

LCMV S Antigenome

Antigenome 30

ctcagatcgacaaagtgctc

LCMV S Antigenome

Antigenome 31

cagtatcctgcgacttcaac

LCMV S Antigenome

Antigenome 32

tcagagggaactccaactat

LCMV S Antigenome

Antigenome 33

tagtttcgagcctacacctc

LCMV S Antigenome

Antigenome 34

tttgaccacacactcatgag

LCMV S Antigenome

Antigenome 35

ttttgcaatctgacctctgc

LCMV S Antigenome

Antigenome 36

agaattgaccttcaccaatg

LCMV S Antigenome

Antigenome 37

acatcagtatggggacttct

LCMV S Antigenome

Antigenome 38

gcatgttcagccaacaactc

LCMV S Antigenome

Antigenome 39

cacatctgaacctgaccatg

LCMV S Antigenome

Antigenome 40

ccaatttaagtcagtggagt

LCMV S Antigenome

Antigenome 41

acccgacatttacaaaggag

LCMV S Antigenome

Antigenome 42

gtggcatgtacggtcttaag

LCMV S Antigenome

Antigenome 43

cagtttcctacttctggctg

LCMV S Antigenome

Antigenome 44

cctgtgggatattcgcattg

LCMV S Antigenome

Antigenome 45

aaggctgtctacaattttgc

LCMV S Antigenome

Antigenome 46

ttgtgcttatcgtgatcacg

LCMV S Antigenome

Antigenome 47

ctcacatcatcgatgaggtg

LCMV S Antigenome

Antigenome 48

gtgacaatgtttgaggctct

137

CHAPTER 4:
A MAP OF THE ARENAVIRUS NUCLEOPROTEIN-HOST PROTEIN
INTERACTOME REVEALS THAT JUNÍN VIRUS SELECTIVELY IMPAIRS
THE ANTIVIRAL ACTIVITY OF DOUBLE-STRANDED RNA-ACTIVATED
PROTEIN KINASE (PKR)

Benjamin R. King1,2, Dylan Hershkowitz1, Philip L. Eisenhauer1, Marion E. Weir3,#,
Christopher M. Ziegler1,2, Joanne Russo1,§, Emily A. Bruce1, Bryan A. Ballif3, Jason
Botten1,4*

1

Department of Medicine, Division of Immunobiology,

2

Cellular, Molecular, and

Biomedical Sciences Graduate Program, 3Department of Biology,

4

Department of

Microbiology and Molecular Genetics, University of Vermont, Burlington, VT 05405,
USA, #Current address: Cell Signaling Technology, Beverly, MA, 01915, §Current
address: Department of Integrative Physiology and Pathobiology, Tufts University School
of Medicine, Boston, MA 02111, *Corresponding author

Running Title: Junín virus antagonizes the antiviral activity of PKR
138

4.1. Abstract
Arenaviruses are enveloped negative-strand RNA viruses that cause significant
human disease. Encoding only four proteins to accomplish the viral life cycle, each
arenavirus protein likely plays unappreciated accessory roles during infection. Here, we
used immunoprecipitation and mass spectrometry to identify human proteins that interact
with the nucleoprotein (NP) of the Old World arenavirus lymphocytic choriomeningitis
(LCMV) and the New World arenavirus Junín Candid #1 (JUNV). Bioinformatic analysis
of the identified protein partners of NP revealed that host translation appears to be a key
biological process engaged during infection. In particular, NP associates with the dsRNAactivated protein kinase (PKR), a well-characterized antiviral protein that inhibits capdependent protein translation initiation via phosphorylation of eIF2α. JUNV infection leads
to increased expression of PKR as well as its redistribution to viral replication and
transcription factories. Further, phosphorylation of PKR, which is a prerequisite for its
ability to phosphorylate eIF2α, is readily induced by JUNV. However, JUNV prevents this
pool of activated PKR from phosphorylating eIF2α, even following exposure to the
synthetic dsRNA poly(I:C), a potent PKR agonist. This blockade of PKR function was
highly specific as LCMV was unable to similarly inhibit eIF2α phosphorylation. JUNV’s
ability to antagonize the antiviral activity of PKR appears to be complete as silencing of
PKR expression had no impact on viral propagation. In summary, we have provided a
detailed map of the host machinery engaged by the arenavirus NP and identified an
antiviral pathway that is subverted by JUNV.
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4.2. Importance
Arenaviruses are important human pathogens for which FDA-approved vaccines
do not exist and effective antiviral therapeutics are needed. Design of antiviral treatment
options and elucidation of the mechanistic basis of disease pathogenesis will depend on an
increased basic understanding of these viruses and, in particular, their interactions with
host cell machinery. Identifying host proteins critical for the viral life cycle and/or
pathogenesis represents a useful strategy to uncover new drug targets. This study, for the
first time, reveals the extensive human protein interactome of the arenavirus nucleoprotein
and uncovers a potent antiviral host protein that is neutralized during Junín virus infection.
In so doing, we have gained further insight into the interplay between the virus and the host
innate immune response and provided an important dataset for the field.
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4.3. Introduction
The arenaviruses are a family of enveloped RNA viruses that can cause severe
human disease. In particular, several family members, including Lassa virus (LASV) and
Junín virus (JUNV), cause hemorrhagic fever syndromes (Buchmeier et al., 2007).
Additionally, lymphocytic choriomeningitis virus (LCMV), which has a global
distribution, is an underappreciated human pathogen that represents a significant
teratogenic threat to developing fetuses and is a danger to immunosuppressed populations
(Buchmeier et al., 2007; Fischer et al., 2006). There are currently no FDA-approved
vaccines to prevent arenavirus infection and effective antiviral treatments are limited (Enria
et al., 2008; McCormick et al., 1986). Several of the arenaviruses require biosafety level
(BSL)-4 containment and are designated as Select Agents and potential bioterrorism threats
(Botten et al., 2013). This highlights the critical need for new prevention and treatment
options for these dangerous viruses, and the successful development of a next generation
antiviral therapeutic will depend on an improved understanding of the basic biology of the
arenavirus life cycle.
Arenaviruses have a single-stranded, bisegmented negative-sense RNA genome.
Each genomic RNA segment contains 2 open reading frames arranged in an ambisense
fashion (Buchmeier et al., 2001). The virus encodes only 4 proteins: the nucleoprotein (NP)
and glycoprotein (GPC) on the S genomic segment and the RNA-dependent RNA
polymerase (L) and viral matrix protein (Z) on the L genomic segment (Buchmeier et al.,
2001). These four viral proteins are sufficient to achieve all of the steps of the viral life
cycle. Nevertheless, it is likely that each is highly multifunctional and relies upon
141

interactions with multiple host proteins to facilitate key steps of the viral life cycle and/or
to subvert an effective host immune response.
The canonical role of the arenavirus NP is to encapsidate the viral genomic RNA
and aid the viral polymerase in the process of genome replication (Buchmeier et al., 2001).
NP also acts to prevent the induction of type I IFN via its ability to degrade dsRNA
substrates that could activate cytoplasmic RIG-I like receptors (Hastie et al., 2011a; Qi et
al., 2010). Work by other groups has already demonstrated the ability of the arenavirus NP
to engage in protein-protein interactions with host cellular proteins. However, only a few
host factors engaged by NP are known and the functional importance of these interactions
necessitates further investigation. Among the Old World arenaviruses, it was demonstrated
that ALIX/AIP1, an endosomal sorting complex required for transport (ESCRT) associated
protein, associates with NP and is necessary for the efficient recruitment of NP into Zinduced virus like particles (Shtanko et al., 2011). LCMV NP has been shown to interact
with IKKε, which contributes to its repression of type I IFN induction (Pythoud et al.,
2012). Keratin 1, also an interacting partner of LCMV NP, is important for the virus’s
ability to spread from cell to cell (Labudova et al., 2009). The New World arenavirus JUNV
NP was shown to associate with eIF4A and eIF4GI, and these interactions were important
for translation of viral mRNAs (Linero et al., 2013). Last, JUNV NP was shown to interact
with hnRNP A/B proteins, which were required for viral propagation (Maeto et al., 2011).
While a small number of cellular proteins have been shown to interact and/or colocalize
with the arenavirus NP, a large-scale mapping of the host cellular interactome of NP is
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necessary to fully appreciate the multifunctional role that this viral protein plays during the
viral life cycle.
Besides our appreciation of NP’s role in interfering with type I IFN induction and
its interaction with a handful of cellular proteins, little is known about the additional
accessory role(s) NP may play in the infected cells and how these may be affected by its
interaction with host proteins. To address this gap in our knowledge, we mapped the
cellular protein interactome of the arenavirus NP using LCMV, an Old World arenavirus
member, and the New World JUNV strain Candid #1 (Goni et al., 2006). Our studies
revealed that the arenavirus NP interacts with an extensive array of cellular proteins. In
particular, host protein translation appears to be a major cellular function targeted by the
arenavirus NP. We identified that the double-stranded RNA-activated protein kinase
(PKR), an important antiviral effector, interacts with both the JUNV and LCMV NP. We
show that, despite becoming highly activated during JUNV infection, PKR is unable to
carry out its canonical antiviral function, which is to phosphorylate eIF2α and trigger a
global shutdown of cap-dependent translation. LCMV similarly activates PKR but, unlike
JUNV, appears unable to fully suppress PKR’s kinase activity as transient eIF2α
phosphorylation occurs during LCMV infection. Nevertheless, the replication of both
viruses was unaffected by PKR silencing suggesting that arenaviruses have developed
strategies to neutralize this critical arm of the host innate immune response.
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4.4. Results
4.4.1. Identification of human proteins that associate with the arenavirus
nucleoprotein.
Viruses hijack cellular factors to complete necessary steps of their life cycle and/or
to evade the host immune response. Thus, discovering these host factors has the potential
to identify drug targets or help illuminate cellular pathways targeted by the virus. To
identify the cellular protein partners of the arenavirus NP, we employed a strategy in which
human cells (A549 or HEK 293T) were first infected with either the Old World arenavirus
LCMV strain Armstrong 53b or the New World arenavirus JUNV strain Candid #1
(hereafter referred to as JUNV) (Figure 4.1A). Following establishment of acute infection,
each NP and its associated cellular protein partners were immunoprecipitated from cell
lysates using an NP-specific monoclonal antibody. The immune complexes were separated
by SDS-PAGE, and stained with Coomassie blue to allow visualization of the captured NP
(bait) as well as its interacting host proteins (the prey) (Figure 4.1B to E). The stained SDSPAGE gels were cut into sections, and the proteins contained in each section were digested
with trypsin and extracted for subsequent liquid chromatography tandem mass
spectrometry (LC-MS/MS). Identified proteins were considered valid interactors in a given
run when i) 2 or more unique tryptic peptides were detected from a particular protein in the
infected sample but not the mock control or ii) when a minimum of five-fold more total
tryptic peptides was detected from a particular protein in the infected sample compared to
the mock control. Using these criteria, we identified 509 human proteins that associated
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with JUNV NP and 348 that associated with LCMV NP in at least one experiment (Figure
4.1F and Table S4.1). Of these proteins, 275 had a conserved interaction with JUNV NP
and LCMV NP (Figure 4.1F). Additionally, there was a high degree of reproducibility
when comparing the interacting host proteins between the 2 human cell lines, HEK 293T
and A549, where 83% of interacting proteins identified in HEK 293T cells were also
observed in A549 cells (Figure 4.1G). Thus, this data set represents the first large-scale
map of the arenavirus NP-human protein interactome.
4.4.2. Cellular processes targeted by the arenavirus NP.
We were especially interested in the 275 proteins that exhibited a conserved
interaction with both JUNV NP and LCMV NP as these could represent fundamental and
highly conserved aspects of arenavirus biology. Indeed, conserved hits for both viruses
were, on average, identified by more spectral counts than those of JUNV NP or LCMV NP
alone (Figure 4.2A). Because the strongest interactors were likely those identified by
multiple tryptic peptides, we examined in greater detail the “strong interactors” which were
in the top 25% of all interacting host proteins by spectral counts (Figure 4.2A and Table
4.1). However, it should be noted that the mass spectrometry approach used in this study
is semi-quantitative. It is possible that a strong, specific interacting cellular protein may
not be detected at all or only at very low levels for technical reasons. Nevertheless, to better
characterize the subset of proteins detected by the highest number spectral counts, we used
the NIH DAVID functional annotation and gene-enrichment tool (Huang et al., 2009a, b)
to identify functional groups of proteins that may be over-represented in our dataset. Of
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the annotation clusters identified within this group, protein translation was the top process
engaged by the arenavirus NP (Figure 4.2B), suggesting that this may be a key cellular
process regulated by the virus during infection. Two important host protein partners
involved in translation were eukaryotic translation initiation factor 2 subunit alpha, eIF2α,
a translation initiation factor critical for the cap-dependent assembly of the 43S ribosomal
preinitiation complex (Garcia et al., 2007), and the double-stranded RNA-activated protein
kinase, PKR, which can lead to arrest of cellular translation in response to viral infection
via phosphorylation of eIF2α (Garcia et al., 2007) (Table 4.1 and S4.1). In addition, NIH
DAVID analysis on the subset of proteins interacting with only the JUNV NP or the LCMV
NP revealed functional processes of nucleotide binding or organelle/nuclear lumen being
engaged by the respective NPs (Figure 4.2D and E). Functional categories enriched in this
“strong interactor” subset were very similar to those categories represented by the dataset
as a whole (Figure 4.2B and C).
4.4.3. Biochemical validation of the interaction between cellular proteins and
arenavirus NPs.
We next chose a subset of the identified host proteins and attempted to further
validate their association with a particular arenavirus NP via immunoprecipitation and
Western blot. This subset of proteins included PKR, eIF2α, and Ras GTPase-activating
protein-binding protein 1 (G3BP1) (proteins involved in translation); splicing factor,
proline- and glutamine-rich (SFPQ) (part of several top clusters identified by the DAVID
analysis including RNA processing, binding, and stability); and apoptosis-inducing factor
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1, mitochondrial (AIFM1) (the most abundantly detected interacting partner of JUNV NP
and identified as being part of the organelle/nuclear lumen cluster by the DAVID analysis).
Each protein, with the exception of AIFM1, co-immunoprecipitated as prey with NP (bait)
from cells infected with JUNV or LCMV (Figure 4.3A, lane 3; Figure 4.3B, lane 3).
AIFM1 interacted specifically with JUNV NP but not LCMV NP while eIF2α interacted
weakly with LCMV NP compared to JUNV NP. Reciprocally, PKR, G3BP1, and AIFM1,
when serving as bait for immunoprecipitation from JUNV or LCMV-infected lysates, were
each able to co-precipitate both viral NPs, but JUNV NP interacted more strongly with
both AIFM1 and PKR when compared to LCMV NP (Figure 4.3C to H). Finally, we
addressed whether this subset of host proteins could associate with an arenavirus NP in the
absence of other viral proteins or the full viral genome. G3BP1, eIF2α, AIFM1, and SFPQ
interact with Lassa virus, LCMV, and JUNV NP (expressed via plasmid in HEK 293T
cells) while PKR only associates with JUNV NP (Figure 4.4A). Notably, the strength of
interaction between each host protein and a particular NP was variable (Figure 4.4A).
Additionally, immunoprecipitation of PKR and AIFM1 from transfected HEK 293T cells
was able to co-precipitate each of arenaviral NPs tested (Figure 4.4B and C).
4.4.4. PKR and G3BP1 colocalize with JUNV NP.
We next used fluorescence microscopy to determine whether PKR and G3BP1 were
recruited to the replication and transcription factories of JUNV or LCMV. In JUNVinfected cells, at 72 hours post-infection (hpi), the majority of the cells were infected, and
NP formed large, perinuclear puncta in most cells (Figure 4.5A). At 48 hpi in LCMV147

infected cells, most cells were infected and displayed a variable pattern of cytoplasmic NP
staining. LCMV NP concentrated into puncta that were either small and scattered through
the cytoplasm or large and located near the nucleus (Figure 4.5B). In the setting of JUNV
infection, total PKR signal increased compared to mock cells (Figure 4.5A). While PKR
staining was cytoplasmic in both infected and uninfected cells, JUNV infection resulted in
a relocalization and concentration of PKR in JUNV NP-containing puncta (Figure 4.5A,
see fluorescence intensity profiles). This was specific to JUNV as PKR protein levels were
not upregulated in LCMV-infected cells and PKR remained diffusely localized, without
specifically colocalizing with LCMV NP (Figure 4.5B, see fluorescence intensity profiles).
This finding is consistent with biochemical evidence suggesting that PKR has a stronger
association with JUNV NP compared to LCMV NP (Figure 4.3C and D and 4.4A).
G3BP1 generally displayed a diffuse cytoplasmic staining pattern in uninfected
cells (Figure 4.6), although some minority of uninfected cells spontaneously displayed
distinct cytoplasmic puncta of G3BP1 staining in presumed stress granule structures
(Figure 4.6A). Similar to PKR, a portion of the cytoplasmic G3BP1 concentrated in JUNV
NP puncta (Figure 4.6A, see fluorescence intensity profiles). In LCMV-infected cells,
G3BP1 maintained a predominantly diffuse cytoplasmic staining pattern with slight
enrichment at NP puncta (Figure 4.6B, see fluorescence intensity profiles).
Collectively, these experiments further validate the biological interaction of PKR
and G3BP1 with JUNV NP and define these host proteins as components/markers of

148

presumptive viral replication and transcription factories. Further, they show the specificity
of the NP-PKR interaction for JUNV.
4.4.5. PKR is activated following JUNV infection but does not phosphorylate eIF2α.
Because of the importance of PKR as an antiviral innate immune mediator (Garcia
et al., 2007) and the specificity of the interaction with the JUNV NP (Figure 4.3C and D,
4.4A, and 4.5), we next sought to functionally characterize the importance of this
interaction in the context of both New World and Old World arenavirus infections. Over a
time course of acute infection, cellular protein lysates were probed for phospho-PKR
(T446), a phosphorylation site in the activation loop and a marker of activated PKR. We
also probed for phospho-eIF2α (S51), the target of PKR’s kinase activity and a marker of
global translational shutdown. Both expression and phosphorylation of PKR were strongly
induced late in infection with JUNV, yet there was no concomitant increase in the
phosphorylation of PKR’s target, eIF2α, at these time points (Figure 4.7A to C). In LCMVinfected cells, overall PKR levels did not increase but there was an induction of
phosphorylation of PKR at 36 and 48 hpi. However, in contrast to JUNV, there was a small
yet significant increase in the phosphorylation of eIF2α at these time points (Figure 4.7D
to F). This suggested an ability of JUNV to prevent activated PKR from phosphorylating
its target eIF2α.
4.4.6. JUNV infection blocks poly(I:C)-induced phosphorylation of eIF2α.
The observation that PKR was highly activated (phosphorylated) in JUNV-infected
cells, yet this activated PKR failed to phosphorylate eIF2α, suggested that the virus was
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evading this innate surveillance pathway. To determine whether we could overcome the
ability of the virus to block active PKR from phosphorylating eIF2α, we transfected cells
with poly(I:C), a synthetic dsRNA analog that strongly activates PKR (Garcia et al., 2007).
When comparing mock-cells that had been transfected with lipofectamine but no poly(I:C)
(vehicle control) to those transfected with increasing quantities of poly(I:C),
phosphorylation of PKR was effectively induced by increasing concentrations of poly(I:C)
(Figure 4.8A, B, E, and F). In JUNV-infected cells, there were already high levels of
phospho-PKR (Figure 4.8A and B). However, transfection with poly(I:C) further increased
the induction of PKR phosphorylation (Figure 4.8A and B). In mock-infected cells, the
increased PKR phosphorylation following poly(I:C) transfection led to increased
phosphorylation of eIF2α (Figure 4.8A, C, E, and G). However, there was no increase in
the phosphorylation of eIF2α in JUNV-infected cells (Figure 4.8A and C). In LCMVinfected cells, phosphorylation of PKR could be further induced following poly(I:C)
transfection (Figure 4.8E and F). However, this active PKR was able to phosphorylate
eIF2α and there was no difference between phospho-eIF2α in mock-infected and LCMVinfected cells following poly(I:C) transfection (Figure 4.8E and G). Thus, JUNV appears
to specifically block activated PKR from phosphorylating its downstream target, eIF2α.
4.4.7. JUNV selectively blocks PKR’s functionality.
Though activated PKR’s canonical target is eIF2α, PKR can also activate alternate
signaling pathways. Among these alternate pathways is the activation of NF-κB signaling
(Zamanian-Daryoush et al., 2000), through an incompletely defined pathway. While the
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exact mechanism is unclear, it is known that IκB is degraded following PKR activation and
that this allows the nuclear translocation of the NF-κB transcription factor, and subsequent
expression of NF-κB responsive genes (Zamanian-Daryoush et al., 2000). To determine
whether this alternate PKR signaling pathway remained functional in cells expressing
arenavirus NPs, we also probed cellular protein lysates for IκB to see if it was degraded
following poly(I:C) transfection as would be expected. We saw that whether cells were
uninfected or infected with JUNV or LCMV, they were able to efficiently degrade IκB
following transfection with poly(I:C), suggesting that this alternate PKR signaling function
remains intact (Figure 4.8A, D, E, and H). An alternate possibility is that the observed IκB
degradation could be the result of signaling downstream of other innate immune sensors
capable of responding to dsRNA such as TLR3, RIG-I, or MDA5 (Kawai and Akira, 2008).
4.4.8. Translational profile of cells infected with JUNV or LCMV.
We wanted to examine whether eIF2α phosphorylation observed in LCMV- but not
JUNV-infected cells (Figure 4.7 and 4.8) was functionally correlated with repression of
global translation in these cells. To assess rates of active translation, we utilized a newly
described assay to examine protein translation levels in individual cells infected with either
LCMV or JUNV (David et al., 2012; Schmidt et al., 2009). At various time points
following infection, cells were pulse-labeled with puromycin, which is covalently
incorporated into growing peptide chains. Nascent peptides were detected with a
puromycin-specific monoclonal antibody, and were visualized by confocal microscopy.
Mock-infected cells were labeled with puromycin to determine normal translation rates
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whereas mock-infected cells that were pre-treated with sodium arsenite were labeled to
determine protein production levels in a repressed translational state (Figure 4.9A to D).
While cells infected with either LCMV or JUNV exhibited reduced rates of translation
compared to uninfected cells, the biological importance of this subtle decrease is unclear
as the majority of cells maintained translation rates that were in the “normal range”
observed in mock-infected cells (Figure 4.9A to D). However, at intermediate time points
following infection with LCMV (24-36 hpi), there was a significant increase in cells
exhibiting translation rates that were highly reduced compared to mock-infected cells
(Figure 4.9A, C, and E). A similar pattern was not observed in JUNV-infected cells (Figure
4.9B, D, and E). These data further support the observations shown in Figures 4.7 and 4.8
that LCMV is more sensitive than JUNV to PKR-dependent phosphorylation of eIF2α.
Importantly, these experiments demonstrate that, in most instances, JUNV and LCMV are
capable of infecting host cells without inducing a potent global shutdown of translation,
despite highly activating PKR.
4.4.9. Replication of influenza A virus lacking expression of the NS1 protein is
rescued by siRNA knockdown of PKR.
We wanted to examine whether arenavirus growth would be affected by the
knockdown of PKR by siRNA. In order to validate our siRNA knockdowns, we infected
siRNA treated cells with an influenza A virus (strain Pan-delNS1) lacking expression of
the nonstructural protein NS1, a well-documented PKR antagonist (Bergmann et al., 2000;
Hatada et al., 1999), to demonstrate that we were able to effectively knockdown PKR
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expression to a level that could functionally rescue the replication of this highly PKRsensitive virus. Protein levels of PKR were greatly reduced in cells transfected with a PKRspecific siRNA compared to a scrambled, non-targeting control siRNA (Figure 4.10A). As
expected, the level of viral nucleoprotein in cells and the quantity of released infectious
virus by cells infected with the wild type parental strain Pan/99 were unaffected by PKR
knockdown (Figure 4.10A to C). However, when cells were infected with the mutant PandelNS1, viral nucleoprotein was expressed at higher levels (~eight fold) and significantly
more (~six-fold) infectious virus was released from cells where PKR had been knocked
down following siRNA transfection (Figure 4.10A to C). Together these results show that
our knockdown of PKR by siRNA is sufficient to rescue a PKR-sensitive virus.
4.4.10. JUNV’s antagonism of PKR’s antiviral activity is complete.
We next wished to test whether PKR, which appears unable to phosphorylate its
downstream substrate, eIF2α, during JUNV infection (Figure 4.7A and C), could still exert
an antiviral effect on the propagation of JUNV. Additionally, we were curious if
knockdown of PKR could improve the replication of LCMV by preventing the activation
of eIF2α (Figure 4.7 and 4.8) and the transient translation repression (Figure 4.9) observed
during LCMV infection. To do so, we measured the levels of NP produced in infected cells
(Figure 4.11A, B, D, and E) and infectious virus released from cells (Figure 4.11C and F)
treated with siRNAs to silence PKR expression. Despite nearly complete knockdown of
PKR with either of two distinct PKR-specific siRNAs (Figure 4.11A and D), release of
infectious JUNV and LCMV virus was not impacted when compared to cells treated with
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a scrambled, nonspecific siRNA (Figure 4.11C and F). Levels of JUNV NP were similarly
unaffected by the knockdown of PKR (Figure 4.11B). LCMV NP levels were slightly
increased when PKR was knocked down with one of the two PKR specific siRNAs (Figure
4.11E). This result suggests that JUNV is capable of completely neutralizing the antiviral
actions of PKR and further that PKR is not fundamentally required for the efficient
propagation of JUNV. On the other hand, while eIF2α is activated and translation is
repressed during LCMV infection, knockdown of PKR had no effect on the release of
infectious LCMV virus and a modest effect on production of viral NP, which we believe
to represent the transience of PKR’s restriction on LCMV infection.

4.5. Discussion
The small size of the arenavirus proteome suggests that each viral protein is highly
multifunctional. One strategy to identify additional accessory roles for these proteins is to
identify the host machinery they engage during infection. In this study, we conducted a
large-scale mapping of the human cellular interactome of the Old World and New World
arenavirus NP. While the identified interactome was complex, a large percentage of the
cellular protein partners were shared among Old World and New World NPs (Figure 4.1F).
Bioinformatic analysis revealed a significant enrichment in proteins involved in protein
translation, including the antiviral protein PKR (Figure 4.2 and Table 4.1). Our studies
demonstrate that JUNV, despite activating PKR during infection (Figure 4.7A and B),
selectively and potently inhibits PKR’s ability to phosphorylate its downstream substrate,
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eIF2α (Figure 4.7A and C and 4.8A and C), and subsequently interfere with viral
propagation (Figure 4.11C).
PKR is one of four cellular kinases able to phosphorylate eIF2α and thus globally
shut down cap-dependent translation in response to viral infection (Donnelly et al., 2013).
This type I IFN-stimulated protein consists of two domains: an N terminal domain that
contains two double-stranded RNA binding motifs and a C terminal kinase domain. In nonstressed cells, monomeric PKR is expressed at low basal levels. Upon exposure to a dsRNA
ligand, the N terminal domain binds the dsRNA, PKR dimerizes, and each PKR subunit
trans autophosphorylates at T446 and T451. Phosphorylation of these residues leads to full
activation of PKR, which is then able to phosphorylate eIF2α at S51, leading to capdependent translation shutdown (Figure 4.12) (Garcia et al., 2007; Zhang et al., 2001).
A key finding of our proteomics studies was that both JUNV and LCMV NP
interact with PKR. However, our follow-up biochemical validation (Figure 4.3 and 4.4)
and immunofluorescence microscopy studies (Figure 4.5) suggest that this interaction may
be more biologically-relevant for JUNV NP than LCMV NP. We demonstrate that PKR is
strongly activated in cells infected with JUNV or LCMV (Figure 4.7) and even more so in
infected cells that are transfected with the PKR agonist poly(I:C) (Figure 4.8).
Nevertheless, this active PKR is only able to phosphorylate eIF2α in LCMV-infected cells
as eIF2α phosphorylation by active PKR is strongly blunted in JUNV-infected cells (Figure
4.7 and 4.8). This effect is recapitulated in experiments measuring rates of translation in
infected cells (Figure 4.9), where the majority of cells infected with JUNV or LCMV
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maintain normal rates of translation throughout the course of infection. However, at 36 hpi,
a significant proportion of LCMV infected cells enter a state of translation repression
(Figure 4.9E), which happens to coincide with the spike in observed eIF2α phosphorylation
observed by Western blot (Figure 4.7D and F). Interestingly, this effect of translation
repression appears transient as the proportion of LCMV-infected cells with normal levels
of translation recovers by 48 hpi (Figure 4.9A, C, and E). The finding that siRNA silencing
of PKR, while sufficient to rescue the PKR-sensitive virus IAV Pan-delNS1 (Figure 4.10),
had no effect on the JUNV life cycle (Figure 4.11A to C) and minimal to no effect on that
of LCMV (Figure 4.11D to F) suggests that these viruses are both resistant to PKR’s
antiviral activity. The observation that LCMV remains resistant to PKR is surprising in
light of the previous findings of this paper and could reflect both the transience of PKR’s
ability to control LCMV infection and/or the fact that LCMV possesses complementary
mechanisms to inhibit PKR activity. A final possibility is that PKR could play a proviral
role in the context of arenavirus infection as has previously been described for hepatitis C
virus (Arnaud et al., 2010; Garaigorta and Chisari, 2009). Though, we consider this
possiblity unlikely as PKR knockdown did not reduce the fitness of JUNV or LCMV
(Figure 4.11).
Because protein translation is an absolutely critical process for the production of
new viral components, many viruses, including those that rely on cap-dependent
translation, have evolved mechanisms to interfere with the canonical antiviral role of PKR
(Reineke and Lloyd, 2013). For example, the dsDNA poxvirus, vaccinia, expresses the E3L
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protein, which prevents PKR from binding to dsRNA (Chang et al., 1992; Langland and
Jacobs, 2002). The paramyxovirus measles, a negative strand RNA virus, antagonizes PKR
activation via its nonstructural protein C, which negatively regulates the production of viral
dsRNA intermediates during infection (Toth et al., 2009). In A549 cells, it was shown that
the paramyxovirus respiratory syncytial virus (RSV) antagonizes PKR activity via its N
protein, which binds PKR and decreases its ability to bind eIF2α thus shielding it from
PKR’s kinase activity (Groskreutz et al., 2010). Another report confirmed that RSV
infection leads to the activation of PKR but that it also leads to significant phosphorylation
of eIF2α in HEp-2 cells (Lindquist et al., 2011). The discrepancy between these two studies
may be due to cell type-specific expression of protein phosphatase 2 – the enzyme
responsible for dephosphorylating eIF2α. The nonstructural protein 1 (NS1) of the
orthomyxovirus influenza A directly interacts with PKR and appears to interfere with its
ability to bind dsRNA and become activated (Li et al., 2006; Lu et al., 1995). A common
theme from these examples is that PKR antagonism represents a common strategy
employed by diverse viruses, but the means by which they accomplish this feat is similarly
variable. Among the viruses cited herein, the ability of JUNV to prevent eIF2α
phosphorylation is most similar to that previously described for RSV as in both cases PKR
becomes activated but is unable to phosphorylate eIF2α (Figure 4.7, 4.8, and 4.12)
(Groskreutz et al., 2010).
The exact mechanism used by JUNV to antagonize PKR’s ability to phosphorylate
eIF2α remains unclear. Our studies suggest that NP itself, as well as its ability to interact
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with the cellular factors PKR and eIF2α, may be critical. Indeed, in a related study, Linero
et al. demonstrated that acute JUNV infection or expression of JUNV NP alone is sufficient
to prevent eIF2α phosphorylation and the subsequent formation of cellular stress granules
(SGs) following exposure to the oxidative stressor sodium arsenite (Linero et al., 2011).
Phosphorylaton of eIF2α is a key event in driving the nucleation of SGs, which contain
stalled cellular mRNAs and their associated translation initiation factors and are associated
with inhibition of cap-dependent translation in response to various cellular stresses,
including virus infection (Thomas et al., 2011). Sodium arsenite is thought to induce SG
formation via activation of PKR and/or heme-regulated inhibitor (McEwen et al., 2005;
Patel et al., 2000), which ultimately phosphorylate eIF2α. Therefore, if sodium arsenite
drives eIF2α phosphorylation via PKR, NP may similarly block PKR’s ability to
phosphorylate eIF2α in response to both oxidative stress (sodium arsenite) and dsRNA
intermediates (poly(I:C)).
JUNV has also been shown to block SG formation in response to challenge with
the ER stressors DTT or thapsigargin, both of which lead to the phosphorylation of eIF2α
via activation of protein kinase-like endoplasmic reticulum kinase (PERK), but not PKR
(Harding et al., 2000; Harding et al., 1999). Paradoxically, despite failing to drive SG
formation in JUNV-infected cells, both DTT and thapsigargin potently induced the
phosphorylation of eIF2α in these same cells (Linero et al., 2011). We identified G3BP1,
another cellular protein critical for the nucleation of stress granules (Tourriere et al., 2003),
as an interacting partner of JUNV and LCMV NP (Figure 4.3A, B, G, and H and 4.4A and
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Table S4.1). Further, a related study demonstrated that G3BP1 colocalizes with the
arenavirus Tacaribe NP during infection (Baird et al., 2012). It is possible that JUNV NP
can prevent SG nucleation despite the presence of phosphorylated eIF2α by interfering
with key SG proteins such as G3BP1. Indeed, several other SG proteins were identified as
partners of arenavirus NPs in our study, including eIF3 components, G3BP2, PABC, and
several small ribosomal subunit proteins (Table S4.1 and S4.2) (Anderson and Kedersha,
2008; Buchan and Parker, 2009).
In addition to the antagonism of PKR’s antiviral function reported here,
arenaviruses have been shown to interfere with other innate immune pathways responsible
for antiviral defense, including the RIG-I/MAVS pathway that drives type I IFN
production. In particular, the arenavirus NP has been shown to associate with IKKε and
block its ability to phosphorylate/activate IRF3, which is required for type I IFN production
(Pythoud et al., 2012). LCMV NP has also been shown to block NFκB activition (Rodrigo
et al., 2012). The arenavirus NP further antagonizes the type I IFN response via its 3’ to 5’
exonuclease activity that limits the availability of viral dsRNA replicative intermediates
for recognition by the RIG-I/MAVS pathway (Hastie et al., 2011a; Qi et al., 2010).
Notably, our results would suggest that NP cannot clear all of these dsRNA intermediates
as we presume these are driving the activation of PKR during infection. Intriguingly,
arenaviruses appear highly selective in their antagonism of these innate immune pathways.
For example, Pythoud et al. demonstrated that despite blocking RIG-I/MAVS-dependent
type I IFN production, LCMV leaves MAVS-dependent apoptosis fully functional
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(Pythoud et al., 2015). Likewise, we report here that JUNV can block activated PKR from
phosphorylating eIF2α (Figure 4.7A and C and 4.8A and C), yet leaves this phosphorylated
form of PKR capable of inducing the degradation IκB in response to poly(I:C) (Figure 4.8A
and D), which is a key step upstream of NFκB activation (Garcia et al., 2007; ZamanianDaryoush et al., 2000), though we recommend caution in the interpretation of this finding
as other innate immune sensors are also able to the activate NFκB in response to stimulation
with dsRNA ligands (Kawai and Akira, 2008). These examples of selective antagonism
suggest that arenaviruses have co-evolved with their reservoir rodents so that arenavirusinfected cells within the host, while unable to respond to the infecting arenavirus, can still
mount an effective antimicrobial response against other enviromental pathogens to ensure
the fitness and survival of the host.
The cellular protein partners of the arenavirus NP identified in this study may
provide clues to advance our understanding of how these viruses hijack host cell machinery
to facilitate the viral life cycle. Importantly, each protein partner represents a candidate
target for future antiviral screening. For example, several host proteins that interact with
NP and are required for viral propagation were validated in our study, including hnRNPA1
and hnRNPA2B1 (Maeto et al., 2011), as well as eIF4A and eIF4G, which are components
of the eIF4F translation initiation complex (Baird et al., 2012; Linero et al., 2013) (Table
4.1). Also consistent with these previous studies, eIF4E, the cap-binding component of the
eIF4F complex, was not detected in our work, supporting the hypothesis that JUNV and
other New World arenavirus NPs can replace the cap-binding function of eIF4E to facilitate
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translation of viral mRNAs (Linero et al., 2013). Finally, 8 additional host proteins
identified in our screen – COPA, DDX60L, EIF3A, EIF3G, FAU, FBL, HNRNPK, and
NOP56 (Table S4.1) – had previously been shown to be required for LCMV and VSV
replication (Panda et al., 2011). Our results suggest these proteins may be critical for viral
propagation due to their interaction with the LCMV NP. These examples highlight the
feasibility and the utility of using a proteomics-based approach to identify antiviral targets.
In summary, we have provided the first detailed map of the human proteins
engaged by the arenavirus NP and also highlighted host processes that are likely important
for arenavirus propagation and/or pathogenesis. This information will serve as a useful
resource to guide future studies investigating the importance of arenavirus-host interactions
and defining additional functions of NP. By showing that JUNV can selectively block the
canonical antiviral role of PKR, we have advanced our understanding of the seemingly
multifaceted strategy employed by arenaviruses to curtail an effective innate immune
response. Important questions to address in the future will include dissecting the specific
mechanism used by JUNV to inihibit PKR’s antiviral activity as well as to fully interrogate
the importance of the remaining cellular interacting proteins identified in the proteomics
screen.
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4.6. Materials and Methods
4.6.1. Cells and viruses.
HEK 293T/17 cells (CRL-11268) and A549 (CCL-185) were procured from
American Type Culture Collection (ATCC, Manassas, VA). Vero E6 cells were generously
given by J. L. Whitton (The Scripps Research institute, La Jolla, CA). HEK 293T/17 cells
were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (11965-118) containing
10% fetal bovine serum, 1% Penicillin-Streptomycin (15140-163), 1% MEM NonEssential Amino Acids Solution (11140-050), 1% HEPES Buffer Solution (15630-130),
and 1% GlutaMAX (35050-061) purchased from Thermo Fisher Scientific (Waltham,
MA). A549 cells were cultured in DMEM-F12 (11320-033, Thermo Fisher), supplemented
with 10% fetal bovine serum, and 1% Penicillin-Streptomycin. Vero E6 cells were
maintained in DMEM, containing 10% fetal bovine serum, 1% Penicillin-Streptomycin,
and 1% HEPES Buffer Solution. JUNV strain Candid #1 was generously provided by R.
Tesh (The University of Texas Medical Branch at Galveston) and M. J. Buchmeier
(University of California, Irvine). LCMV Armstrong 53b was obtained from J. L. Whitton.
Titers of LCMV and JUNV were performed by standard plaque assay on Vero E6 cells.
Recombinant influenza A/Panama/2007/99 (Pan/99) wild type virus and recombinant
influenza A Panama/2007/99 ΔNS1 (Pan-delNS1) virus were generously provided by T.
Wolff (Robert Koch-Institut, Berlin) (Matthaei et al., 2013). Cells were infected with IAV
at an MOI of 1 after being washed with serum-free media. Infected cells were cultured in
serum-free DMEM containing 1ug/ml TPCK Trypsin (T1426, Sigma-Aldrich) and 0.14%
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BSA. Titers of IAV Pan/99 were determined by standard plaque assay on MDCK cells
using a low-viscosity overlay (0.5x DMEM, 0.5ug/ml TPCK Trypsin, 0.07% BSA, 1.2%
Avicel (RC591, FMC Biopolymer)) (Matrosovich et al., 2006). Titers of IAV Pan-delNS1
were determined by immunological focus assay on MDCK cells essentially as described in
(Battegay et al., 1991) using a low-viscosity overlay and an IAV NP monoclonal antibody
(ab20343, Abcam, at 1:5,000).
4.6.2. Immunoprecipitations and affinity purifications.
Cells were scraped into the media following infection or transfection, pelleted,
washed with cold PBS, and gently lysed on ice in 25 mM Tris-HCL, pH 7.6 containing 1%
Triton X-100 (T9284, Sigma-Aldrich, St. Louis, MO), 0.5% Nonidet P-40 IGEPAL CA630 (198596, MP Biomedicals, Solon, OH), 140 mM NaCl, 1 mM calcium chloride
(21115, Sigma-Aldrich), and a Complete Mini EDTA-Free Protease Inhibitor Cocktail
tablet (04693159001, Roche Applied Science). Cell lysates were clarified of insoluble
material by centrifugation at 10,000 rpm at 4°C. To pre-clear proteins non-specifically
interacting with the magnetic Protein G beads (Dynabeads Protein G beads, 10004D,
Thermo Fisher), beads were added to lysate and incubated on a rotating platform for 15
minutes at 4°C. Appropriate antibody was added to cell lysates and incubated for 2 hours
at 4°C. Magnetic Protein G beads were added to lysates and incubated for 1 hour at 4°C.
The beads were washed 4 times with ice cold lysis buffer to remove nonspecific proteins.
Bound protein was stripped from the beads into 1x Laemmli Buffer, 5% β-mercaptoethanol
by heating at 100°C for 5 minutes. Immunoprecipitated proteins were separated by SDS163

PAGE as described below. Antibodies used for immunoprecipitations are as follows:
JUNV NP (KA03-AA01, BEI Resources), LCMV NP (1.1.3 and 24A, generously provided
by M. J. Buchmeier) (Buchmeier et al., 1981), AIF (sc-9416, Santa Cruz), G3BP1 (A302033A, Bethyl), and PKR (Y117, Abcam).
Affinity purification of biotinylated viral NPs was performed as follows. Viral NPs
were cloned into a modified pCAGGS plasmid and carried a C-terminal HA epitope tag,
the tobacco etch virus (TEV) protease cleavage site, and a biotin acceptor peptide. Viral
NPs were biotinylated when cotransfected with the plasmid BirA, which expresses a
bacterial biotin ligase. As a control to validate the specificity of the protein-protein
interaction, cells were transfected with an empty vector along with BirA. Cells were lysed
as described above. Biotinylated proteins were captured by incubating cleared lysate with
magnetic streptavidin beads (Dynabeads MyOne Streptavidin T1, 65602, Thermo Fisher)
at 4°C for 2.5 hours. Beads were washed 4 times with cold lysis buffer, and interacting
proteins were stripped from beads into 1x Laemmli buffer containing 5% βmercaptoethanol by heating at 100°C for 5 minutes.
4.6.3. Mass Spectrometry.
To define the cellular protein interactome of JUNV NP and LCMV NP, A549 or
HEK 293T cells were infected with either JUNV C#1 or LCMV Armstrong 53b. Following
infection, the viral NPs were immunoprecipitated (as described above) along with
associated cellular proteins. After denaturation, the immune complexes were separated by
SDS-PAGE on Novex 4-20% Tris-Glycine polyacrylamide gels. Gels were Coomassie
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stained (0.02% Brilliant Blue R (B7920, Sigma-Aldrich) in 32% methanol, 22% acetic
acid) at room temperature overnight. Gels were destained for 6-8 hours in a solution
containing 30% methanol and 10% acetic acid. Each lane was cut out of the gel in 13
(JUNV NP) or 15 (LCMV NP) slices (cut maps available upon request). In-gel trypsin
digestion of proteins was performed with Sequencing Grade Modified Trypsin (V5111,
Promega, Madison, WI at 6 ng/μL) in 50 mM ammonium bicarbonate overnight at 37°C
as previously reported (Ballif et al., 2006). Peptides were extracted from the digested gel
slices with 50% acetonitrile (MeCN) and 2.5% formic acid (FA) and dried using a vacuum
centrifuge. Dried peptides were resuspended in 2.5% MeCN and 2.5% FA and loaded onto
a 12 cm reverse-phase Magic C18 microcapillary column (5 μm, 200 Å, Michrom
Bioresources, Inc., Auburn, CA) utilizing a MicroAS autosampler (Thermo Scientific,
Pittsburgh, PA). Peptides were eluted with a 5-35% MeCN (0.15% FA) gradient using a
Surveyor Pump Plus HPLC (Thermo Scientific) over 40 min, after a 15min isocratic
loading with 2.5% MeCN and 0.15% FA. An LTQ-XL linear ion trap mass spectrometer
(Thermo Scientific) was used to acquire mass spectra of eluted peptides over the entire run
using 10 MS/MS scans following each survey scan. Raw data were searched against the
human IPI forward and reverse concatenated databases using SEQUEST software allowing
a 2 Da mass tolerance for peptide matches. Cysteine residues were required to have a static
increase in 71.0 Da for acylamide adduction. A 16.0 Da differential modification on
methionine residues was permitted. Host proteins were accepted as legitimate NP protein
partners if they were identified by 2 or more unique tryptic peptides in samples infected
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with either JUNV or LCMV but not in the corresponding uninfected control. Alternatively,
proteins were included if there was a 5-fold higher quantity of total tryptic peptides that
were detected for a particular human protein from a viral infected sample compared to the
sample from the corresponding uninfected control. Using these filters, the false discovery
rate of peptides was less than 1%.
Bioinformatic analysis of cellular protein partners was performed with the NIH
DAVID functional annotation tool (Version 6.7; https://david.ncifcrf.gov/) (Huang et al.,
2009a, b).
4.6.4. SDS-PAGE and Western Blot.
Novex 4-20% Tris-Glycine polyacrylamide gels or NuPAGE™ Novex™ 4-12%
Bis-Tris Midi Protein Gels (WG1402BOX, Thermo Scientific) were used to separate
protein lysates by SDS-PAGE. MOPS SDS Running Buffer (NP0001, Thermo Scientific)
was used with the NuPage Bis-Tris polyacrylamide gels. Protein was transferred from gels
onto nitrocellulose membranes using the iBlot Gel Transfer Device and the iBlot Transfer
Stack nitrocellulose membranes (IB3010-01, Thermo Scientific). Membranes were
blocked with 5% milk in PBS for 1 hour at room temperature. Primary antibodies and
secondary antibodies were diluted in PBS containing 5% milk, 3% FBS, and 0.05%
Nonidet P-40 IGEPAL CA-630). Blots were incubated in diluted primary antibody
overnight at 4°C. Primary antibodies used for Western blot were: PKR (sc-707, Santa Cruz,
at 1:1000), IκBα (9242, Cell Signaling, at 1:1000), rabbit anti-actin (A2066, Sigma
Aldrich, at 1:5000), mouse anti-actin (A5441, Sigma Aldrich, at 1:5000), SFPQ (NB100166

61044, Novus, at 1:2500), eIF2α (sc-11386, Santa Cruz, at 1:1000), p-eIF2α S51 (3398,
Cell Signaling, at 1:1000), G3BP1 (A302-033A, Bethyl, at 1:2500), AIF (sc-9416, Santa
Cruz, at 1:1000), p-PKR T446 (E120, Abcam, at 1:1000), anti-JUNV NP (NA05-AG12,
BEI-Resources, at 1:200), anti-LCMV NP (2165, M. J. Buchmeier, at 1:10,000), and IAV
NP (ab20343, Abcam, at 1:1,000). Unbound primary antibody was washed from blots by
3 consecutive washes in Western wash solution (PBS with 0.5% Nonidet P-40 IGEPAL
CA-630). Blots were incubated with diluted secondary antibody for 2 hours at room
temperature: goat anti-mouse (H+L) (71045-3, Novagen, at 1:10,000), goat anti-mouse
(light chain only) (AP200P, Millipore, at 1:10,000), goat anti-rabbit (H+L) (111-035-045,
Jackson, at 1:10,000), mouse anti-rabbit (light chain only) (211-032-171, at 1:10,000), or
rabbit anti-goat peroxidase (401515, Calbiochem, at 1:10,000). Finally, blots were washed
3 more times with Western wash before developing with chemiluminescent substrate
(either Pierce ECL Western Blotting Substrate (32109), SuperSignal West Pico (34080) or
Femto (34096) Chemiluminescent Substrate, Thermo Scientific). Alternately, blots were
probed with fluorescently labeled secondary antibodies: IRDye 800CW goat anti-rabbit
IgG (H+L) (926-32211, LI-COR, at 1:20,000), IRDye 800CW goat anti-mouse IgG (H+L)
(926- 32210, LI-COR, at 1:20,000), IRDye 680RD goat anti-mouse IgG (H+L) (92668070, LICOR, at 1:20,000), and IRDye 680RD goat anti-rabbit IgG (H+L) (926-68071,
LICOR, at 1:20,000) and visualized with an Odyssey Infrared Imaging System (LI-COR
Biosciences, Lincoln, NE).
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4.6.5. Plasmids and transfection.
To validate the interaction of identified cellular proteins, the arenaviral NPs were
subcloned into a modified pCAGGS expression vector as previously described (CornillezTy et al., 2009; Klaus et al., 2013). This vector expresses an NP fusion protein containing
3 C-terminal elements: a hemagglutinin (HA) epitope tag (YPYDVPDYA), the tobacco
etch virus (TEV) protease cleavage site (ENLYFQG), and a 23 amino acid biotin acceptor
peptide (BAP) (MASSLRQILDSQKMEWRSNAGGS). The BAP sequence can be
biotinylated when cells are cotransfected with a plasmid that encodes the bacterial biotin
ligase BirA, and the biotinylated NP can be affinity purified as described (Cornillez-Ty et
al., 2009; Klaus et al., 2013). The NP sequences subcloned into the pCAGGS expression
vector were (for each NP, an NCBI Gene Identifier number and a Protein Locus number
are listed): LASV strain Josiah (NC_004296, NP_694869), LCMV Armstrong 53b
(DQ408671, ABD73126), and JUNV strain Candid 1 (HQ126699, AEB32437).
Transfection of HEK 293T cells was done using Polyethylenimine (PEI) (23966,
Polysciences, Inc., Warrington, PA) (5 µg of PEI (10010049, Thermo Fisher) per 1 µg
DNA).
4.6.6. Confocal Microscopy.
The localization of the viral NP and cellular proteins in JUNV- or LCMV-infected
A549 cells was visualized by confocal microscopy. A549 cells were seeded onto #1.5 12
mm glass cover slips (12-545-81, Thermo Scientific). The day after seeding, cells were
infected or not (mock) with JUNV at an MOI of 0.1 or LCMV at an MOI of 0.01. Cells
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were fixed 48 or 72 hr after infection with 4% PFA (15714, Electron Microscopy Sciences)
in 1x PBS. Cells were permeabilized in PBS with 0.1% Triton X-100 and 1% BSA and
then blocked in PBS containing 3% BSA for 30 minutes at room temperature.
Cells were incubated with a primary antibody diluted in 1% BSA in 1x PBS at room
temperature for 1 hour. NA05-AG12 (mouse) to detect JUNV NP was diluted at 1:100,
1.1.3 (mouse) for LCMV NP was diluted 1:500, anti-PKR antibody (rabbit monoclonal,
Y117, Abcam) was diluted 1:100, and anti-G3BP1 (A302-033A, Bethyl) was diluted
1:100. Coverslips were washed 4 times in 1x PBS at room temperature. Coverslips were
incubated with secondary antibody diluted in 1% BSA in 1x PBS for 30 minutes at room
temperature. Secondary antibodies were Alexa Fluor 488-conjugated goat anti-mouse IgG
(H+L) (A-11029, Thermo Scientific) (1:800) and Alexa Fluor 647-conjugated goat antirabbit IgG (H+L) (A-21245, Thermo Scientific) (1:800). Coverslips were washed 3 times
in PBS, stained with 4’, 6-diamidino-2-phenylindole hydrochloride 30 (DAPI) (D9542,
Sigma Aldrich), and washed a final time in PBS, and mounted onto glass slides using
ProLong Gold Antifade Reagent (P36934, Thermo Fisher). Confocal microscopy was
performed with a Zeiss LSM 510 Laser Scanning Confocal Microscope. Images were
acquired with a 63X objective lens with a numerical aperture of 1.4. Images were acquired
at 1.0 Airy unit for the Alexa Fluor 647 dye. Pinhole diameter for the DAPI and Alexa
Fluor 488 channels were set accordingly.
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4.6.7. Puromycylation of nascent polypeptides.
To label newly-synthesized peptides in infected cells growing on glass coverslips,
cells were incubated for 5 minutes at 37°C in puromycylation media: DMEM/F12, 10%
FBS, 1% Pen-Strep supplemented with 91 µM puromycin (P8833, Sigma-Aldrich) and 208
µM emetine (E2375, Sigma-Aldrich) as previously described (David et al., 2012). As a
negative control, some cells were pretreated with complete media containing 500 µM
Sodium Arsenite (1.06277, Sigma-Aldrich) for 15 minutes at 37°C before labeling with
puromycylation media. Following the labeling reaction, cells were briefly washed with
cold DPBS (with calcium and magnesium) (14040133, Thermo Fisher). Cells were washed
with cold permeabilization buffer (50 mM Tris HCl, 5 mM MgCl2, 25 mM KCl, 0.015%
Digitonin (D141, Sigma-Aldrich)) to remove free puromycin before being fixed in 3% PFA
in 1x PBS for 15 minutes at room temperature. Cells were prepared for confocal
microscopy as described above. LCMV NP was labeled with the 1.1.3 antibody (at 6.8
µg/ml), and JUNV NP was labeled with the NA05 antibody (at 10 µg/ml), with both
antibodies directly conjugated to Alexa Fluor 488 (Thermo Fisher).Puromycin was
detected with the monoclonal antibody 12D10 directly conjugated to Alexa Fluor® 647 (at
1 ug/ml, MABE343-AF647, Sigma-Aldrich). Puromycin levels were quantitated in
individual cells with a customized image analysis pipeline in CellProfiler (Broad Institute)
(Kamentsky et al., 2011).
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4.6.8. Poly(I:C) transfections.
For a single well in a six well plate, 0 µg, 0.5 µg, or 5 µg of poly(I:C) (P0913,
Sigma Aldrich) was added to 125 µL Opti-Mem Media (31985070, Thermo Fisher) and
mixed well. 3 µL of Lipofectamine 2000 (11668019, Thermo Fisher) was added to a second
tube containing 125 µL Opti-Mem and mixed gently. The solution containing poly(I:C)
was added to the solution containing Lipofectamine 2000, mixed gently, and incubated at
room temperature for 10 minutes. Media was aspirated from the wells and replaced with 2
ml of fresh warm complete A549 media. The poly(I:C)/Lipofetamine transfection mix was
added dropwise to the well. The transfected cells were incubated at 37°C for 6 hours at
which time cells were lysed and analyzed by Western blot.
4.6.9. siRNA.
siRNAs were reverse transfected in A549 cells in a 12 well plate format as follows.
To 100 µL of Opti-Mem, 2 µL of Lipofectamine RNAi Max (13778075, Thermo Fisher)
was added and mixed gently. To another 100 µL of Opti-Mem, 12 pmoles of siRNA was
added and mixed. The siRNA-containing solution was added to the lipofectaminecontaining solution and allowed to incubate at room temperature for 5 minutes. 200 µL of
this mixture were added to an empty well of a 12 well plate. Next, 40,000 A549 cells in 1
ml of complete A549 media were added to the Opti-MEM/siRNA-containing well and
incubated at 37°C. Two days post-transfection, the media was replaced with fresh
prewarmed complete A549 media. siRNA-transfected A549 cells were infected 72 hours
post-siRNA transfection. Silencer Select siRNAs were used for knockdown experiments:
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Silencer Select Negative Control No. 1 siRNA: “siSCR” (4390843, Thermo Fisher),
“siPKR-1” (s11185, 4390824, Thermo Fisher) (Figure 4.10 and 4.11), and “siPKR-2”
(s229501, 4392420, Thermo Fisher) (Figure 4.11).
4.6.10. Statistics.
Statistical analyses were performed in GraphPad software. Two-way ANOVA
with post-hoc Tukey’s multiple comparisons test was used for Figure 4.8. One-way
ANOVA with Dunnett’s multiple comparisons test was used for Figures 4.7, 4.9C, 4.9D,
and 4.11. One-way ANOVA with Tukey’s multiple comparisons test was used for Figure
4.9E. Unpaired two-tailed Student’s T-test was used for Figure 4.10.
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4.9. Tables
Table 4.1. The top 25% most abundantly detected conserved protein partners of JUNV C#1 and
LCMV Armstrong 53b NP.
Gene symbol, description, and IPI ID for the most abundantly detected host protein partners of the arenavirus
NP are listed below. The most abundant interactors were defined as those having the highest average number
of spectral counts (total peptides) from the JUNV (n=8 independent experiments) or LCMV (n=4 independent
experiments) mass spectrometry.

Gene symbol
AIFM1
ASPH
CCT6A
CCT7
CKAP4
CKAP5
CLTC
DDX3X
DDX5
DHX9
EEF1A2
FLNA
FLNB
HADHA

HIST2H2BE
HNRNPA1
HNRNPA2B1
HNRNPA2B1
HNRNPK
HNRNPM
HNRNPU
HSPA8
IGF2BP1
ILF2
IQGAP1
KIAA1618
LMNA
MAP1B
MATR3
MOV10
MYBBP1A
MYO1B
MYO1C
MYO6
NCL
NCL
NPM1
PABPC1
PARP1
PLEC1
PKR
PRKDC

Peptide
spectral counts

Gene Description

IPI ID

JUNV

LCMV

programmed cell death 8 (apoptosis-inducing factor)
aspartate beta-hydroxylase
chaperonin containing TCP1, subunit 6A (zeta 1)
chaperonin containing TCP1, subunit 7 (eta)
cytoskeleton-associated protein 4
cytoskeleton associated protein 5
clathrin, heavy polypeptide (Hc)
DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5
DEAH-Box Helicase 9
eukaryotic translation elongation factor 1 alpha 2
filamin A, alpha (actin binding protein 280)
filamin B, beta (actin binding protein 278)
hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme
A thiolase/enoyl-Coenzyme A hydratase (trifunctional protein),
alpha subunit
histone 2, H2be
heterogeneous nuclear ribonucleoprotein A1
heterogeneous nuclear ribonucleoprotein A2/B1
heterogeneous nuclear ribonucleoprotein A2/B1
heterogeneous nuclear ribonucleoprotein K
heterogeneous nuclear ribonucleoprotein M
heterogeneous nuclear ribonucleoprotein U (scaffold attachment
factor A)
heat shock 70kDa protein 8
insulin-like growth factor 2 mRNA binding protein 1
interleukin enhancer binding factor 2, 45kDa
IQ motif containing GTPase activating protein 1
chromosome 17 open reading frame 27
lamin A/C
microtubule-associated protein 1B
matrin 3
Mov10, Moloney leukemia virus 10, homolog (mouse)
MYB binding protein (P160) 1a
myosin IB
myosin IC
myosin VI
nucleolin
nucleolin
anaplastic lymphoma kinase (Ki-1)
poly(A) binding protein, cytoplasmic 1
poly (ADP-ribose) polymerase family, member 1
plectin 1, intermediate filament binding protein 500kDa
Double Stranded RNA Activated Protein Kinase (eukaryotic
translation initiation factor 2-alpha kinase 2)
protein kinase, DNA-activated, catalytic polypeptide

IPI00000690
IPI00294834
IPI00027626
IPI00018465
IPI00141318
IPI00028275
IPI00024067
IPI00215637
IPI00017617
IPI00844578
IPI00014424
IPI00302592
IPI00289334
IPI00031522

89
23
43
40
22
13
19
18
12
32
16
16
13
22

3
8
3
4
9
12
18
18
24
27
8
77
21
15

IPI00003935
IPI00215965
IPI00396378
IPI00386854
IPI00216049
IPI00171903
IPI00479217

8
13
17
3
24
25
15

39
16
12
27
15
32
12

IPI00003865
IPI00008557
IPI00005198
IPI00009342
IPI00642126
IPI00021405
IPI00008868
IPI00017297
IPI00444452
IPI00005024
IPI00376344
IPI00010418
IPI00008455
IPI00183526
IPI00444262
IPI00220740
IPI00008524
IPI00449049
IPI00014898
IPI00019463

31
20
12
14
76
31
14
12
17
28
10
27
9
22
22
14
29
24
55
18

18
19
19
20
3
105
10
20
16
6
30
55
18
17
13
26
39
30
307
7

IPI00296337

60

46

175

RPL10A
RPL12
RPL13P12
RPL23
RPL23A
RPL3
RPL4
RPL5
RPL6
RPL7
RPL7A
RPLP0
RPLP2
RPS18
RPS19
RPS3
RPS3A
RPS4X
RRBP1
SFPQ
SLC25A5
TMPO
TMPO
TUBB2C
XRCC5
XRCC6

ribosomal protein L10a
ribosomal protein L12
ribosomal Protein L13 pseudogene 12
ribosomal protein L23
ribosomal protein L23a
ribosomal protein L3
ribosomal protein L4
ribosomal protein L5
ribosomal protein L6
ribosomal protein L7
ribosomal protein L7a
ribosomal protein, large, P0
ribosomal protein, large, P2
ribosomal protein S18
ribosomal protein S19
ribosomal protein S3
ribosomal protein S3A
ribosomal protein S4, X-linked
ribosome binding protein 1 homolog 180kDa (dog)
splicing factor proline/glutamine-rich (polypyrimidine tract binding
protein associated)
solute carrier family 25 (mitochondrial carrier; adenine nucleotide
translocator), member 5
thymopoietin
thymopoietin
tubulin, beta 2C
X-ray repair complementing defective repair in Chinese hamster
cells 5 (double-strand-break rejoining; Ku autoantigen, 80kDa)
X-ray repair complementing defective repair in Chinese hamster
cells 6 (Ku autoantigen, 70kDa)
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IPI00412579
IPI00024933
IPI00397611
IPI00010153
IPI00021266
IPI00550021
IPI00003918
IPI00000494
IPI00329389
IPI00030179
IPI00299573
IPI00008530
IPI00008529
IPI00013296
IPI00215780
IPI00011253
IPI00419880
IPI00217030
IPI00215743
IPI00010740

15
15
13
14
12
19
20
22
25
14
16
39
22
12
9
14
11
13
40
17

12
11
13
19
15
14
9
17
28
18
17
31
15
14
21
31
20
22
6
16

IPI00007188

27

27

IPI00030131
IPI00216230
IPI00007752
IPI00220834

9
4
14
14

43
34
8
13

IPI00644712

15

18

4.10. Figures

Figure 4.1. Identification of human proteins that associate with the arenavirus nucleoprotein.
(A) Overview of experimental approach to identify human cellular protein partners of the arenavirus
nucleoprotein in the context of infected cells. A549 or HEK 293T cells were infected with either JUNV
Candid #1, LCMV Armstrong 53b, or uninfected (mock). Cells were lysed and NP was immunoprecipitated
with monoclonal antibodies. The immunoprecipitated fractions were separated by SDS-PAGE and lanes were
cut into multiple slices. Proteins were digested with trypsin, peptides were extracted from each slice, and
proteins were identified by tandem-mass spectrometry. (B-E) Representative Coomassie-stained gels of
immunoprecipitated NP from (B) JUNV- or mock-infected A549 cells (C) LCMV- or mock-infected A549
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cells (D) JUNV- or mock-infected HEK 293T cells, or (E) LCMV- or mock-infected HEK 293T cells.
Immunoprecipitated NP is indicated by an arrowhead in each gel. Background bands composed of IgG heavy
and light chains are denoted with asterisks. (F) Venn diagram representing the number of host proteins
interacting with JUNV NP, LCMV NP, or both. (G) Venn diagram representing the number of host protein
partners (of either JUNV or LCMV NP) identified in A549 cells, HEK 293T cells, or both. The Coomassie
gels shown in panels (B-E) are representative of 2 independent experiments.
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Figure 4.2. Bioinformatic analysis of host protein partners of the arenavirus NP.
(A) A frequency distribution histogram showing the number of individually identified peptides per protein
for host proteins interacting with JUNV NP only, LCMV NP only, or both viral NPs (conserved). Vertical
dashed line indicates the threshold above which the 25% most abundant conserved interacting proteins were
detected. (B) A bioinformatics NIH DAVID functional annotation clustering analysis showing the most
highly enriched biological function categories represented in the list of the 25% most abundantly detected
and conserved interacting proteins (n= 69) displayed in Table 4.1. (C) A bioinformatics NIH DAVID
functional annotation clustering analysis showing the most highly enriched biological function categories
represented in the entire list of interacting proteins (n= 582). (D) NIH DAVID analysis on the subset of
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proteins displaying specific interactions with only the JUNV NP (n=234). (E) NIH DAVID analysis on the
subset of proteins displaying specific interactions with only the LCMV NP (n=73). For panels (A-E),
interacting human proteins that were detected in at least 1 of the 2 independent experiments for JUNV in
either A549 or HEK 293T cells and/or 1 of the 2 independent experiments for LCMV in either A549 or HEK
293T cells were used for bioinformatic analysis.
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Figure 4.3. Biochemical validation of the interaction between cellular proteins and arenavirus NPs in
infected cells.
(A) JUNV NP (bait) was immunoprecipitated from lysates of A549 cells infected (JUNV) or not (mock) with
JUNV, and associated cellular proteins (prey) were detected by Western blot. (B) LCMV NP (bait) was
immunoprecipitated from lysates of A549 cells infected (LCMV) or not (mock) with LCMV Armstrong 53b,
and associated cellular proteins (prey) were detected by Western blot. (C and D) A549 cells were infected
with JUNV (C) or LCMV (D), or uninfected (mock); at 72 hpi (JUNV) or 48 hpi (LCMV),
immunoprecipitations from infected lysates were performed using either a monoclonal antibody to the C
terminus of PKR (bait) or a species-matched control IgG, and associated JUNV NP (C) or LCMV NP (D)
prey were detected by Western blot. (E and F) AIFM1 (bait) was immunoprecipitated from lysates of A549
cells infected or not (mock) with JUNV (E) or LCMV Armstrong 53b (F) using an AIFM1-specific
polyclonal antibody and AIFM1 (bait) and associated NP (prey) were detected by Western blot. (G and H)
G3BP1 (bait) was immunoprecipitated from lysates of A549 cells infected with JUNV (72 hpi) (G) or LCMV
Armstrong 53b (48 hpi) (H) using either a polyclonal antibody to G3BP1 (bait) or a control rabbit IgG, and
G3BP1 (bait) and associated NP (prey) were detected by Western blot. Protein bands composed of the IgG
heavy chain in (D, E, F, and H) are denoted with an asterisk. Data are representative of 2 (A and B)), 4 (C),
5 (D), or 1 (E-H) independent experiments.
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Figure 4.4. Biochemical validation of interactions between arenavirus NPs expressed from plasmid
and endogenous host proteins.
(A) HEK 293T cells were co-transfected with a plasmid encoding each respective arenavirus NP with a Cterminal HA epitope tag, the TEV cleavage site, and a biotin acceptor peptide, along with a second plasmid
that encodes BirA, a bacterial biotin ligase, to ensure biotinylation of the viral NPs. As a control, cells were
co-transfected with the BirA plasmid and an empty vector (p0). Biotinylated NPs and associated host proteins
were affinity purified from cell lysates (input) using magnetic streptavidin beads and captured proteins were
detected by Western blot. (B and C) HEK 293T cells were transfected with a plasmid encoding each
respective arenavirus NP with a C-terminal HA epitope tag, the TEV cleavage site, and a biotin acceptor
peptide or, as a control, an empty vector (p0). (B) PKR (bait) was immunoprecipitated with a monoclonal
antibody to the C terminus of PKR or with an irrelevant rabbit IgG. PKR (bait) and associated viral NP (prey)
were detected by Western blot. (C) AIFM1 (bait) was immunoprecipitated with a polyclonal antibody.
AIFM1 (bait) and associated viral NP (prey) were detected by Western blot. Data are representative of 2 (A),
3 (B), or 2 (C) independent experiments.
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Figure 4.5. PKR colocalizes with JUNV but not LCMV NP.
A549 cells were (A) infected (JUNV) or not (mock) with JUNV and fixed at 72 hpi (n=5) or (B) infected
(LCMV) or not (mock) with LCMV Arm53b and fixed at 48 hpi (n=4). Cells were stained for NP (green)
and PKR (red) and visualized by confocal immunofluorescence microscopy. Inset shows higher
magnification of the boxed areas. A fluorescence plot profile is included to show NP and PKR signal intensity
along the white line indicated in the magnified region in the merge panel from either JUNV or LCMV infected
cells. Scale bar = 10µm.
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Figure 4.6. G3BP1 colocalizes with JUNV and LCMV NP.
A549 cells were (A) infected (JUNV) or not (mock) with JUNV and fixed at 72 hpi (n=1) or (B) infected
(LCMV) or not (mock) with LCMV Arm53b and fixed at 48 hpi (n=1). Cells were stained for NP (green)
and G3BP1 (red) and visualized by confocal immunofluorescence microscopy. Inset shows higher
magnification of the boxed areas. A fluorescence plot profile is included to show NP and G3BP1 signal
intensity along the white line indicated in the magnified region in the merge panel from either JUNV or
LCMV infected cells. Scale bar = 10µm.
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Figure 4.7. PKR is activated following JUNV infection but cannot phosphorylate eIF2α.
A549 cells were infected with JUNV (A-C) or LCMV (D-F). Infected cell lysates were collected during a
time course of acute infection. Viral NPs, phosphorylated PKR (T446), total PKR, phosphorylated eIF2α
(S51), total eIF2α, and β-actin were visualized by Western blot (A and D). Phosphorylated PKR (B and E)
and phosphorylated eIF2α (C and F) were quantified, and compared using one-way ANOVA. Data are
presented as mean fold change ± SEM from 2 independent experiments featuring 3 technical replicates per
experiment. ns – not significant, P>0.05; *, P≤0.05; **, P≤0.01; ***, P≤0.001; ****, P≤0.0001

186

Figure 4.8. JUNV infection blocks poly(I:C)-induced phosphorylation of eIF2α.
A549 cells infected with either JUNV (A-D) or LCMV (E-H) or uninfected (mock) were transfected with the
indicated quantities of poly(I:C) to induce PKR activation. Viral NPs, phosphorylated PKR (T446), total
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PKR, phosphorylated eIF2α (S51), total eIF2α, IκB, and β-actin were visualized by Western blot (A and E).
Phosphorylated PKR (B and F), phosphorylated eIF2α (C and G), and IκB (D and H) were quantified, and
compared using two-way ANOVA. Data are presented as mean fold change ± SEM from 2 independent
experiments featuring 3 technical replicates per experiment. ns – not significant, P>0.05; *, P≤0.05; **,
P≤0.01; ***, P≤0.001; ****, P≤0.0001
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Figure 4.9. Translational profile of cells infected with JUNV or LCMV.
(A and B) Cells were either infected with LCMV (A) (n=2) or JUNV (B) (n=2), mock-infected, or treated
with 500 µM Sodium Arsenite, and rates of translation were assessed by labeling newly synthesized peptides
with puromycin. (C and D) Puromycin levels were quantitated in individual cells receiving no puromycin,
mock-infected cells labeled with puromycin, mock-infected cells treated with Sodium Arsenite prior to
puromycin labeling, or in cells infected with LCMV(C) or JUNV (D) at different time points following
infection. Each individual cell was normalized to the mean level of puromycylation of mock-infected cells.
The puromycin labeling of individual cells is represented by single dots, the mean puromycin labeling is
represented by a solid red horizontal line in each condition, red error bars represent ± SD and were compared
between mock and each time point by one-way ANOVA. A red dashed line, which represents the threshold
for translational repression, was set as the mean level of puromycylation in mock-infected cells labeled with
puromycin minus (1.96*SD). (C) No Puro, n=44 cells; Arsenite, n=194 cells; Mock, n=191 cells; LCMV
12h, n=113 cells; LCMV 24h, n=276 cells; LCMV 36h, n=260 cells; LCMV 48h, n=269 cells. (D) No Puro,
n=40 cells; Arsenite, n=205 cells; Mock, n=215 cells; JUNV 24h, n=161 cells; JUNV 48h, n=198 cells;
JUNV 72h, n=205 cells. (E) The proportion of individual cells that fall below the translational repression
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threshold in each condition were compared with one-way ANOVA. Though all possible comparisons
between LCMV-infected cultures at different times post-infection in panel (E) were made, for clarity, only
significant differences are shown. In panels (A) and (B), the borders between adjacent cells are represented
by dashed white lines. Scale bar = 10µm. ns – not significant, P>0.05; *, P≤0.05; ****, P≤0.0001.
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Figure 4.10. Loss of functional PKR enhances growth of mutant delNS1 but not WT influenza A virus.
A549 cells were transfected with a non-targeting scrambled siRNA (siSCR) or with a PKR-specific siRNA.
Three days following siRNA transfection, cells were infected with either WT influenza A virus (IAV) Pan/99,
a mutant IAV that does not express NS1 (Pan-delNS1), or mock-infected, and supernatants and cellular
protein lysates were collected at 16 hpi. Protein levels of IAV nucleoprotein (NP) were detected by Western
blot (A) and quantified, normalized to β-actin levels, and normalized to the mean of levels of NP in siSCR
transfected cells (B). PKR expression in mock-infected cells was visualized by Western blot to confirm
knockdown (A). The quantities of infectious virus in the supernatants was determined by plaque assay (for
IAV Pan/99) or by focus assay (for IAV Pan-delNS1) (C). The effect of PKR knockdown on viral NP levels
as well as released infectious virus was determined using a two-tailed, unpaired T-test (B and C). Data are
presented as mean plaque forming units (PFU)/ml ± SEM or mean focus forming units (FFU)/ml ± SEM
from 2 independent experiments featuring 2 technical replicates per experiment. ns – not significant, P>0.05;
**, P≤0.01
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Figure 4.11. Loss of functional PKR does not impact arenavirus propagation.
A549 cells were transfected with a non-targeting scrambled siRNA (siSCR) or with one of two PKR-specific
siRNAs (siPKR #1, siPKR #2). Three days after siRNA transfection, cells were infected with JUNV (A-C)
or LCMV (D-F), and supernatants and cellular protein lysates were collected at 48 (JUNV and LCMV) and
72 hpi (JUNV only). Protein levels of PKR and viral NP were visualized by Western blot (A and D). NP
protein levels were quantified, normalized to β-actin levels, and normalized to the mean of levels of NP in
siSCR transfected cells at 48hpi and were compared by one-way ANOVA (B and E). The quantities of
infectious virus in the supernatants were determined by plaque assay and were compared by one-way
ANOVA (C and F). Data are presented as mean ± SEM from 2 independent experiments featuring 3 technical
replicates per experiment. Data are presented as mean PFU/ml ± SEM from 2 independent experiments
featuring 3 technical replicates per experiment in panels A to C (JUNV) or 3 independent experiments
featuring 3 technical replicates per experiment in panels D to F (LCMV). ns – not significant, P>0.05; **,
P≤0.01

192

Figure 4.12. JUNV infection blocks PKR’s antiviral activity.
Inactive PKR exists in an unphosphorylated, monomeric form. Upon binding a dsRNA ligand with its Nterminal dsRNA binding domains, PKR dimerizes and undergoes an autophosphorylation event (at T446 and
T451). This activated form of PKR phosphorylates eIF2α at serine 51, which leads to a global cap-dependent
translation shutdown. The results of this study show that PKR is able to become phosphorylated in cells
infected with JUNV but is deficient in its ability to phosphorylate its target eIF2α. We hypothesize that the
viral NP may be responsible for blocking this step as it was shown to interact with both PKR and eIF2α.
Other functions of active PKR such as the activation of NF-κB (as assayed by IκB degradation) remain intact.
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4.12. Supplemental Tables
Table S4.1. Complete list of cellular proteins that were detected as interacting with the JUNV or
LCMV NP.
The average number of spectral counts (total peptides) detected by mass spectrometry from host proteins that
associated with the JUNV NP in A549 cells (n=4) or HEK 293T cells (n=4); or with the LCMV NP in A549
cells (n=2) or HEK 293T cells (n=2).
Peptide Spectral Count
Gene symbol

Gene Description

IPI id

JUNV

LCMV

A549

HEK
293T

A549

HEK
293T

ATP-binding cassette, sub-family F (GCN20),
member 1
ATP-binding cassette, sub-family F (GCN20),
member 2
acyl-Coenzyme A dehydrogenase family, member
11

IPI00013495

5.3

0.0

0.0

4.0

IPI00005045

3.0

1.0

0.0

3.5

IPI00420065

0.0

1.8

0.0

0.0

ACIN1

apoptotic chromatin condensation inducer 1

IPI00007334

0.0

0.5

0.0

0.0

ACTA2

actin, alpha 2, smooth muscle, aorta

IPI00008603

0.0

3.5

0.0

0.0

ACTB

actin, beta

IPI00021439

20.0

0.0

0.0

0.0

ACTBL2

similar to RIKEN cDNA 4732495G21 gene

IPI00003269

3.8

1.0

0.0

0.0

ADAR

adenosine deaminase, RNA-specific

IPI00025057

6.3

2.8

4.0

0.0

AGRN

agrin

IPI00374563

4.0

0.0

0.0

0.0

AHNAK

AHNAK nucleoprotein (desmoyokin)

IPI00021812

1.8

0.0

13.0

0.0

AIFM1

programmed cell death 8 (apoptosis-inducing
factor)

IPI00000690

75.8

101.5

0.0

1.5

AIMP1

small inducible cytokine subfamily E, member 1
(endothelial monocyte-activating)

IPI00006252

0.0

2.5

0.0

1.5

AIMP2

JTV1 gene

IPI00011916

0.0

0.0

3.0

0.0

AK2

adenylate kinase 2

IPI00172460

0.0

1.5

0.0

0.0

AKR1B10

aldo-keto reductase family 1, member B10 (aldose
reductase)

IPI00105407

2.0

0.0

0.0

0.0

AKR1C2

aldo-keto reductase family 1, member C2
(dihydrodiol dehydrogenase 2; bile acid binding
protein; 3-alpha hydroxysteroid dehydrogenase,
type III)

IPI00005668

2.5

0.0

5.0

0.0

ANXA1

annexin A1

IPI00218918

11.5

0.0

0.0

0.0

ANXA2

annexin A2

IPI00418169

9.3

0.0

0.0

0.0

ANXA2P2

Putative annexin A2-like protein

IPI00334627

20.5

0.0

0.0

0.0

AP1B1

adaptor-related protein complex 1, beta 1 subunit

IPI00328257

5.8

0.0

1.5

1.5

AP2A1

adaptor-related protein complex 2, alpha 1 subunit

IPI00256684

5.5

0.0

1.5

0.0

AP2A2

adaptor-related protein complex 2, alpha 2 subunit

IPI00016621

3.8

0.0

3.5

0.0

AP2B1

adaptor related protein complex 2, beta 1 subunit

IPI00784156

4.3

0.0

0.0

0.0

ASPH

aspartate beta-hydroxylase

IPI00294834

11.3

0.0

7.5

0.0

ATAD3A

ATPase family, AAA domain containing 3A

IPI00295992

0.0

2.3

1.5

2.0

ABCF1
ABCF2
ACAD11
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ATAD3B

ATPase family, AAA domain containing 3B

IPI00045921

1.3

2.0

0.0

4.0

ATAD3B

ATPase family, AAA domain containing 3B

IPI00178879

0.0

1.3

0.0

0.0

IPI00006482

0.0

0.5

0.0

0.0

IPI00177817

5.0

0.0

0.0

0.0

ATP1A1
ATP2A2

ATPase, Na+/K+ transporting, alpha 1
polypeptide
ATPase, Ca++ transporting, cardiac muscle, slow
twitch 2

ATP5A1

ATP synthase, H+ transporting, mitochondrial F1
complex, alpha subunit 1, cardiac muscle

IPI00440493

1.8

0.0

0.0

0.0

ATP5C1

ATP synthase, H+ transporting, mitochondrial F1
complex, gamma polypeptide 1

IPI00395769

5.5

0.0

3.5

0.0

ATP5J2

ATP synthase, H+ transporting, mitochondrial F0
complex, subunit F2

IPI00219291

2.3

0.0

0.0

0.0

ATP5L

ATP synthase, H+ transporting, mitochondrial F0
complex, subunit G

IPI00027448

2.8

0.0

0.0

0.0

ATXN2L

ataxin 2-like

IPI00456359

1.3

0.8

3.5

2.0

BANF1

barrier to autointegration factor 1

IPI00026087

2.0

0.0

0.0

1.5

BAT2

HLA-B associated transcript 2

IPI00010700

0.0

6.0

0.0

0.0

BAT2D1

BAT2 domain containing 1

IPI00083708

1.0

3.8

2.0

0.0

BRI3BP

BRI3 binding protein

IPI00103599

2.0

0.0

0.0

0.0

BUB3

BUB3 budding uninhibited by benzimidazoles 3
homolog (yeast)

IPI00013468

3.8

0.0

2.5

0.0

BXDC2

brix domain containing 2

IPI00181728

2.8

0.0

0.0

0.0

C14orf156

chromosome 14 open reading frame 156

IPI00009922

0.0

0.0

1.5

0.0

C14orf166

chromosome 14 open reading frame 166

IPI00006980

0.8

0.0

10.5

5.0

C16orf80

gene trap locus 3 (mouse)

IPI00001655

0.0

0.0

2.5

0.0

C19orf66

hypothetical protein FLJ11286

IPI00167592

1.8

0.0

0.0

0.0

C1orf57

chromosome 1 open reading frame 57

IPI00031570

0.0

3.8

0.0

0.0

C1QBP

complement component 1, q subcomponent
binding protein

IPI00014230

1.5

2.8

5.0

0.0

C22orf28

hypothetical protein HSPC117

IPI00550689

2.8

0.0

2.0

0.0

CAD

carbamoyl-phosphate synthetase 2, aspartate
transcarbamylase, and dihydroorotase

IPI00301263

6.8

1.0

0.0

0.0

CALM1;CAL
M3;CALM2

calmodulin 2 (phosphorylase kinase, delta)

IPI00075248

0.0

0.0

1.5

0.0

cell cycle associated protein 1

IPI00783872

7.3

14.5

11.5

9.5

IPI00005969

0.5

0.0

0.0

0.0

IPI00010320

0.0

0.0

2.0

0.0

CAPRIN1
CAPZA1
CBX1

capping protein (actin filament) muscle Z-line,
alpha 1
chromobox homolog 1 (HP1 beta homolog
Drosophila )

CCDC124

hypothetical protein BC013949

IPI00060627

0.0

0.0

1.5

3.5

CCT2

chaperonin containing TCP1, subunit 2 (beta)

IPI00297779

27.8

12.8

0.0

0.0

CCT3

chaperonin containing TCP1, subunit 3 (gamma)

IPI00290770

66.8

29.5

0.0

0.0

CCT5

chaperonin containing TCP1, subunit 5 (epsilon)

IPI00010720

54.5

19.3

0.0

0.0
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CCT6A

chaperonin containing TCP1, subunit 6A (zeta 1)

IPI00027626

52.8

23.0

1.5

0.0

CCT7

chaperonin containing TCP1, subunit 7 (eta)

IPI00018465

56.0

24.3

2.0

0.0

CCT8

chaperonin containing TCP1, subunit 8 (theta)

IPI00302925

54.0

21.5

0.0

0.0

CENPV

proline rich 6

IPI00376481

0.0

0.0

3.0

0.0

CEP170

centrosomal protein 170kDa

IPI00186194

1.5

1.0

0.0

0.0

CHCHD4

coiled-coil-helix-coiled-coil-helix domain
containing 4

IPI00177428

9.8

7.0

0.0

0.0

CIRBP

cold inducible RNA binding protein

IPI00180954

0.0

0.0

0.0

1.5

CKAP4

cytoskeleton-associated protein 4

IPI00141318

25.3

1.8

9.0

0.0

CKAP5

cytoskeleton associated protein 5

IPI00028275

11.5

11.0

11.5

0.0

CLASP1

cytoplasmic linker associated protein 1

IPI00396279

1.5

1.3

0.0

0.0

CLASP2

cytoplasmic linker associated protein 2

IPI00024382

1.3

0.8

2.0

0.0

CLTC

clathrin, heavy polypeptide (Hc)

IPI00024067

9.3

0.0

9.0

0.0

CNOT1

CCR4-NOT transcription complex, subunit 1

IPI00166010

0.0

5.3

0.0

0.0

CNP

2',3'-cyclic nucleotide 3' phosphodiesterase

IPI00220993

2.3

0.0

0.0

0.0

COL18A1

collagen, type XVIII, alpha 1

IPI00022822

0.8

0.0

0.0

0.0

COL1A2

collagen, type I, alpha 2

IPI00304962

0.0

3.8

0.0

0.0

COPA

coatomer protein complex, subunit alpha

IPI00295857

0.8

0.0

0.0

0.0

coronin 1C

IPI00798401

0.0

0.0

10.5

0.0

IPI00012998

3.0

0.0

0.0

0.0

IPI00107745

0.0

0.0

2.5

0.0

CORO1C
CPSF6
CROP

cleavage and polyadenylation specific factor 6,
68kDa
cisplatin resistance-associated overexpressed
protein

CSDA

cold shock domain protein A

IPI00031801

5.5

0.0

6.0

0.0

CSDE1

cold shock domain containing E1, RNA-binding

IPI00470891

1.3

0.0

0.0

0.0

CSNK1A1L

casein kinase 1, alpha 1-like

IPI00167096

0.0

0.0

2.0

0.0

CTNND1

catenin (cadherin-associated protein), delta 1

IPI00182469

2.5

0.0

0.0

0.0

DAP3

death associated protein 3

IPI00018120

3.3

0.0

0.0

0.0

DDX1

DEAD (Asp-Glu-Ala-Asp) box polypeptide 1

IPI00293655

8.0

2.5

15.0

15.5

DDX17

DEAD (Asp-Glu-Ala-Asp) box polypeptide 17

IPI00023785

8.0

7.3

0.0

7.0

DDX21

DEAD (Asp-Glu-Ala-Asp) box polypeptide 21

IPI00015953

10.3

7.3

6.5

4.0

DDX23

DEAD (Asp-Glu-Ala-Asp) box polypeptide 23

IPI00006725

2.8

1.0

0.0

0.0

DEAD (Asp-Glu-Ala-Asp) box polypeptide 24

IPI00006987

2.5

0.0

0.0

0.0

IPI00215637

19.0

3.3

17.0

9.5

IPI00293616

1.5

0.0

0.0

0.0

DDX24

DDX3Y;LOC1
00130220

DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Xlinked
DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Ylinked

DDX46

DEAD (Asp-Glu-Ala-Asp) box polypeptide 46

IPI00329791

1.3

0.0

2.5

0.0

DDX5

DEAD (Asp-Glu-Ala-Asp) box polypeptide 5

IPI00017617

14.5

8.5

13.0

10.5

DDX50

DEAD (Asp-Glu-Ala-Asp) box polypeptide 50

IPI00031554

0.0

0.0

0.0

2.0

DDX54

DEAD (Asp-Glu-Ala-Asp) box polypeptide 54

IPI00152510

2.3

0.0

0.0

0.0

DDX6

DEAD (Asp-Glu-Ala-Asp) box polypeptide 6

IPI00030320

0.0

0.0

0.0

1.5

DDX3X
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DDX60

hypothetical protein FLJ20035

IPI00217606

6.0

0.0

0.0

0.0

DDX60L

DEAD-Box Helicase 60-Like

IPI00853133

2.5

0.0

0.0

0.0

DECR1

2,4-dienoyl CoA reductase 1, mitochondrial

IPI00003482

3.3

2.0

3.5

0.0

DERA

2-deoxyribose-5-phosphate aldolase homolog (C.
elegans)

IPI00219677

9.3

0.0

0.0

0.0

DHX15

DEAH (Asp-Glu-Ala-His) box polypeptide 15

IPI00396435

8.8

4.3

2.5

2.5

DHX29

DEAH (Asp-Glu-Ala-His) box polypeptide 29

IPI00217413

5.3

5.5

3.0

0.0

DHX30

DEAH (Asp-Glu-Ala-His) box polypeptide 30

IPI00164906

0.0

0.5

0.0

0.0

DHX30

DEAH (Asp-Glu-Ala-His) box polypeptide 30

IPI00411733

4.0

8.0

8.5

6.5

DHX36

DEAH (Asp-Glu-Ala-His) box polypeptide 36

IPI00027415

4.8

2.8

2.0

4.5

DHX57

DEAH (Asp-Glu-Ala-Asp/His) box polypeptide
57

IPI00168885

1.8

0.0

0.0

0.0

DHX9

DEAH (Asp-Glu-Ala-His) box polypeptide 9

IPI00844578

34.5

28.8

20.5

6.0

DIMT1L

dimethyladenosine transferase

IPI00004459

0.0

0.0

2.0

1.5

DNAJA1

DnaJ (Hsp40) homolog, subfamily A, member 1

IPI00012535

0.0

0.0

0.0

1.5

DNAJA3

DnaJ (Hsp40) homolog, subfamily A, member 3

IPI00179187

1.0

0.0

1.5

1.5

DNAJC13

DnaJ (Hsp40) homolog, subfamily C, member 13

IPI00307259

4.5

0.8

2.5

0.0

DOCK6

dedicator of cytokinesis 6

IPI00184772

1.5

0.0

0.0

0.0

DOCK7

dedicator of cytokinesis 7

IPI00183572

0.0

0.8

0.0

0.0

DPM1

dolichyl-phosphate mannosyltransferase
polypeptide 1, catalytic subunit

IPI00022018

0.0

0.0

0.0

2.0

DRG1

developmentally regulated GTP binding protein 1

IPI00031836

8.3

0.0

4.5

5.0

DSP

desmoplakin

IPI00013933

4.8

2.8

0.0

0.0

DYNC1H1

dynein, cytoplasmic 1, heavy chain 1

IPI00456969

4.5

2.5

0.0

0.0

EBNA1BP2

EBNA1 binding protein 2

IPI00745955

0.5

0.0

0.0

0.0

ECT2

epithelial cell transforming 2

IPI00748143

1.3

0.0

0.0

0.0

EDC4

autoantigen

IPI00376317

0.0

1.0

0.0

0.0

EEF1A1

chemokine (C-C motif) receptor 5

IPI00025447

6.5

2.0

0.0

0.0

EEF1A2

eukaryotic translation elongation factor 1 alpha 2

IPI00014424

11.8

0.0

4.0

0.0

IPI00003588

0.0

0.0

0.0

2.5

IPI00003519

1.8

1.0

7.0

0.0

IPI00019463

17.0

1.3

7.0

3.0

EEF1E1
EFTUD2
EIF2AK2

eukaryotic translation elongation factor 1 epsilon
1
elongation factor Tu GTP binding domain
containing 2
eukaryotic translation initiation factor 2-alpha
kinase 2

EIF2S1

eukaryotic translation initiation factor 2, subunit 1
alpha, 35kDa

IPI00219678

12.0

2.3

10.5

3.5

EIF2S2

eukaryotic translation initiation factor 2, subunit 2
beta, 38kDa

IPI00021728

0.0

0.0

2.5

2.0

EIF3A

eukaryotic translation initiation factor 3, subunit
10 theta, 150/170kDa

IPI00029012

2.5

1.5

5.5

0.0
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EIF3B

eukaryotic translation initiation factor 3, subunit 9
eta, 116kDa

IPI00396370

0.0

0.0

2.0

0.0

EIF3CL;EIF3
C

eukaryotic translation initiation factor 3, subunit
8, 110kDa

IPI00016910

0.0

0.0

2.0

0.0

EIF3F

eukaryotic translation initiation factor 3, subunit 5
epsilon, 47kDa

IPI00654777

0.8

0.0

0.0

3.0

EIF3G

eukaryotic translation initiation factor 3, subunit 4
delta, 44kDa

IPI00290460

0.8

0.0

0.0

0.0

EIF3L

eukaryotic translation initiation factor 3, subunit 6
interacting protein

IPI00465233

0.0

1.3

0.0

2.5

EIF4A1;SNOR
A67

eukaryotic translation initiation factor 4A, isoform
1

IPI00025491

0.0

0.0

1.5

0.0

EIF4A3

DEAD (Asp-Glu-Ala-Asp) box polypeptide 48

IPI00009328

0.0

0.0

0.0

2.0

EIF4B

eukaryotic translation initiation factor 4B

IPI00012079

1.3

0.0

0.0

0.0

EIF4G1

eukaryotic translation initiation factor 4 gamma, 1

IPI00220365

0.8

0.8

5.5

0.0

EIF4G1

eukaryotic translation initiation factor 4 gamma, 1

IPI00386533

2.5

1.3

2.5

0.0

EIF4G3

eukaryotic translation initiation factor 4 gamma, 3

IPI00328268

0.0

0.5

0.0

0.0

EIF5A2

eukaryotic translation initiation factor 5A2

IPI00006935

1.0

0.0

0.0

0.0

EIF5B

eukaryotic translation initiation factor 5B

IPI00299254

10.0

10.5

6.5

0.0

ELAVL1

ELAV (embryonic lethal, abnormal vision,
Drosophila)-like 1 (Hu antigen R)

IPI00301936

4.0

3.8

14.0

10.0

EMD

emerin (Emery-Dreifuss muscular dystrophy)

IPI00032003

1.8

2.5

14.5

2.0

EMG1

EMG1 nucleolar protein homolog (S. cerevisiae)

IPI00025347

0.0

0.0

2.5

0.0

EPPK1

epiplakin 1

IPI00010951

0.8

0.0

9.5

0.0

EPRS

glutamyl-prolyl-tRNA synthetase

IPI00013452

9.3

11.3

5.5

2.5

ERLIN1

SPFH domain family, member 1

IPI00007940

2.3

0.0

0.0

0.0

EWSR1

Ewing sarcoma breakpoint region 1

IPI00009841

0.0

0.0

0.0

1.5

EXOSC10

exosome component 10

IPI00009464

2.8

0.8

1.5

0.0

EXOSC6

exosome component 6

IPI00073602

0.0

1.8

0.0

0.0

EXOSC9

exosome component 9

IPI00029697

1.0

0.0

0.0

0.0

FAM120A

chromosome 9 open reading frame 10

IPI00039626

6.3

0.0

11.5

4.0

FAM164A

chromosome 8 open reading frame 70

IPI00329753

0.5

0.0

0.0

0.0

FAM83H

family with sequence similarity 83 member H

IPI00784320

0.0

0.0

4.0

0.0

FAM91A1

family with sequence similarity 91, member A1

IPI00152671

1.0

0.0

0.0

0.0

FARSA

phenylalanine-tRNA synthetase-like, alpha
subunit

IPI00031820

0.0

1.8

0.0

0.0

FARSB

phenylalanine-tRNA synthetase-like, beta subunit

IPI00300074

3.3

2.5

1.5

3.0

FASN

fatty acid synthase

IPI00026781

1.5

0.0

0.0

0.0

FAU

Finkel-Biskis-Reilly murine sarcoma virus (FBRMuSV) ubiquitously expressed (fox derived);
ribosomal protein S30

IPI00019770

3.3

0.0

0.0

0.0
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FBL

fibrillarin

IPI00025039

1.5

0.0

3.5

0.0

FLNA

filamin A, alpha (actin binding protein 280)

IPI00302592

11.8

0.0

38.5

0.0

FLNB

filamin B, beta (actin binding protein 278)

IPI00289334

6.5

0.0

10.5

0.0

FLNC

filamin C, gamma (actin binding protein 280)

IPI00178352

3.8

0.0

0.0

0.0

FMR1

fragile X mental retardation 1

IPI00215720

3.3

5.8

0.0

6.5

IPI00221354

0.0

1.3

0.0

0.0

IPI00016249

4.8

2.0

4.0

3.5

IPI00016250

0.0

5.0

0.0

4.5

IPI00012442

8.3

6.8

10.5

12.0

IPI00009057

1.5

3.5

0.0

6.0

FUS
FXR1
FXR2
G3BP1
G3BP2

fusion (involved in t(12;16) in malignant
liposarcoma)
fragile X mental retardation, autosomal homolog
1
fragile X mental retardation, autosomal homolog
2
Ras-GTPase-activating protein SH3-domainbinding protein
Ras-GTPase activating protein SH3 domainbinding protein 2

G6PD

glucose-6-phosphate dehydrogenase

IPI00216008

2.8

0.0

0.0

0.0

GCN1L1

GCN1 general control of amino-acid synthesis 1like 1 (yeast)

IPI00001159

3.3

0.8

0.0

0.0

GIGYF2

trinucleotide repeat containing 15

IPI00647635

0.0

0.5

0.0

0.0

GNB2L1

guanine nucleotide binding protein (G protein),
beta polypeptide 2-like 1

IPI00641950

1.3

3.3

0.0

0.0

GNL3

guanine nucleotide binding protein-like 3
(nucleolar)

IPI00003886

2.0

4.5

0.0

5.0

GRWD1

glutamate-rich WD repeat containing 1

IPI00027831

3.0

0.0

0.0

0.0

GTF2I

general transcription factor II, i

IPI00054042

2.8

0.0

2.0

0.0

GTF3C1

general transcription factor IIIC, polypeptide 1,
alpha 220kDa

IPI00414481

0.5

0.0

0.0

0.0

GTPBP1

GTP binding protein 1

IPI00010463

0.0

1.3

0.0

0.0

GTPBP4

GTP binding protein 4

IPI00385042

4.3

0.0

0.0

2.0

H1FX

H1 histone family, member X

IPI00021924

5.5

0.0

4.5

2.0

H2AFV

H2A histone family, member V

IPI00018278

3.8

0.0

0.0

5.0

H2AFY

H2A histone family, member Y

IPI00059366

3.0

0.0

8.0

0.0

HADHA

hydroxyacyl-Coenzyme A dehydrogenase/3ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme
A hydratase (trifunctional protein), alpha subunit

IPI00031522

24.3

8.0

15.0

0.0

HADHB

hydroxyacyl-Coenzyme A dehydrogenase/3ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme
A hydratase (trifunctional protein), beta subunit

IPI00022793

2.0

0.0

0.0

0.0

HDLBP

high density lipoprotein binding protein (vigilin)

IPI00022228

3.8

1.0

5.5

0.0

HERC5

hect domain and RLD 5

IPI00008821

1.3

1.3

0.0

0.0

HIST1H1C

histone 1, H1c

IPI00217465

3.3

1.5

0.0

0.0
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HIST1H4J;HIS
T1H4E;HIST1
H4H;HIST1H4
K;HIST2H4A;
HIST1H4D;HI
ST1H4F;HIST
2H4B;HIST1H
4C;HIST1H4B;
HIST1H4I;HIS
T1H4L;HIST1
H4A;HIST4H4

histone 2, H4

IPI00453473

8.3

0.0

0.0

0.0

HIST2H2BE

histone 2, H2be

IPI00003935

0.0

2.0

32.5

6.0

HNRNPA0

heterogeneous nuclear ribonucleoprotein A0

IPI00011913

2.3

0.0

8.5

2.0

HNRNPA1

heterogeneous nuclear ribonucleoprotein A1

IPI00215965

14.0

8.5

10.0

5.5

HNRNPA2B1

heterogeneous nuclear ribonucleoprotein A2/B1

IPI00386854

0.8

1.8

15.5

11.0

HNRNPA2B1

heterogeneous nuclear ribonucleoprotein A2/B1

IPI00396378

5.5

11.0

7.0

4.5

HNRNPA3

heterogeneous nuclear ribonucleoprotein A3

IPI00419373

7.5

5.8

12.0

4.0

HNRNPAB

heterogeneous nuclear ribonucleoprotein A/B

IPI00106509

4.5

3.5

4.0

0.0

HNRNPC

heterogeneous nuclear ribonucleoprotein C
(C1/C2)

IPI00216592

9.3

2.8

10.5

3.0

HNRNPCL1

heterogeneous nuclear ribonucleoprotein C-like 1

IPI00027569

4.5

0.0

0.0

3.0

HNRNPD

heterogeneous nuclear ribonucleoprotein D (AUrich element RNA binding protein 1, 37kDa)

IPI00028888

3.8

4.0

2.0

3.5

HNRNPF

heterogeneous nuclear ribonucleoprotein F

IPI00003881

2.8

0.0

8.5

3.0

HNRNPH1

heterogeneous nuclear ribonucleoprotein H1 (H)

IPI00013881

0.0

0.0

2.5

0.0

HNRNPH3

heterogeneous nuclear ribonucleoprotein H3
(2H9)

IPI00013877

2.0

0.0

7.5

0.0

HNRNPK

heterogeneous nuclear ribonucleoprotein K

IPI00216049

23.5

6.0

19.5

3.5

HNRNPL

heterogeneous nuclear ribonucleoprotein L

IPI00027834

2.5

1.8

7.5

4.0

HNRNPM

heterogeneous nuclear ribonucleoprotein M

IPI00171903

30.0

7.8

12.5

19.0

HNRNPR

heterogeneous nuclear ribonucleoprotein R

IPI00012074

6.8

2.0

6.5

4.5

HNRNPU

heterogeneous nuclear ribonucleoprotein U
(scaffold attachment factor A)

IPI00479217

19.5

11.3

9.0

9.0

HNRNPUL1

heterogeneous nuclear ribonucleoprotein U-like 1

IPI00013070

11.3

2.8

4.5

2.5

HNRNPUL2

heterogeneous nuclear ribonucleoprotein U-like 2

IPI00456887

3.3

0.0

0.0

0.0

HNRPDL

heterogeneous nuclear ribonucleoprotein D-like

IPI00011274

2.3

2.3

3.5

2.0

HP1BP3

heterochromatin protein 1, binding protein 3

IPI00640417

2.0

0.0

0.0

0.0

HRNR

hornerin

IPI00398625

2.0

0.0

0.0

0.0

HSD17B12

hydroxysteroid (17-beta) dehydrogenase 12

IPI00007676

3.0

2.3

0.0

0.0

HSP90AA1

heat shock protein 90kDa alpha (cytosolic), class
A member 1

IPI00382470

3.0

1.5

0.0

0.0

HSPA1A;HSP
A1B

heat shock 70kDa protein 1A

IPI00304925

7.8

0.0

0.0

5.0

HSPA1L

heat shock 70kDa protein 7 (HSP70B)

IPI00301277

4.8

2.3

4.0

5.5

HSPA2

heat shock 70kDa protein 2

IPI00007702

1.5

0.0

0.0

0.0
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HSPA5

heat shock 70kDa protein 5 (glucose-regulated
protein, 78kDa)

IPI00003362

0.0

0.0

4.0

4.0

HSPA8

heat shock 70kDa protein 8

IPI00003865

31.0

0.0

19.5

8.0

HSPD1

heat shock protein family D (Hsp60) member 1

IPI00784154

2.8

0.0

0.0

0.0

IARS

isoleucine-tRNA synthetase

IPI00644127

3.3

2.0

5.5

2.5

IFI16

interferon, gamma-inducible protein 16

IPI00003443

2.8

0.0

0.0

0.0

IPI00024254

1.0

0.0

0.0

0.0

IPI00008557

19.8

21.0

17.0

21.5

IPI00179713

4.0

2.5

0.0

4.0

IPI00165467

3.0

1.0

3.0

6.5

IPI00658000

7.3

6.3

10.0

9.5

IFIT3
IGF2BP1
IGF2BP2
IGF2BP3
IGF2BP3

interferon-induced protein with tetratricopeptide
repeats 3
insulin-like growth factor 2 mRNA binding
protein 1
insulin-like growth factor 2 mRNA binding
protein 2
insulin-like growth factor 2 mRNA binding
protein 3
insulin-like growth factor 2 mRNA binding
protein 3

IGLC1;IGLV1
-44;IGLV140;IGLV321;IGLV211;IGLV214;IGL@;IGL
C2;IGLC3

immunoglobulin lambda constant 1 (Mcg marker)

IPI00154742

3.8

0.0

0.0

0.0

ILF2

interleukin enhancer binding factor 2, 45kDa

IPI00005198

12.8

11.3

7.5

11.5

ILF3

interleukin enhancer binding factor 3, 90kDa

IPI00219330

14.5

8.5

10.5

16.0

ILK-2;CCT4

chaperonin containing TCP1, subunit 4 (delta)

IPI00302927

44.0

17.0

0.0

0.0

IMMT

inner membrane protein, mitochondrial (mitofilin)

IPI00009960

2.5

1.3

1.5

0.0

IMP3

IMP3, U3 small nucleolar ribonucleoprotein,
homolog (yeast)

IPI00019488

0.0

0.0

2.0

0.0

IPO7

importin 7

IPI00007402

2.5

1.0

0.0

0.0

IQGAP1

IQ motif containing GTPase activating protein 1

IPI00009342

13.8

0.0

19.5

0.0

ISG15

interferon, alpha-inducible protein (clone IFI15K)

IPI00375631

14.0

0.0

0.0

0.0

KARS

lysyl-tRNA synthetase

IPI00014238

1.5

1.8

0.0

3.0

KHDRBS1

KH domain containing, RNA binding, signal
transduction associated 1

IPI00008575

0.8

1.8

0.0

4.0

KIAA0020

pumilio RNA binding family member 3

IPI00791325

0.8

0.0

4.0

0.0

KIAA1618

KIAA1618

IPI00217287

22.0

0.0

0.0

0.0

KIAA1618

KIAA1618

IPI00218094

19.5

0.0

0.0

0.0

KIAA1618

chromosome 17 open reading frame 27

IPI00642126

76.3

0.0

1.5

0.0

KIAA1967

KIAA1967

IPI00182757

3.0

0.0

0.0

0.0

KIF2A

kinesin heavy chain member 2

IPI00010368

3.0

0.0

0.0

0.0

KIFC1

kinesin family member C1

IPI00306400

0.0

2.5

0.0

0.0

KPNB1

karyopherin (importin) beta 1

IPI00001639

4.3

1.5

4.0

0.0

KTN1

kinectin 1 (kinesin receptor)

IPI00328753

2.0

0.0

0.0

0.0

LACTB

lactamase, beta

IPI00294186

5.8

0.0

2.5

0.0
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LAMA5

laminin subunit alpha 5

IPI00783665

5.3

0.0

0.0

0.0

LAMB1

laminin, beta 1

IPI00013976

3.0

0.0

0.0

0.0

LAMC1

laminin, gamma 1 (formerly LAMB2)

IPI00298281

2.5

0.0

0.0

0.0

LARP1

La ribonucleoprotein domain family, member 1

IPI00185919

11.0

7.8

14.5

8.0

LARP4

La ribonucleoprotein domain family, member 4

IPI00043638

0.0

0.0

0.0

1.5

LARP4B

La ribonucleoprotein domain family member 4B

IPI00827634

1.0

0.0

0.0

3.5

LARS

leucyl-tRNA synthetase

IPI00103994

0.0

2.5

2.0

1.5

LBA1

tetratricopeptide repeat and ankyrin repeat
containing 1

IPI00847543

1.8

0.0

0.0

0.0

LEMD2

LEM domain containing 2

IPI00168336

0.0

0.0

8.5

0.0

LIG3

ligase III, DNA, ATP-dependent

IPI00000156

0.0

1.0

7.0

0.0

LMNA

lamin A/C

IPI00021405

23.0

0.0

52.5

0.0

LMNB1

lamin B1

IPI00217975

1.3

0.8

13.0

0.0

LOC26010

DNA polymerase-transactivated protein 6

IPI00023532

4.8

0.0

0.0

0.0

LOC442497;SL
C3A2

solute carrier family 3 (activators of dibasic and
neutral amino acid transport), member 2

IPI00027493

6.0

0.0

0.0

0.0

IPI00183920

1.3

0.0

0.0

1.5

LOC652595
LRPPRC

leucine rich pentatricopeptide repeat containing

IPI00783271

7.8

2.8

15.5

0.0

LRRC59

leucine rich repeat containing 59

IPI00396321

8.3

2.3

10.0

4.5

LUC7L2

LUC7-like 2 (S. cerevisiae)

IPI00006932

1.5

0.0

0.0

2.0

MACF1

microtubule-actin crosslinking factor 1

IPI00256861

3.0

0.0

0.0

0.0

MAP1B

microtubule-associated protein 1B

IPI00008868

13.8

0.0

5.0

0.0

MAP4

microtubule-associated protein 4

IPI00220113

0.0

3.5

5.0

3.0

MAP4

microtubule-associated protein 4

IPI00396171

2.5

0.0

0.0

0.0

MAP7

microtubule-associated protein 7

IPI00020771

8.5

0.0

0.0

0.0

MARS

methionine-tRNA synthetase

IPI00008240

0.0

2.0

0.0

5.0

MATR3

matrin 3

IPI00017297

7.5

7.8

13.0

7.0

MCM3

MCM3 minichromosome maintenance deficient 3
(S. cerevisiae)

IPI00013214

1.0

0.0

0.0

0.0

MDN1

MDN1, midasin homolog (yeast)

IPI00167941

0.0

0.8

0.0

0.0

antigen identified by monoclonal antibody Ki-67

IPI00004233

0.0

0.0

2.5

0.0

IPI00154590

0.0

0.0

3.5

0.0

IPI00444452

14.0

20.8

10.5

21.5

MKI67
MKI67IP
MOV10

MKI67 (FHA domain) interacting nucleolar
phosphoprotein
Mov10, Moloney leukemia virus 10, homolog
(mouse)

MPRIP

myosin phosphatase-Rho interacting protein

IPI00166518

2.3

1.5

6.5

0.0

MRPL11

mitochondrial ribosomal protein L11

IPI00007001

0.0

0.0

1.5

0.0

MRPS22

mitochondrial ribosomal protein S22

IPI00013146

0.0

0.0

1.5

0.0

MRPS27

mitochondrial ribosomal protein S27

IPI00022002

1.3

0.0

0.0

0.0

MRPS9

mitochondrial ribosomal protein S9

IPI00641924

2.8

0.0

0.0

0.0
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MRTO4

chromosome 1 open reading frame 33

IPI00106491

0.0

0.0

2.0

1.5

MSH2

mutS homolog 2, colon cancer, nonpolyposis type
1 (E. coli)

IPI00017303

1.5

0.0

0.0

0.0

MSH6

mutS homolog 6 (E. coli)

IPI00106847

3.3

0.5

3.0

0.0

MSI2

musashi homolog 2 (Drosophila)

IPI00073713

0.0

0.0

0.0

2.0

MTDH

metadherin

IPI00328715

1.8

0.0

0.0

0.0

MTUS1

mitochondrial tumor suppressor 1

IPI00428447

1.8

0.0

0.0

0.0

MVP

major vault protein

IPI00000105

1.3

0.0

0.0

0.0

MX1

myxovirus (influenza virus) resistance 1,
interferon-inducible protein p78 (mouse)

IPI00167949

2.8

0.0

0.0

0.0

MYBBP1A

MYB binding protein (P160) 1a

IPI00005024

32.5

22.5

7.5

2.0

MYH10

myosin, heavy polypeptide 10, non-muscle

IPI00397526

12.5

5.3

0.0

0.0

MYH9

myosin, heavy polypeptide 9, non-muscle

IPI00019502

144.8

2.0

0.0

0.0

MYL12B

myosin regulatory light chain MRLC2

IPI00033494

6.8

0.0

0.0

0.0

MYL6;MYL6B

myosin, light polypeptide 6, alkali, smooth muscle
and non-muscle

IPI00335168

6.5

0.0

0.0

0.0

MYL9

myosin, light polypeptide 9, regulatory

IPI00030929

5.3

0.0

0.0

0.0

MYO1B

myosin IB

IPI00376344

10.0

0.0

29.5

0.0

MYO1C

myosin IC

IPI00010418

27.5

6.5

27.5

0.0

MYO1D

myosin ID

IPI00329719

0.0

3.0

1.5

0.0

MYO1E

myosin IE

IPI00329672

3.0

0.0

3.5

0.0

MYO6

myosin VI

IPI00008455

0.0

2.3

9.0

0.0

MYO9B

myosin IXB

IPI00306933

0.5

0.0

0.0

0.0

NACA

nascent-polypeptide-associated complex alpha
polypeptide

IPI00023748

3.3

0.0

0.0

0.0

NAT10

N-acetyltransferase 10

IPI00300127

0.0

0.0

2.0

0.0

NCBP1

nuclear cap binding protein subunit 1, 80kDa

IPI00019380

4.3

1.0

4.5

9.0

NCL

nucleolin

IPI00183526

29.8

15.0

19.0

14.5

NCL

nucleolin

IPI00444262

25.3

12.8

9.5

16.5

NME4

non-metastatic cells 4, protein expressed in

IPI00012972

2.3

0.0

0.0

0.0

NMNAT1

nicotinamide nucleotide adenylyltransferase 1

IPI00009726

0.0

0.8

0.0

0.0

NOL6

nucleolar protein family 6 (RNA-associated)

IPI00152890

0.0

0.0

2.0

0.0

NOM1

nucleolar protein with MIF4G domain 1

IPI00145593

1.8

0.0

0.0

0.0

NONO

non-POU domain containing, octamer-binding

IPI00304596

2.5

6.8

5.5

0.0

NOP2

nucleolar protein 1, 120kDa

IPI00294891

8.8

2.3

5.0

0.0

NOP56

nucleolar protein 5A (56kDa with KKE/D repeat)

IPI00411937

0.0

0.0

3.5

0.0

NOP58

nucleolar protein NOP5/NOP58

IPI00006379

2.5

0.0

2.0

0.0

NPM1

anaplastic lymphoma kinase (Ki-1)

IPI00220740

12.0

5.3

15.5

10.5

NSUN2

NOL1/NOP2/Sun domain family, member 2

IPI00306369

5.3

0.0

0.0

0.0
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NUFIP2

nuclear fragile X mental retardation protein
interacting protein 2

IPI00002349

0.0

0.0

2.0

3.0

NUMA1

nuclear mitotic apparatus protein 1

IPI00006196

0.5

0.0

0.0

0.0

NUP133

nucleoporin 133kDa

IPI00291200

0.0

0.0

2.0

0.0

OAS2

2'-5'-oligoadenylate synthetase 2, 69/71kDa

IPI00217049

2.0

0.0

0.0

0.0

OAS3

2'-5'-oligoadenylate synthetase 3, 100kDa

IPI00002405

16.8

0.0

0.0

0.0

OGDH

oxoglutarate (alpha-ketoglutarate) dehydrogenase
(lipoamide)

IPI00098902

3.8

0.0

0.0

0.0

PA2G4

proliferation-associated 2G4, 38kDa

IPI00299000

0.0

1.3

0.0

0.0

PABPC1

poly(A) binding protein, cytoplasmic 1

IPI00008524

35.8

21.5

39.5

38.5

PABPC4

poly(A) binding protein, cytoplasmic 4 (inducible
form)

IPI00012726

6.3

3.5

7.0

13.5

PARP1

poly (ADP-ribose) polymerase family, member 1

IPI00449049

20.0

15.5

24.0

20.5

PARP9

poly (ADP-ribose) polymerase family, member 9

IPI00027803

0.5

0.0

0.0

0.0

PCBP2

poly(rC) binding protein 2

IPI00012066

0.0

0.0

0.0

3.5

PDCD11

programmed cell death 11

IPI00400922

0.0

0.0

3.0

0.0

PELP1

proline, glutamic acid and leucine rich protein 1

IPI00006702

0.8

3.0

0.0

0.0

PFDN2

prefoldin subunit 2

IPI00006052

2.5

0.0

0.0

0.0

PFKP

phosphofructokinase, platelet

IPI00009790

0.0

0.0

2.0

0.0

PGAM5

phosphoglycerate mutase family member 5

IPI00063242

3.3

1.8

5.5

3.0

PGAM5

phosphoglycerate mutase family member 5

IPI00788907

2.5

0.0

0.0

0.0

PHB2

prohibitin 2

IPI00027252

1.0

0.0

0.0

0.0

PLEC1

plectin 1, intermediate filament binding protein
500kDa

IPI00014898

67.5

1.5

153.5

0.0

PNO1

putatative 28 kDa protein

IPI00024524

0.0

0.0

1.5

0.0

POLRMT

polymerase (RNA) mitochondrial (DNA directed)

IPI00298738

2.5

0.0

2.0

0.0

PPIB

peptidylprolyl isomerase B (cyclophilin B)

IPI00646304

0.0

0.0

2.0

0.0

IPI00005705

0.0

0.8

0.0

0.0

IPI00183002

0.0

0.0

1.5

0.0

PPP1CC
PPP1R12A

protein phosphatase 1, catalytic subunit, gamma
isoform
protein phosphatase 1, regulatory (inhibitor)
subunit 12A

PRDX1

peroxiredoxin 1

IPI00000874

0.0

0.0

4.0

0.0

PRIC285

peroxisomal proliferator-activated receptor A
interacting complex 285

IPI00249304

24.0

2.5

0.0

0.0

PRKDC

protein kinase, DNA-activated, catalytic
polypeptide

IPI00296337

76.5

43.0

46.0

0.0

PRKRA

protein kinase, interferon-inducible double
stranded RNA dependent activator

IPI00021167

0.0

1.8

0.0

0.0

PRPF40A

pre-mRNA processing factor 40 homolog A

IPI00337385

0.0

0.5

0.0

0.0

PRPF8

PRP8 pre-mRNA processing factor 8 homolog
(yeast)

IPI00007928

1.8

2.0

3.5

0.0

PRPH

peripherin

IPI00013164

0.0

0.0

2.5

0.0
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PSMC5

proteasome (prosome, macropain) 26S subunit,
ATPase, 5

IPI00023919

1.3

0.0

0.0

0.0

PSPC1

paraspeckle component 1

IPI00103525

0.0

1.0

0.0

0.0

PTBP1

polypyrimidine tract binding protein 1

IPI00179964

6.3

8.3

10.5

0.0

PTCD3

pentatricopeptide repeat domain 3

IPI00783302

0.5

0.0

0.0

0.0

PTK2

PTK2 protein tyrosine kinase 2

IPI00012885

1.0

0.0

0.0

0.0

PTPLAD1

protein tyrosine phosphatase-like A domain
containing 1

IPI00008998

4.0

0.0

3.0

0.0

PTRF

polymerase I and transcript release factor

IPI00176903

6.3

0.0

0.0

0.0

PURA

purine-rich element binding protein A

IPI00023591

0.0

0.5

3.0

2.5

PYGM

phosphorylase, glycogen; muscle (McArdle
syndrome, glycogen storage disease type V)

IPI00218130

1.3

0.0

0.0

0.0

QARS

glutaminyl-tRNA synthetase

IPI00026665

1.0

0.0

1.5

3.5

RAI14

retinoic acid induced 14

IPI00292953

2.8

2.0

11.0

0.0

RALY

RNA binding protein, autoantigenic (hnRNPassociated with lethal yellow homolog (mouse))

IPI00011268

0.5

0.0

3.5

0.0

RANBP2

RAN binding protein 2

IPI00221325

0.0

0.0

2.5

0.0

RARS

arginyl-tRNA synthetase

IPI00004860

2.8

3.5

1.5

2.5

RBM14;RBM4

RNA binding motif protein 14

IPI00013174

0.0

5.0

3.0

4.5

RBM25

RNA binding motif protein 25

IPI00004273

0.5

0.0

0.0

0.0

RBM28

RNA binding motif protein 28

IPI00304187

2.5

0.0

0.0

0.0

RBM39

RNA-binding region (RNP1, RRM) containing 2

IPI00163505

3.5

1.8

0.0

3.0

RBMX

RNA binding motif protein, X-linked

IPI00304692

0.8

0.0

0.0

0.0

RECQL

RecQ protein-like (DNA helicase Q1-like)

IPI00178431

1.3

0.0

0.0

0.0

RFC1

replication factor C (activator 1) 1, 145kDa

IPI00375358

0.0

1.5

0.0

0.0

RFC2

replication factor C (activator 1) 2, 40kDa

IPI00017412

0.0

0.0

2.0

0.0

RFC4

replication factor C (activator 1) 4, 37kDa

IPI00017381

3.3

0.0

2.5

0.0

RFC5

replication factor C (activator 1) 5, 36.5kDa

IPI00031514

1.5

0.0

0.0

0.0

RIF1

RAP1 interacting factor homolog (yeast)

IPI00293845

0.0

0.0

3.5

0.0

RNF213

ring finger protein 213

IPI00470478

12.8

0.0

0.0

0.0

RPA1

replication protein A1, 70kDa

IPI00020127

0.0

2.5

13.0

2.5

RPA2

replication protein A2, 32kDa

IPI00013939

0.0

0.0

5.5

0.0

RPL10A

ribosomal protein L10a

IPI00412579

6.8

20.0

6.0

5.5

RPL10L

ribosomal protein L10-like

IPI00064765

0.0

0.0

3.0

0.0

RPL10P16

ribosomal protein L10 pseudogene 16

IPI00374260

2.0

0.0

0.0

0.0

RPL11

ribosomal protein L11

IPI00376798

5.5

2.5

0.0

0.0

RPL12

ribosomal protein L12

IPI00024933

18.8

10.5

5.0

11.0

RPL13

ribosomal protein L13

IPI00465361

7.3

1.0

6.5

4.5

RPL13A

ribosomal protein L13a

IPI00304612

5.8

1.0

2.0

3.5
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RPL13P12

ribosomal protein L13 pseudogene 12

IPI00397611

9.0

9.8

9.5

9.5

RPL14

ribosomal protein L14

IPI00555744

3.0

0.0

0.0

0.0

RPL15

ribosomal protein L15

IPI00470528

0.0

6.0

8.0

4.0

RPL18

ribosomal protein L18

IPI00215719

13.5

11.3

9.0

7.5

RPL18A

ribosomal protein L18a

IPI00026202

5.8

1.8

9.5

3.0

RPL19

ribosomal protein L19

IPI00025329

6.8

2.5

4.5

0.0

RPL21P19;RP
L21;RPL21P16

ribosomal protein L21

IPI00247583

10.0

8.3

8.5

6.0

RPL22

ribosomal protein L22

IPI00219153

0.0

1.3

0.0

0.0

RPL23

ribosomal protein L23

IPI00010153

7.3

6.8

15.5

12.5

RPL23A

ribosomal protein L23a

IPI00021266

14.3

8.8

11.0

12.0

RPL24

ribosomal protein L24

IPI00306332

6.3

7.5

7.5

4.5

RPL26L1

ribosomal protein L26-like 1

IPI00007144

6.0

4.8

8.0

7.0

RPL27

ribosomal protein L27

IPI00219155

10.3

2.8

4.0

4.0

RPL27A

ribosomal protein L27a

IPI00456758

5.3

4.0

0.0

0.0

RPL28

ribosomal protein L28

IPI00182533

5.0

2.3

0.0

0.0

RPL3

ribosomal protein L3

IPI00550021

19.3

18.0

15.0

13.0

RPL30

ribosomal protein L30

IPI00219156

12.8

6.0

11.0

13.5

RPL31

ribosomal protein L31

IPI00026302

5.5

4.0

0.0

0.0

RPL34

ribosomal protein L34

IPI00219160

4.3

1.5

5.5

4.0

RPL35

ribosomal protein L35

IPI00412607

2.0

3.3

3.5

3.0

RPL35A

ribosomal protein L35a

IPI00029731

7.8

6.3

3.5

4.0

RPL36

ribosomal protein L36

IPI00216237

6.8

1.8

5.5

5.5

RPL36AL

ribosomal protein L36a-like

IPI00056494

1.0

0.0

0.0

0.0

RPL37A

ribosomal protein L37a

IPI00414860

0.0

1.8

0.0

0.0

RPL38

ribosomal protein L38

IPI00215790

6.3

0.0

0.0

0.0

RPL4

ribosomal protein L4

IPI00003918

27.8

12.3

9.0

9.0

RPL5

ribosomal protein L5

IPI00000494

15.5

11.8

13.5

11.5

RPL6

ribosomal protein L6

IPI00329389

22.8

27.8

26.5

29.0

RPL7;RPL7P3
2

ribosomal protein L7

IPI00030179

15.5

11.8

17.5

18.5

RPL7A

ribosomal protein L7a

IPI00299573

17.5

15.0

17.5

8.5

IPI00075558

2.5

1.8

0.0

0.0

RPL7AP27
RPL7L1

ribosomal protein L7-like 1

IPI00456940

0.0

0.0

2.5

0.0

RPL8

ribosomal protein L8

IPI00012772

8.0

3.8

8.5

6.0

RPL9

ribosomal protein L9

IPI00031691

1.8

3.8

14.5

7.0

RPLP0

ribosomal protein, large, P0

IPI00008530

40.3

37.0

29.0

32.0

RPLP1

ribosomal protein, large, P1

IPI00008527

7.0

2.5

0.0

4.0

RPLP2

ribosomal protein, large, P2

IPI00008529

22.8

20.8

6.5

8.0
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RPN1

ribophorin I

IPI00025874

2.3

0.0

2.0

0.0

RPS10

ribosomal protein S10

IPI00008438

4.3

1.8

0.0

7.0

RPS11

ribosomal protein S11

IPI00025091

5.3

0.0

4.5

3.0

RPS13

ribosomal protein S13

IPI00221089

12.0

6.3

11.5

6.5

RPS14

ribosomal protein S14

IPI00026271

7.5

2.3

9.5

6.0

RPS15

ribosomal protein S15

IPI00479058

1.0

0.0

2.0

0.0

RPS15A

ribosomal protein S15a

IPI00221091

6.0

3.5

6.5

4.0

RPS16

ribosomal protein S16

IPI00221092

9.0

4.8

16.5

15.5

RPS17

ribosomal protein S17

IPI00221093

5.8

1.8

10.5

0.0

RPS18;LOC10
0130553

ribosomal protein S18

IPI00013296

16.8

5.0

16.0

11.0

RPS19

ribosomal protein S19

IPI00215780

10.8

5.5

22.0

19.5

RPS2

ribosomal protein S2

IPI00013485

7.3

4.3

14.5

14.0

RPS20

ribosomal protein S20

IPI00012493

0.8

0.0

5.5

6.0

RPS23

ribosomal protein S23

IPI00218606

8.0

0.0

9.0

5.0

RPS24

ribosomal protein S24

IPI00029750

8.8

4.8

12.5

5.5

RPS25

ribosomal protein S25

IPI00012750

3.8

0.0

0.0

8.0

RPS27

ribosomal protein S27

IPI00397358

0.5

0.0

3.5

0.0

RPS27

ribosomal protein S27 (metallopanstimulin 1)

IPI00513971

0.0

0.0

2.5

0.0

RPS28

ribosomal protein S28

IPI00719622

0.0

0.0

3.5

0.0

RPS3

ribosomal protein S3

IPI00011253

20.3

7.3

33.5

28.5

RPS3A

ribosomal protein S3A

IPI00419880

15.3

4.5

22.0

8.5

RPS4X

ribosomal protein S4, X-linked

IPI00217030

18.0

8.3

25.5

17.5

RPS5

ribosomal protein S5

IPI00008433

0.0

0.5

4.0

0.0

RPS6

ribosomal protein S6

IPI00021840

8.0

4.0

9.0

6.0

RPS7

ribosomal protein S7

IPI00013415

1.3

6.8

8.5

5.5

IPI00008293

1.5

0.0

3.5

1.5

IPI00216587

10.3

7.3

8.0

4.5

RPS7P4
RPS8

ribosomal protein S8

RPS9

ribosomal protein S9

IPI00221088

3.0

5.5

19.5

8.0

RPSAP12

ribosomal protein SA pseudogene 12

IPI00398958

3.3

0.0

2.0

0.0

RRBP1

ribosome binding protein 1 homolog 180kDa
(dog)

IPI00215743

55.3

4.8

6.0

0.0

RRP12

KIAA0690

IPI00101186

1.8

0.0

0.0

0.0

RSL1D1

ribosomal L1 domain containing 1

IPI00008708

0.5

0.0

0.0

0.0

S100A10

S100 calcium binding protein A10 (annexin II
ligand, calpactin I, light polypeptide (p11))

IPI00183695

2.8

0.0

0.0

0.0

SAMD9

sterile alpha motif domain containing 9

IPI00217018

1.5

0.0

0.0

0.0

SAMHD1

SAM domain and HD domain 1

IPI00294739

2.3

0.5

0.0

0.0

SEMG1

semenogelin I

IPI00023020

7.0

0.0

0.0

0.0
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SEMG2

semenogelin II

IPI00025415

2.5

0.0

0.0

0.0

SERBP1

SERPINE1 mRNA binding protein 1

IPI00410693

4.8

5.0

4.5

0.0

SF3A1

splicing factor 3a, subunit 1, 120kDa

IPI00017451

0.5

1.0

1.5

0.0

SF3B1

splicing factor 3b, subunit 1, 155kDa

IPI00026089

2.8

0.0

3.5

0.0

SF3B2

splicing factor 3b, subunit 2, 145kDa

IPI00221106

2.8

0.0

1.5

0.0

SFPQ

splicing factor proline/glutamine-rich
(polypyrimidine tract binding protein associated)

IPI00010740

9.8

23.5

8.0

8.0

SFRS1

splicing factor, arginine/serine-rich 1 (splicing
factor 2, alternate splicing factor)

IPI00215884

9.8

5.0

13.0

7.0

SFRS2

splicing factor, arginine/serine-rich 2

IPI00005978

3.0

0.0

0.0

1.5

SFRS3

splicing factor, arginine/serine-rich 3

IPI00010204

2.3

0.0

0.0

2.5

SFRS5

splicing factor, arginine/serine-rich 5

IPI00012341

2.5

0.0

0.0

0.0

SFRS6

splicing factor, arginine/serine-rich 6

IPI00012345

0.0

1.5

0.0

0.0

SFRS7

splicing factor, arginine/serine-rich 7, 35kDa

IPI00003377

3.5

2.5

4.0

4.0

SFXN1

sideroflexin 1

IPI00009368

0.0

2.5

0.0

0.0

SGPL1

sphingosine-1-phosphate lyase 1

IPI00099463

1.0

0.0

0.0

0.0

SKIV2L2

superkiller viralicidic activity 2-like 2 (S.
cerevisiae)

IPI00647217

2.3

0.0

0.0

1.5

SLC25A1

solute carrier family 25 (mitochondrial carrier;
citrate transporter), member 1

IPI00294159

1.3

0.0

0.0

0.0

SLC25A11

solute carrier family 25 (mitochondrial carrier;
oxoglutarate carrier), member 11

IPI00219729

1.5

6.0

2.0

2.5

SLC25A12

solute carrier family 25 (mitochondrial carrier,
Aralar), member 12

IPI00386271

1.0

0.0

0.0

0.0

SLC25A13

solute carrier family 25, member 13 (citrin)

IPI00007084

2.8

5.0

1.5

1.5

SLC25A3

solute carrier family 25 (mitochondrial carrier;
phosphate carrier), member 3

IPI00022202

7.0

4.0

2.0

0.0

SLC25A5

solute carrier family 25 (mitochondrial carrier;
adenine nucleotide translocator), member 5

IPI00007188

30.8

17.0

27.0

0.0

SLC25A6

solute carrier family 25 (mitochondrial carrier;
adenine nucleotide translocator), member 4

IPI00291467

7.3

0.0

7.5

0.0

SLC2A1

solute carrier family 2 (facilitated glucose
transporter), member 1

IPI00220194

0.8

0.0

0.0

0.0

IPI00216046

0.0

0.0

4.5

0.0

IPI00297211

0.0

0.0

1.5

0.0

IPI00291939

0.0

1.3

2.0

0.0

SMARCA1

SMARCA5
SMC1A

SWI/SNF related, matrix associated, actin
dependent regulator of chromatin, subfamily a,
member 1
SWI/SNF related, matrix associated, actin
dependent regulator of chromatin, subfamily a,
member 5
SMC1 structural maintenance of chromosomes 1like 1 (yeast)
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SMC2 structural maintenance of chromosomes 2like 1 (yeast)

IPI00007927

2.0

1.0

0.0

0.0

SMC3

chondroitin sulfate proteoglycan 6 (bamacan)

IPI00219420

0.0

0.0

6.5

0.0

SMC4

SMC4 structural maintenance of chromosomes 4like 1 (yeast)

IPI00328298

1.8

1.3

0.0

0.0

SMCHD1

structural maintenance of chromosomes flexible
hinge domain containing 1

IPI00465022

1.0

0.0

0.0

0.0

SND1

staphylococcal nuclease domain containing 1

IPI00140420

0.5

0.0

0.0

1.5

SNORA7A;RP
L32

ribosomal protein L32

IPI00395998

5.0

0.0

0.0

0.0

IPI00168235

0.0

2.5

0.0

0.0

IPI00420014

2.3

1.3

3.0

0.0

IPI00302850

0.0

0.0

0.0

2.5

IPI00017963

2.8

0.0

0.0

3.5

SMC2

SNRNP200
SNRNP200
SNRPD1
SNRPD2

activating signal cointegrator 1 complex subunit
3-like 1
activating signal cointegrator 1 complex subunit
3-like 1
small nuclear ribonucleoprotein D1 polypeptide
16kDa
small nuclear ribonucleoprotein D2 polypeptide
16.5kDa

SNRPE

small nuclear ribonucleoprotein polypeptide E

IPI00029266

1.5

0.0

0.0

0.0

SNRPG

small nuclear ribonucleoprotein polypeptide G

IPI00016572

1.5

0.0

2.0

0.0

SPATS2

spermatogenesis associated, serine-rich 2

IPI00329345

2.3

0.0

0.0

0.0

SPTAN1

spectrin, alpha, non-eythrocytic 1

IPI00744706

2.3

0.0

12.0

0.0

SPTBN1

spectrin, beta, non-erythrocytic 1

IPI00005614

1.8

0.0

13.5

0.0

SQRDL

sulfide quinone reductase-like (yeast)

IPI00009634

1.8

0.0

0.0

0.0

SRP14

signal recognition particle 14kDa (homologous
Alu RNA binding protein)

IPI00293434

3.3

0.0

6.5

2.0

SRP9;SRP9L1

signal recognition particle 9kDa

IPI00216125

0.5

0.0

0.0

0.0

SRPK1

SFRS protein kinase 1

IPI00290439

0.0

0.0

0.0

3.5

SRPK2

SFRS protein kinase 2

IPI00333420

0.8

0.0

0.0

0.0

SRRM1

serine/arginine repetitive matrix 1

IPI00328293

1.0

0.0

0.0

0.0

SRRM2

serine/arginine repetitive matrix 2

IPI00782992

2.5

10.0

4.5

7.0

SRRT

ARS2 protein

IPI00220038

3.0

0.0

0.0

0.0

SSB

Sjogren syndrome antigen B (autoantigen La)

IPI00009032

1.8

0.0

0.0

3.0

SSBP1

single-stranded DNA binding protein 1

IPI00029744

0.0

0.0

14.0

1.5

SSRP1

structure specific recognition protein 1

IPI00005154

6.3

3.0

0.0

0.0

IPI00030781

0.8

0.0

0.0

0.0

IPI00000001

1.0

0.5

0.0

0.0

STAT1
STAU1

signal transducer and activator of transcription 1,
91kDa
staufen, RNA binding protein, homolog 1
(Drosophila)

STRAP

serine/threonine kinase receptor associated protein

IPI00294536

1.0

0.0

0.0

0.0

STT3B

STT3, subunit of the oligosaccharyltransferase
complex, homolog B (S. cerevisiae)

IPI00152377

1.0

0.0

0.0

0.0

SUB1

SUB1 homolog (S. cerevisiae)

IPI00221222

3.0

1.8

0.0

0.0

SUPT16H

suppressor of Ty 16 homolog (S. cerevisiae)

IPI00026970

8.5

7.5

0.0

0.0

SYNCRIP

synaptotagmin binding, cytoplasmic RNA
interacting protein

IPI00018140

12.3

3.3

11.5

13.5
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TAF15

TAF15 RNA polymerase II, TATA box binding
protein (TBP)-associated factor, 68kDa

IPI00020194

0.5

0.0

0.0

0.0

TARDBP

TAR DNA binding protein

IPI00025815

1.8

0.0

0.0

0.0

TBCB

cytoskeleton associated protein 1

IPI00293126

1.0

0.0

0.0

0.0

TBL2

transducin (beta)-like 2

IPI00000948

4.0

0.0

1.5

0.0

TCOF1

Treacher Collins-Franceschetti syndrome 1

IPI00165041

4.3

0.5

0.0

0.0

TCP1

t-complex 1

IPI00290566

70.8

36.0

0.0

0.0

TEX10

testis expressed sequence 10

IPI00549664

0.0

0.0

0.0

2.0

TFAM

transcription factor A, mitochondrial

IPI00020928

0.0

0.0

3.0

0.0

TGM2

transglutaminase 2 (C polypeptide, proteinglutamine-gamma-glutamyltransferase)

IPI00294578

5.0

0.0

0.0

0.0

THOC2

THO complex 2

IPI00158615

0.0

0.0

1.5

0.0

THOC4

THO complex 4

IPI00328840

2.0

0.0

0.0

2.5

THOC6

THO complex 6 homolog (Drosophila)

IPI00301252

0.0

0.0

2.0

0.0

THRAP3

thyroid hormone receptor associated protein 3

IPI00104050

0.0

2.0

0.0

0.0

TIMM50

translocase of inner mitochondrial membrane 50
homolog (yeast)

IPI00418497

3.3

0.0

0.0

0.0

TJP1

tight junction protein 1 (zona occludens 1)

IPI00216219

2.3

0.0

9.0

0.0

TMCO1

transmembrane and coiled-coil domains 1

IPI00026111

1.8

0.0

0.0

0.0

TMOD3

tropomodulin 3 (ubiquitous)

IPI00005087

1.3

0.0

0.0

0.0

TMPO

thymopoietin

IPI00030131

4.3

0.0

43.0

0.0

TMPO

thymopoietin

IPI00216230

1.8

0.0

34.0

0.0

TNFAIP2

tumor necrosis factor, alpha-induced protein 2

IPI00304866

2.0

0.0

0.0

0.0

TOP1

topoisomerase (DNA) I

IPI00413611

5.0

1.5

0.0

3.0

TOP2A

topoisomerase (DNA) II alpha 170kDa

IPI00178667

0.0

0.0

12.0

0.0

TOP2B

topoisomerase (DNA) II beta 180kDa

IPI00027280

0.0

0.0

7.5

0.0

TPM1

tropomyosin 1 (alpha)

IPI00000230

5.0

0.0

0.0

0.0

TRAM1

translocation associated membrane protein 1

IPI00219111

10.8

0.0

0.0

0.0

TRIM21

tripartite motif-containing 21

IPI00018971

26.0

2.8

0.0

0.0

TRIM25

tripartite motif-containing 25

IPI00029629

9.3

0.0

0.0

0.0

TRIM28

tripartite motif-containing 28

IPI00438229

3.3

0.0

0.0

0.0

TRIP12

thyroid hormone receptor interactor 12

IPI00032342

2.0

0.0

2.0

0.0

TROVE2

TROVE domain family, member 2

IPI00019450

2.0

2.5

2.5

2.0

TSR1

TSR1, 20S rRNA accumulation, homolog (yeast)

IPI00292894

6.3

0.0

4.5

2.5

TUBA1C

tubulin, alpha 6

IPI00166768

10.0

0.0

0.0

0.0

TUBA4A

tubulin, alpha 1 (testis specific)

IPI00007750

9.0

5.0

0.0

0.0

TUBB

tubulin, beta

IPI00011654

8.5

4.5

0.0

0.0

TUBB1

tubulin, beta 1

IPI00006510

1.8

0.8

2.5

0.0
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TUBB2C

tubulin, beta 2C

IPI00007752

7.8

13.5

4.0

0.0

TUFM

Tu translation elongation factor, mitochondrial

IPI00027107

7.5

0.0

2.5

1.5

TXN

thioredoxin

IPI00216298

9.8

14.8

0.0

0.0

U2AF1

U2(RNU2) small nuclear RNA auxiliary factor 1

IPI00005613

3.5

0.0

0.0

0.0

U2AF2

U2 (RNU2) small nuclear RNA auxiliary factor 2

IPI00031556

4.3

3.8

0.0

0.0

UBC;RPS27A;
UBB

ribosomal protein S27a

IPI00179330

7.5

1.5

13.0

0.0

UBTF

upstream binding transcription factor, RNA
polymerase I

IPI00014533

2.5

0.0

0.0

1.5

UGDH

UDP-glucose dehydrogenase

IPI00031420

2.3

0.0

0.0

0.0

UNC45B

unc-45 homolog B (C. elegans)

IPI00217428

0.8

0.0

0.0

0.0

UPF1

UPF1 regulator of nonsense transcripts homolog
(yeast)

IPI00034049

1.8

2.5

12.5

5.0

UQCRC2

ubiquinol-cytochrome c reductase core protein II

IPI00305383

3.5

0.0

0.0

0.0

USP10

ubiquitin specific peptidase 10

IPI00291946

1.3

3.0

6.5

7.0

USP39

ubiquitin specific peptidase 39

IPI00419844

0.0

0.0

0.0

2.5

UTP20;LOC65
3877

UTP20, small subunit (SSU) processome
component, homolog (yeast)

IPI00004970

0.5

0.0

1.5

0.0

VIM

vimentin

IPI00418471

0.0

8.3

0.0

0.0

VRK1

vaccinia related kinase 1

IPI00019640

0.0

0.0

2.0

0.0

XPO1

exportin 1 (CRM1 homolog, yeast)

IPI00298961

0.5

1.0

0.0

0.0

XPOT

exportin, tRNA (nuclear export receptor for
tRNAs)

IPI00306290

1.0

1.3

0.0

0.0

XRCC1

X-ray repair complementing defective repair in
Chinese hamster cells 1

IPI00002564

0.0

0.0

1.5

0.0

XRCC5

X-ray repair complementing defective repair in
Chinese hamster cells 5 (double-strand-break
rejoining; Ku autoantigen, 80kDa)

IPI00220834

10.5

3.8

16.5

10.0

XRCC6

X-ray repair complementing defective repair in
Chinese hamster cells 6 (Ku autoantigen, 70kDa)

IPI00644712

15.0

6.8

24.0

12.0

XRN2

5'-3' exoribonuclease 2

IPI00100151

12.8

1.5

6.5

2.0

YBX1

Y box binding protein 1

IPI00031812

9.0

2.0

5.0

4.0

YTHDC2

YTH domain containing 2

IPI00010200

2.5

1.0

1.5

0.0

YWHAQ

tyrosine 3-monooxygenase/tryptophan 5monooxygenase activation protein, theta
polypeptide

IPI00018146

2.3

0.0

0.0

0.0

IPI00187011

2.0

0.0

0.0

0.0

ZC3H4
ZC3HAV1

zinc finger CCCH-type, antiviral 1

IPI00332936

10.5

0.0

2.5

2.0

ZC3HAV1

zinc finger CCCH-type, antiviral 1

IPI00410067

1.5

0.0

0.0

0.0

ZCCHC3

zinc finger, CCHC domain containing 3

IPI00011550

0.0

0.0

0.0

5.5

ZNFX1

zinc finger, NFX1-type containing 1

IPI00165981

3.3

0.0

0.0

0.0

-

keratin 8-like 1

IPI00017870

2.3

0.0

21.0

0.0
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-

IPI00069693

4.3

0.0

3.5

0.0

-

IPI00176692

3.8

0.0

0.0

4.0

-

IPI00394699

9.3

3.0

5.0

7.0
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Table S4.2. Stress granule proteins that interact with arenavirus NP.
Cellular proteins with a known association with stress granules are listed, including the multiple ribosomal
S proteins (RPS) that are constituents of the small ribosomal subunit.
Gene Symbol

Gene Description

IPI ID

CAPRIN1

Cell Cycle Associated Protein 1

IPI00783872

DDX6

DEAD (Asp-Glu-Ala-Asp) box polypeptide 6

IPI00030320

EIF3A

eukaryotic translation initiation factor 3, subunit 10 theta, 150/170kDa

IPI00029012

EIF3B

eukaryotic translation initiation factor 3, subunit 9 eta, 116kDa

IPI00396370

EIF3CL;EIF3C

eukaryotic translation initiation factor 3, subunit 8, 110kDa

IPI00016910

EIF3F

eukaryotic translation initiation factor 3, subunit 5 epsilon, 47kDa

IPI00654777

EIF3G

eukaryotic translation initiation factor 3, subunit 4 delta, 44kDa

IPI00290460

EIF3L

eukaryotic translation initiation factor 3, subunit 6 interacting protein

IPI00465233

EIF4A1;SNORA67

eukaryotic translation initiation factor 4A, isoform 1

IPI00025491

EIF4A3

DEAD (Asp-Glu-Ala-Asp) box polypeptide 48

IPI00009328

EIF4G1

eukaryotic translation initiation factor 4 gamma, 1

IPI00220365

EIF4G3

eukaryotic translation initiation factor 4 gamma, 3

IPI00328268

ELAVL1

ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 (Hu antigen R)

IPI00301936

FXR1

fragile X mental retardation, autosomal homolog 1

IPI00016249

FXR2

fragile X mental retardation, autosomal homolog 2

IPI00016250

G3BP1

Ras-GTPase-activating protein SH3-domain-binding protein

IPI00012442

G3BP2

Ras-GTPase activating protein SH3 domain-binding protein 2

IPI00009057

GNB2L1

guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1

IPI00641950

PABPC1

poly(A) binding protein, cytoplasmic 1

IPI00008524

PABPC4

poly(A) binding protein, cytoplasmic 4 (inducible form)

IPI00012726

RPS10

ribosomal protein S10

IPI00008438

RPS11

ribosomal protein S11

IPI00025091

RPS13

ribosomal protein S13

IPI00221089

RPS14

ribosomal protein S14

IPI00026271

RPS15

ribosomal protein S15

IPI00479058

RPS15A

ribosomal protein S15a

IPI00221091

RPS16

ribosomal protein S16

IPI00221092

RPS17

ribosomal protein S17

IPI00221093

RPS18;LOC100130553

ribosomal protein S18

IPI00013296

RPS19

ribosomal protein S19

IPI00215780

RPS2

ribosomal protein S2

IPI00013485

RPS20

ribosomal protein S20

IPI00012493

RPS23

ribosomal protein S23

IPI00218606

RPS24

ribosomal protein S24

IPI00029750

219

RPS25

ribosomal protein S25

IPI00012750

RPS27

ribosomal protein S27 (metallopanstimulin 1)

IPI00513971

RPS27

ribosomal protein S27

IPI00397358

RPS28

ribosomal protein S28

IPI00719622

RPS3

ribosomal protein S3

IPI00011253

RPS3A

ribosomal protein S3A

IPI00419880

RPS4X

ribosomal protein S4, X-linked

IPI00217030

RPS5

ribosomal protein S5

IPI00008433

RPS6

ribosomal protein S6

IPI00021840

RPS7

ribosomal protein S7

IPI00013415

RPS7P4

ribosomal protein S7 pseudogene 4

IPI00008293

RPS8

ribosomal protein S8

IPI00216587

RPS9

ribosomal protein S9

IPI00221088

STAU1

staufen, RNA binding protein, homolog 1 (Drosophila)

IPI00000001

YBX1

Y box binding protein 1

IPI00031812

220

CHAPTER 5: SUMMARY OF FINDINGS AND FUTURE DIRECTIONS
5.1. Arenvirus genome transcription and replication
How viruses establish long lived persistent infections in their rodent hosts has
been an important question motivating researchers since the discovery of this key feature
of arenavirus infections. The methods researchers took toward examining these questions
evolved along with cell culture and molecular biology technologies over time. Early work
spearheaded by Hotchin et al. during the late 1960’s and 1970’s used cell culture models
and measured viral release from infected cells as a primary metric of active infection.
Tracking release of infectious particles from infected cultures and from individual cells
isolated from those cultures over time led to the emergence of a model whereby arenavirus
persistence was hypothesized to be repeated cycles of transient infections of individual
cells within a large population of cells (Hotchin, 1973, 1974a, b).
During the 1980’s and 1990’s with the advent of more advanced molecular
biology, gene cloning, and nucleic acid sequencing technologies, it became possible to
probe the genetic events of arenavirus infection more directly. It was found that the
arenaviruses had a bi-segmented, single-stranded, negative-sense genome (Leung et al.,
1977). Researchers discovered that the arenaviruses possessed an interesting “ambisense”
coding strategy where each genomic RNA segment encodes two genes but in opposite
polarity (Auperin et al., 1984b; Salvato and Shimomaye, 1989; Southern et al., 1987). This
suggested that these viruses to control the relative timing of specific gene expression events
based on the polarity of the viral genes on the genomic RNA that would be delivered to
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newly infected cells, which was subsequently demonstrated in cells infected with TCRV
(Franze-Fernandez et al., 1987). It was shown that purified virus packaged both genomic
and antigenomic RNA (Franze-Fernandez et al., 1987). Further, it was shown that smaller
than expected genomic RNAs appear in infected cells over time, suggesting that viral
RNAs may accumulate deletions following the initial phase of acute infection (Francis and
Southern, 1988a, b).
These initial experiments led to the systematic exploration of the genetic nature
of persistence in both in vitro and in vivo models of infection primarily by Southern et al.
in the 1980’s and 1990’s. They observed that viral RNA is maintained in persistently
infected mouse tissue and in persistently infected cell culture (Francis and Southern, 1988a,
b). They suggested that the genetic signature of reduced arenavirus replication during
persistence was due to the appearance of short deletions in the 3’ and 5’ UTR regions of
the viral genomic RNAs, and that these deletions selectively inhibited gene transcription
but permitted genome replication (Meyer and Southern, 1994). Lastly, they proposed that
terminal deletions could be repaired by the viral polymerase leading to a rescue of viral
genome that was both transcription and replication competent, thus allowing productive
infection of cells to reset (Meyer and Southern, 1997). With this new data, the field seems
to have largely forgotten the original work by Hotchin et al., with more recent reviews of
the subject making no mention of his work on persistence, and focus instead on the work
of Southern et al. to explain the mechanism by which infected cells become persistently
infected (Labudova et al., 2016).
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We were not convinced that the genetic model put forth by Southern et al. told
the whole story for two primary reasons. First, Southern et al. suggest that persistently
infected cells maintain high levels of genomic material during persistence and the
expression of this genetic material is regulated by the presence or absence of terminal
deletions that can be repaired. However, this does not completely match observations from
the work of Hotchin et al., which showed that the vast majority of individual cells cloned
from persistently infected cultures did not produce infectious virus (Hotchin, 1973).
Second, Southern et al. suggest a repair mechanism of the genomic terminal deletions
(from 2-38 base pairs in length) relying solely on addition of random non-templated
nucleotides (Meyer and Southern, 1997). While, it is possible that this method could repair
very short deletions of just a few lost bases, the probability that a viral polymerase could
correctly repair longer deletions becomes vanishingly improbable. We thus hypothesized
that neither the hypotheses of Hotchin or Southern were complete and that recent
improvements in fluorescence in situ hybridization (FISH) permitting the labeling of single
RNA molecules could bring these two models of persistence into harmony.
The work presented in Chapter 2 leveraged cutting-edge single-molecule RNA
FISH (smFISH) and a high-throughput imaging and analysis pipeline to follow the kinetics
of genome transcription and replication in single cells during a time course of infection
from one hour to several weeks following initial infection. This work allowed us to confirm
previous data showing the temporal separation between the expression of the viral NP and
GPC genes providing further appreciation for the ability of this ambisense coding strategy
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to temporally control viral gene expression programs (Franze-Fernandez et al., 1987).
Further, though previous work indicated that S antigenomic RNA was packaged in LCMV
virions, we never detected expression of GPC in the initial hours following infection
suggesting that if antigenome is packaged in infectious virions, this RNA is
transcriptionally incompetent upon initial RNP release into the cytoplasm of the newly
infected cells (Franze-Fernandez et al., 1987). Additionally, data from Chapter 2 suggest
that a subpopulation of viral particles do not package the L segment. This observation could
suggest that recruitment of viral genetic material into budding virions is not a highly
regulated process and virions packaging various suites of encapsidated RNAs could occur
as has recently been demonstrated to be the case for Rift Valley fever virus using a similar
smFISH approach (Wichgers Schreur and Kortekaas, 2016).
Strikingly, when we imaged thousands of individual cells from persistently
infected cells over time, we noted that, at some time points in the persistent phase, the
majority of cells in the population had no detectable viral RNAs and at other time points,
close to 100% of cells in the population had detectable viral RNAs. Moreover, the
transition between these states occurred cyclically over time similar the cycles of release
of infectious virus during persistence as previously reported in the literature (LehmannGrube et al., 1969). This suggested to us that the model of Hotchin appears to be correct,
and individual cells experience cyclic self-limited transient infections during persistence.
While we do not question the veracity of the results of Southern et al., we suggest that the
terminal deletions that occur in genomes during persistence most likely are a mechanism
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employed by the virus to limit its own transcription and replication within a cell and to
eventually clear active infection. We think it more likely that these cells become re-infected
from virus produced by reservoir cells containing viral genomic RNA with intact 3’ and 5’
UTRs than the alternative where genomes in each persistently infected cell are repaired by
the viral L polymerase through the addition of random non-templated bases.
A serious limitation of the study presented in Chapter 2 was the poor signal-tonoise ratio (SNR) of the FISH probe sets that were designed to specifically hybridize to the
genomic (but not the viral mRNAs). This fact led us to use probe sets that targeted the viral
mRNAs along with their respective genomic or antigenomic RNA species. The strength of
this approach is that we can simultaneously visualize a greater range of viral RNA species
in single infected cells. However, we lose the ability to definitively know the identity of
the RNAs we are visualizing. Future work to improve the binding sensitivity of genome
specific FISH probe sets would be worthwhile. We hypothesized that encapsidation of viral
genomic and antigenomic RNA by nucleoprotein could prevent probe access and limit
probe sensitivity. If this is the case, we believe that performing a brief protease digestion
of fixed cells prior to FISH staining, as has previously been reported (Buxbaum et al.,
2014), could allow us to overcome this technical barrier. The added insight gained from
this would improve our ability to quantitatively characterize the rates of genome replication
and even allow us to estimate rates of genome degradation. These data would be
instrumental for the creation of a mathematical model describing the genetic events of
arenavirus infection, a tool that could be invaluable to help predict how various mutations
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to the viral L polymerase, Z protein, or NP (all known regulators of the viral gene
expression program) could affect the kinetics of viral growth and/or alter the propensity of
the virus to establish persistent infection.
5.2. Arenavirus Replication Complexes
As obligate intracellular parasites, viruses are unable to replicate independently
of a host cell. It is becoming increasingly clear that a range of viruses create specific niches
at subcellular sites to facilitate various steps of their life cycle (den Boon et al., 2010;
Novoa et al., 2005a). Though comparatively little is known about how negative-strand
viruses take advantage of cellular compartments, there are a few notable recent examples
in the literature (Bruce et al., 2010; Novoa et al., 2005b). For example, it was shown that
Influenza A virus (IAV) is dependent on Rab11 positive recycling endosomes for optimal
replication (Amorim et al., 2011; Eisfeld et al., 2011). Two independent groups used
smFISH to demonstrate that the Rab11 positive recycling endosome is a site where the
different viral genomic segments assemble and are transported to the plasma membrane
(Chou et al., 2013; Lakdawala et al., 2014).
We were motivated to explore what role membrane bound compartments may
play in facilitating the life cycle of the prototypic arenavirus LCMV by several key
findings: (i) the observation that IAV, a negative-strand virus with a segmented RNA
genome, intimately relies upon a cellular membrane bound organelle, (ii) that the
arenavirus NP localizes to defined punctate structures in the cytoplasm of infected cells
(Baird et al., 2012; Knopp et al., 2015), and (iii) that arenaviral RNPs copurify with cellular
226

membrane (Baird et al., 2012). In Chapter 3, we used smFISH probe sets to specifically
label and visualize S segment genomic and antigenomic RNA in cells acutely infected with
LCMV. Viral genomic RNA localized in defined cytoplasmic foci whose size, brightness,
and subcellular localization evolved over the course of acute infection. We confirmed that
these cytoplasmic foci were sites of active viral replication by demonstrating the
colocalization of S genomic RNA with S antigenomic RNA, its replicative complementary
intermediate, and nucleoprotein, which encapsidates the genomic and antigenomic RNA.
Taking advantage of a previously published siRNA screen showing that Rab5c was
required for optimal LCMV growth (Panda et al., 2011), we showed that LCMV S genome
concentrates at Rab5c positive early endosomal membranes in a proportion of infected
cells. Thus, to address the question of how the virus may benefit from concentrating its
genetic material at this endosomal membrane, we examined whether the virus was
recruiting other viral structural components to this site. Indeed, we showed, that in a portion
of infected cells there was a high degree of colocalization between the viral S genome and
viral glycoprotein, suggesting that the virus may be utilizing intracellular membrane bound
compartments as sites for the assembly of nascent viral components before being
transported to the plasma membrane where budding occurs, a finding that contradicts the
current dogma of arenavirus assembly.
Obvious next steps to confirm and extend these findings are to fully define all of
the viral components that may be assembled at the intracellular sites identified in Chapter
3 and to characterize the mechanisms they use to traffic to the plasma membrane. Indeed,
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elements of this work are currently underway. We have shown that the viral Z protein
strongly colocalizes with Rab5c positive endosomes in a subpopulation of LCMV infected
cells (C. M. Ziegler, E. A. Bruce, B. R. King, and J. Botten, Unpublished Data) providing
some evidence that all the viral components pre-assemble intracellularly. Additionally, we
have observed that disruption of the microtubule cytoskeleton by treating cells with
nocodazole results in a dramatic redistribution of viral components in infected cells (B. R.
King and J. Botten, Unpublished Data). However, infectious viral output is unaffected
following microtubule disruption suggesting that the virus may employ redundant
intracellular transport mechanisms permitting intracellular viral assembly and trafficking
as has also recently been reported for IAV (Nturibi et al., 2017). It will be important to
further explore the role of microtubules in trafficking and, additionally, to consider actindependent pathways as alternative routes the virus may take to reach the plasma membrane.
To better understand the role played by Rab5c in promoting these processes, infection of
cells should be performed in cells stably transduced with a drug-inducible dominant
negative Rab5c. Imaging the localization of the different viral components following the
disruption of Rab5c function will be highly informative and should include the Rab5a and
Rab5b isoforms to determine the specificity of this pathway. Furthermore, immunogold
EM studies to examine the ultrastructural detail of viral replication complexes in the
cytoplasm of infected cells will provide additional critical insights.
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5.3. The NP host-protein interactome
In addition to its canonical role of encapsidation of the viral single-stranded RNA
genome, over the past years NP’s multifunctional nature has become clear. Structural
investigations have yielded insight into how the viral NP is able to bind viral RNA and has
also revealed a C terminal domain with a previously unrecognized 3’ to 5’ exonuclease
activity (Hastie et al., 2011a; Qi et al., 2010; Zhang et al., 2013). This has provided the first
mechanistic explanation of how the arenavirus NP is able to inhibit the activation of the
host type I IFN response. Other documented roles played by NP in the arenavirus life cycle
are interaction with viral Z protein (Levingston Macleod et al., 2011; Ortiz-Riano et al.,
2011), important for the recruitment of viral RNPs into budding virions (Levingston
Macleod et al., 2011), regulation of apoptosis (Wolff et al., 2013a), modulation of innate
immunity signaling (Pythoud et al., 2012; Rodrigo et al., 2012), and regulation of cellular
translation by preventing the induction of stress granules in infected cells (Linero et al.,
2011). By playing such diverse roles, in the life cycle, we had hypothesized that virus must
interact with a wide range of cellular proteins, and that these protein-protein interactions
would facilitate these, and potentially, as yet, undescribed steps of the viral life cycle.
In Chapter 4, we performed tandem mass spectrometry to identify the host
cellular protein partners of the Old World arenavirus LCVM NP and the New World
arenavirus JUNV. Here we established the first wide-scale interactome map of the host cell
machinery engaged by diverse arenaviruses during infection, giving us an unprecedented
view of the diverse biological functions performed by NP. Bioinformatic analysis of this
protein-protein interaction map suggested that host cellular translation was a major
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biological function that was highly associated with NP. This was fascinating in view of the
observation that JUNV NP is able to prevent the assembly of stress granules in response to
cellular stress in viral infected cells and cells ectopically expressing NP (Linero et al.,
2011). Mining the data set for master regulators of cellular translation, we identified the
eIF2α kinase PKR, a cytoplasmic sensor of dsRNA (most often a result of viral infection)
that phosphorylates eIF2α and leads to global translation arrests.
The identification of this cellular factor led us to functionally characterize the NPPKR interaction and the PKR signaling pathway in infected cells. We found that the NPPKR interaction appeared to be stronger for JUNV NP than for LCMV NP. Additionally,
we found that while PKR was activated in JUNV infected cells, it was unable to
phosphorylate eIF2α, and translation rates remained normal. On the other hand, the weaker
LCMV NP-PKR interaction was not as robust at interfering with PKR’s activity. This result
is interesting considering studies showing divergence in the ability of the Old World and
New World NP’s ability to prevent robust induction of type I IFN. LASV and LCMV NP
were both shown to strongly inhibit the expression of type I IFN (Hastie et al., 2011a;
Martinez-Sobrido et al., 2009; Martinez-Sobrido et al., 2007; Qi et al., 2010). However,
JUNV, in one study, did not exhibit the same exonuclease activity (Zhang et al., 2013) and
poorly inhibits type I IFN induction (Huang et al., 2012). This data fits with the model of
PKR inhibition revealed in our study. We conjecture that because JUNV NP is unable to
prevent the induction of type I IFN, it must develop additional strategies to limit the
antiviral activity of individual IFN stimulated genes (e.g. PKR) to promote viral growth in
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infected cells. The imperative of Old World arenavirus (e.g. LASV or LCMV) NP to inhibit
the activity of various interferon stimulated genes may be relaxed as the expression of these
genes remains low.
Moreover, the identification of PKR as a functionally important host protein
partner of JUNV NP was interesting in light of the work showing that stress granule
induction is inhibited in JUVN infected cells and in cells expressing JUNV NP (Linero et
al., 2011). The large-scale map of arenavirus NP and host cellular protein interactions from
this study has allowed us to hypothesize that the interaction between JUNV NP and PKR
may be the mechanism utilized by the virus to maintain normal rates of translation in cells
experiencing stress that would normally lead to the phosphorylation of eIF2α and the
formation of stress granules.
The conclusion of Chapter 4 that JUNV NP is able to inhibit the activity of PKR
has also been explored recently by Huang et al. (Huang et al., 2017). They show that
infection with wild type JUNV strain Romero leads to both activation of PKR and eIF2α
phosphorylation, in contrast to our result showing no eIF2α phosphorylation (Huang et al.,
2017). Nevertheless, the authors demonstrated that in PKR deficient cells, WT JUNV
replication was marginally impaired, suggesting that active PKR is not playing an antiviral
role in New World arenavirus infections and may even be beneficial for viral growth
(Huang et al., 2017). Additional work is needed to reconcile the results of our two studies
and to explore the possibility that NP’s engagement with PKR may be one mechanism by
which JUNV C#1 is attenuated.
231

Beyond the ability of arenaviruses to modulate host cellular translation, this work
has provided an important data set to the field that will serve as an important hypothesis
generating tool in the future. Another tantalizing question that have emerged from our data,
but remain to be tested in more detail, is how JUNV NP is involved in the balance between
apoptosis initiation versus its inhibition. Interestingly, the most abundantly detected
cellular protein partner of JUNV NP was apoptosis inducing factor 1 (AIFM1), which is
released from the mitochondria following stress and is translocated to the nucleus where it
is involved in nuclear fragmentation during the apoptotic program (Lipton and BossyWetzel, 2002). It remains to be explored how this interaction may be critical in regulating
the precarious balancing act between cell survival and apoptosis noted in studies of JUNV
infected cells (Kolokoltsova et al., 2014; Wolff et al., 2013a).
5.4. Conclusion
In conclusion, I have had the opportunity to explore a broad range of questions
related to the arenavirus life cycle during my dissertation. The principle that unifies the
diverse projects described herein is how the virus utilizes specific subcellular niches and
cellular machinery to promote effective viral transcription, replication, and additional steps
of the virus life cycle. The work we have performed has allowed us to revisit long standing
conflicting hypotheses of persistence, to develop new paradigms of how arenaviruses may
rely on cellular organelles to promote assembly, and identify additional ways in which
arenaviruses hijack cellular machinery to avoid an effective innate immune response. It is
our hope that the conclusions of this work and the future studies it inspires will lead to the
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development of novel antiviral therapeutics that can be used to better treat these devastating
infections that touch so many people around the world.
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